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 Americans‟ adoption of the Internet has spawned the increased usage of this medium for direct-to-
consumer advertising by pharmaceutical manufacturers, despite the widespread controversy over the ethics of the 
practice, the educational value of direct-to-consumer advertising, and the ultimate cost of the practices to the public. 
While the U.S. Food and Drug Administration regulates the industry‟s advertising within traditional media, the 
agency does not yet impose standards for direct-to-consumer advertising of prescription medications on the Internet. 
This content analysis of the visual and textual cues of 100 direct-to-consumer Web sites for prescription medications 
identifies the unexpected strong presence of gain frames relative to loss frames, as well as the manufacturers‟ focus 
on educating consumers, evident within the Web sites‟ considerable utilization of informational advertising appeals 
and informational rewards. Possibly, the Internet‟s ability to support rich media and the virtually unlimited space on 
the Web sites encourages these manufacturers to employ informational appeals and offer a variety of informational 
rewards. While the data reveal the manufacturers‟ strong usage of interactive elements, the industry can improve by 
fully utilizing the features of the Internet to truly benefit patients as an information source, while attracting 
prospective consumers. While several shortcomings are evident, including the infrequent usage of minority actors 
within the advertisements, the pharmaceutical industry appears to have effectively regulated itself through applying 
the U.S. Food and Drug Administration‟s direct-to-consumer advertising standards for traditional media to the 
World Wide Web.  Implications of these findings for the pharmaceutical industry and the public are discussed, in 













CHAPTER 1. INTRODUCTION 
 
As Americans obtain more prescriptions (Veracity, 31 July 2005, ¶ 4), health care costs have increased 
(Cline & Young, 2004, p. 135), the pharmaceutical industry has become more profitable (Jaramillo, 2006, p. 271), 
and class action lawsuits over allegedly-misleading direct-to-consumer advertisements have become more frequent 
(Willett, 2005, ¶ 12-13). Furthermore, concerned consumers now receive medical information from sources other 
than physicians, such as friends, family, and prescription drug Web sites (Lee, Salmon, & Paek, 2007, p. 17; Von 
Koop et al., 2003, as cited in Macias & Lewis, 2004, p. 43). Thus, research on direct-to-consumer advertising holds 
major implications for the pharmaceutical industry‟s spending habits, consumers‟ consultation of Web sites for 
medical information, mass communicators‟ development of advertising plans for these products, and scholars‟ future 
investigation into this phenomenon. 
While pharmaceutical manufacturers have included direct-to-consumer advertising in their promotional 
activities since the early twentieth century, the implications of the Food and Drug Administration‟s 1997 relaxation 
of the regulations for direct-to-consumer advertising have increased the industry‟s usage of the practices 
significantly. These regulatory changes require direct-to-consumer advertisers to allot equal weight to the risks and 
benefits of the advertised medications, encourage consumers to seek further information through physicians or other 
sources, and persuade consumers to partake in “medically sound” behavior to treat the respective conditions or 
illnesses (21 U.S.C. Sec. 352[n]; 21 C.F.R. Sec. 202.1[e]). Since 1997, pharmaceutical manufacturers have become 
more aggressive in targeting potential consumers by employing many of the strategies and tactics of commercial 
advertisers (Jaramillo, 2006, p. 277), such as using Internet advertising to promote their products directly to 
consumers (Macias & Lewis, 2004, p. 43).  
The Internet‟s excellent interactive capabilities offer considerable opportunities for pharmaceutical 
manufacturers to present advertising messages (Coyle & Thorson, 2001, p. 75). Since Americans‟ adoption of the 
Internet in the mid-1990s (Rainie et al., 2005, p. 57-59), the medium has become a major information source on 
virtually every subject imaginable (Menon, Deshpande, Perri, & Zinhan, 2003, as cited in Huh, DeLorme, & Reid, 
2005, p. 712), including health and wellbeing (Winter, 2007, ¶ 2; Henkel, 2002, as cited in Huh, DeLorme, & Reid, 
2005, p. 712). Some Americans believe that the Internet is a better source for health information than even their 
healthcare providers (Macias & Lewis, 2004, p. 43), likely because of the plethora of content immediately available 






Spain, Siegel, & Ramsey, 2001, as cited in Huh, DeLorme, & Reid, 2005, p. 712), important concerns for consumers 
who want to keep their illnesses confidential.  
Even as early as 1998, prescription medications were among the Internet‟s four most frequently advertised 
product categories (Wilke, 1998, as cited in Huh, DeLorme, & Reid, 2005, p. 712). Manufacturers such as Pfizer 
offer links to product information on their home pages (Pfizer, 2008d), host stand-alone Web sites for their products, 
and strategically advertise on third-party Web sites, especially sites with health-related content, and on popular 
search engines such as Google. In addition, print and broadcast direct-to-consumer advertisements increasingly refer 
consumers to the Web sites of the advertised prescription medications. In 1996, a year before the FDA‟s relaxation 
of the direct-to-consumer regulations, only 14 percent of direct-to-consumer advertisements featured URLs; by 
1998, 57 percent of advertisements offered Web addresses (Wilkes, Bell, & Kravitz, 2000, as cited in Huh, 
DeLorme, & Reid, 2005, p. 712). 
Unfortunately, drug abusers have also discovered the benefits of the World Wide Web; some addicts 
illegally obtain medications through online pharmacies that suspiciously do not require prescriptions. Medications 
available at these online pharmacies include more than lifestyle drugs such as Viagra; users can also obtain 
powerful, addictive painkillers such as Oxycontin and Lortab pills through these sites (Narcanon Southern 
California, 2008, ¶ 2; WLWT, 28 February 2007, ¶ 3). Moreover, many of these online pharmacies are based in 
foreign countries and offer black-market or synthetic versions of drugs approved by the Food and Drug 
Administration (Drug Enforcement Administration Office of Diversion Control, 2008, ¶ 3; WLWT, 28 February 
2007, ¶ 6). According to the U.S. Office of Diversion Control, “patients” qualify for the prescription through an 
online questionnaire instead of a personal consultation, and consumers who purchase controlled medications on the 
Internet may receive jail time because of the absence of a doctor/patient relationship (Drug Enforcement 
Administration Office of Diversion Control, 2008, ¶ 1). Luckily, many of the Internet‟s major search engines, 
including Google, MSN Search, Yahoo!, and AOL Search, have united to combat the potential consequences of 
obtaining medications from online pharmacies by rejecting advertising from these companies (Narcanon Southern 
California, 2008, ¶ 9). The Drug Enforcement Administration also recently launched Operation Cyber Chase, a 
campaign to eliminate online pharmacies operating illegally (Drug Enforcement Administration Office of Diversion 






Americans‟ reliance on the Internet for health information, the increasingly aggressive promotion of 
medications to consumers, and the ubiquity of direct-to-consumer advertising campaigns have captured the attention 
of many social science researchers, mass communication practitioners, governmental agencies, and consumers.  
Especially following the Food and Drug Administration‟s relaxation of the stringent regulations for direct-to-
consumer advertising in 1997, the advertising practices of the pharmaceutical industry have inspired ethical debates 
(Willett, 2005, ¶ 11), concern among consumers (Rockoff, 3 August 2005,  ¶ 9) and voluntary moratoriums 
(Jaramillo, 2006, p. 269; Aikin, 25 October 2005, p. 6; Willett, 2005, ¶ 1).  
 
1.1 Purpose of Study 
 
This quantitative content analysis explores the visual and textual cues which comprise the gain and loss 
frames and the transformational and informational advertising appeals of the home pages of 100 Web sites for 
prescription medications that ranked among IMS Health‟s list of the top-selling drugs in the United States from 
January to December 2006, the most recent data publicly available free-of-charge (Lamb, 2007, p. 34-37). 
Moreover, the present study investigates whether advertisers have capitalized on the unique qualities of the Internet, 
including the medium‟s ability to support features that attract consumers, such as colorful graphics, audio, video, 
and interactive elements. Thus, the present research contributes to the foundation of research on emergent trends in 
Internet promotion of pharmaceuticals and investigates how pharmaceutical manufacturers are encouraging 
consumers to take the necessary steps to obtain prescriptions for the advertised medications.    
Scholars have addressed the need for further research on the advertising tactics used in direct-to-consumer 
campaigns; Roth (2003) notes the scant data on this subject and considers his content analysis on the effects of 
advertisers‟ message strategies on consumers to be “exploratory” (p. 181). The benefits of ongoing research on how 
advertisers utilize the Internet are also noteworthy. First, since the Internet is the most recently developed medium 
available to advertisers, subsequent studies on this communication channel are necessary to satisfactorily establish 
the medium‟s uses and gratifications for both advertisers and consumers. Also, the Internet‟s relatively short lead 
time allows advertisers to update and modify content frequently, so this medium requires continuous monitoring 
because Web content can change considerably in such a short interval (Macias & Lewis, 2004, p. 48). Due to 
advertisers‟ ability to instantly update the sites or add new content as frequently as desired or necessary, academic 






advertisements from the same brand.  For example, Macias and Lewis (2004), whose research framework strongly 
guides this study, compiled data for their content analysis of prescription drug Web sites in March 2001 and 
identified only 90 functioning Web sites for these products (p. 47). Merely seven years after Macias and Lewis‟ 
(2004) study, virtually every top-ranking brand of prescription medications sold in the United States now offers a 
Web site. Ongoing research on direct-to-consumer Internet advertising is crucial because the product selection can 
also change quickly: for instance, the U.S. Food and Drug Administration can withdraw medications from the 
market, manufacturers may discontinue or voluntarily recall products, or drug classes may become obsolete (U.S. 
Food and Drug Administration, 2008a, ¶ 3, 5).  
Since the Internet and direct-to-consumer advertising on the Web are relatively new phenomena, current 
research should incorporate and test existing theories while combining elements from a variety of studies to depict 
how modern pharmaceutical advertisers are communicating with potential customers. Therefore, the present study is 
a composite of influential direct-to-consumer advertising studies conducted over the past five years on the visual and 
textual cues present in these types of campaigns, and will contribute to existing research by illuminating the Internet 
advertising tactics of current pharmaceutical advertisers. The studies which contribute to the present research design 
are recent content analyses of print and Internet direct-to-consumer advertising campaigns which have helped 
researchers, practitioners, and consumers document pharmaceutical manufacturers‟ advertising tactics following the 
Food and Drug Administration‟s 1997 amendments to the once-stringent regulations of the practice (Jaramillo, 
2006, p. 261; see Macias, Pashupati, & Lewis, 2007; Mastin, Andsager, Choi, & Lee, 2007; Young & Cline, 2005; 
Kaphingst, Rudd, Dejong, & Daltroy, 2005; Menon et al., 2003).  
For example, Young & Cline (2005, p. 351), Cline and Young (2004, p. 132), and Macias and Lewis (2004, 
p. 46-47), indicate that frames of direct-to-consumer advertising can be comprised of both visual and textual cues 
that coalesce to communicate the overall message to the audience. The influence of these advertising frames is 
powerful enough to affect viewers‟ attitudes toward a featured product, the parent company, or the entire industry. 
Visual cues common within direct-to-consumer advertising include humans, cartoons, trade characters, body parts, 
the advertised products, and combinations of these subjects (Cline & Young, 2004, p. 137), while textual cues 
pharmaceutical advertisers utilize include instrumental motivational cues and informational rewards to convey 
product risks and benefits to consumers and encourage them to seek additional information (Young & Cline, 2005, 






advertising message strategies pharmaceutical companies employ in direct-to-consumer prescription drug print 
advertisements (p. 181).  
While the samples of Young and Cline (2005, p. 353), Cline and Young (2004, p. 131), and Roth (2003, p. 
183) are direct-to-consumer magazine advertisements, Choi and Lee (2007, p. 138) and Macias and Lewis (2004, p. 
47) examine forms of direct-to-consumer advertising on the Internet such as prescription drug Web sites. For 
example, Choi and Lee (2007) focus on the relationship between how consumers‟ processing of Internet information 
for prescription medications on the Internet determines whether they will speak with their healthcare providers about 
acquiring the advertised medication (p. 138).  
Fewer Internet-focused studies concern the attributes of the Web sites for pharmaceutical products than on 
consumers‟ perceptions of online health information, yet several important studies on prescription medication Web 
sites have emerged. Huh, DeLorme, and Reid (2005) argue that Web sites for prescription medications fail to 
provide the risk data crucial for consumers to make an informed decision about whether to seek a prescription for 
the advertised product because of the Web sites‟ omission of adequate comparative data (p. 712).  Contrastingly, 
Macias and Lewis (2004) found that prescription drug Web sites typically offer risk and benefit data that is more 
substantive than print advertisements, which remain a major expenditure for direct-to-consumer pharmaceutical 
advertisers (p. 43). Like Macias and Lewis‟ (2004, p. 47) study, the objectives of the present research focus upon the 
attributes of the World Wide Web that provide a better opportunity for pharmaceutical manufacturers to tout their 
products than print advertisements, while still providing sufficient information on the risks and potential side effects 
of the advertised medications.   
 
1.2 Significance of Direct-to-Consumer Advertising Research 
 
 
The relationship between the pharmaceutical industry, the Food and Drug Administration, and the mass 
communication field has intrigued many social science researchers since the agency‟s 1997 amendments to the 
regulations on direct-to-consumer advertising. The present study can further contribute to academia‟s understanding 
of the relationship between pharmaceutical companies‟ use of prescription drug Web sites as informational or 
transformational, the visual and textual cues within the direct-to-consumer advertisements, and how this presentation 
may affect patients‟ drug inquiry. In addition, since the academic study of direct-to-consumer advertising on the 






of Roth (2003, p. 181-183), Cline and Young (2004, p. 138-139), Young and Cline (2005, p. 354), and Macias and 
Lewis (2004, p. 46) on the prevalent frames and advertising appeals within the direct-to-consumer advertisements to 
help fortify the foundation for future research on the pharmaceutical industry‟s advertising practices. 
Continuous study of the facets of direct-to-consumer advertising on the Internet can also help the Food and 
Drug Administration evaluate the online practices of pharmaceutical manufacturers, which the agency currently 
does not directly monitor (Knowles, 1997, ¶ 1). Research on the textual and visual cues within direct-to-consumer 
advertisements can also help the U.S. Food and Drug Administration (FDA) examine pharmaceutical advertisers‟ 
claims, as well as determine the necessity of future modifications to the regulations and the scope of these potential 
amendments. Finally, this study may aid New Zealand in anticipating and appropriately responding to future trends 
in direct-to-consumer advertising, since the nation remains the only country other than to the United States to allow 
this type of promotion (Health Action International, 2001, p. 1). This data may also help Britain better evaluate the 
risks and benefits of allowing direct-to-consumer advertising, since the country is currently considering whether to 
permit these practices in the near future (Hoffman & Wilkes, 15 May 1999, ¶ 1).   
In order for pharmaceutical manufacturers to continue investing heavily in research and development—the 
companies devoted $55.2 billion to research and development of biopharmaceuticals in 2007 (Sharer, 2007, p. 4-
5)—these organizations and their shareholders require copious data on potentially misleading advertising messages 
displayed on the drug brands‟ Web sites. Manufacturers can also employ this data to avoid future lawsuits on 
misleading advertising, especially if the results of the present study indicate that manufacturers should offer more 
information on the drug to prospective consumers, despite the absence of Internet advertising regulations from the 
Food and Drug Administration (Knowles, 1997, ¶ 1). 
This study‟s data may also benefit the in-house and contract research organizations of the pharmaceutical 
industry (Yen, 22 June 2001, ¶ 1) by introducing new facets of direct-to-consumer advertising for future study 
(Bodenheimer, 2000, ¶ 1). For example, Takeda Pharmaceuticals utilizes its own in-house research and development 
department (Takeda Pharmaceuticals, 2008, ¶ 2). The industry‟s independent research organizations that may benefit 
include the Kaiser Family Foundation, IMS Health, and the National Institute for Mental Health.  
Health care providers and medical professionals‟ associations may also benefit from this content analysis of 
the visual and textual cues of prescription drug Web sites. The data may enable doctors to anticipate the arguments 






brands.  Medical professionals‟ organizations such as the American Psychological Association, the American 
Psychiatric Association, the American Medical Association, and the Pharmaceutical Researchers and Manufacturers 
of America frequently address direct-to-consumer advertising within their respective publications, ethical codes, and 
Web sites (Pharmaceutical Research and Manufacturers of America [PhRMA], 2008, p. 2). Data from this study can 
potentially help these associations determine whether further modification of their respective criteria for accepting 
pharmaceutical manufacturers‟ advertising for publication in trade journals is necessary. 
Further, since the pharmaceutical industry‟s advertising practices, especially on the World Wide Web, are 
not as established as the tactics of advertisers for mainstream products, categorizing the Web sites‟ content can 
indicate potential areas of improvement to these practices as soon as possible. Improvements in the communication 
tactics of pharmaceutical advertisers will benefit consumers and advertising professionals, in addition to the 
pharmaceutical industry. In addition, this research offers the unique opportunity to examine the campaigns‟ 
attributes which motivate consumers to obtain pharmaceutical manufacturers‟ products, since they are not readily 
accessible like mainstream commercial products (Jaramillo, 2006, p. 262). Research on direct-to-consumer 
marketing can help advertising agencies, especially those specializing in pharmaceutical advertising, avoid potential 
lawsuits for misleading advertising claims or violation letters from the Food and Drug Administration (U.S. Food 
and Drug Administration, 2008c, ¶ 3). Advertising professionals managing pharmaceutical manufacturers‟ accounts 
can also apply this data to subsequent campaigns to accurately present the risks and benefits of the medications, and 
thereby persuade consumers in a more straightforward manner.   
Research on advertising message frames of direct-to-consumer advertising potentially impacts millions of 
American consumers because the visual and textual cues that comprise these frames can shape target audience‟s 
beliefs and attitudes toward the product and advertiser (Cline & Young, 2004, p. 131), while motivating them to ask 
their doctors about the advertised products (Willett, 2005, ¶ 11). A better understanding of direct-to-consumer 
pharmaceutical campaigns can also improve prospective patients‟ abilities to interpret the advertisements‟ 
arguments. Further, ensuring that the frames and appeals identified within the advertising campaigns match the 
advertisers‟ intent may result in better-informed patients who can communicate more effectively with their doctors. 
The knowledge gleaned from this content analysis of prescription medication Web sites may also help awaken the 






Lewis, 2004, p. 46), and help them determine the benefits and risks of accessing prescription medication 






CHAPTER 2. LITERATURE REVIEW 
The proliferation of prescription drug advertising, especially the in-depth information that accompanies the 
campaigns, invites consumers to participate more fully in maintaining their health (Smith, 1998, as cited in Singh & 
Smith, 2005, p. 369), and Ratzan (2007, p. 101), Lee, Salmon, and Paek (2007, p. 107), and Mastin, Andsager, Choi, 
and Lee (2007, p. 49) argue that as prospective patients gain awareness of the prescription medications through 
direct-to-consumer advertising, they are more likely to hold positive attitudes toward these practices. Lee, Salmon, 
and Paek (2007) conducted a survey to assess consumers‟ attitudes toward direct-to-consumer advertising, focusing 
upon consumers‟ sources of health information and consumer socialization (p. 107, 115). The study revealed 
consumers‟ likelihood of holding favorable views increases according to whether they consult their families, friends, 
or the media for health information, as opposed to their physician alone (p. 107). However, Lee, Salmon, and Paek 
(2007) explain that consumers that obtain medical information from the media via direct-to-consumer 
advertisements, as well as their family and friends, are also more likely to inquire about particular pharmaceuticals 
during their doctors‟ appointments (p. 107). 
Numerous studies explore the degree pharmaceutical advertising influences the audience‟s sense of control 
over maintaining their health. For instance, Wilson and Till (2007) identified the correlation between respondents‟ 
interest in health maintenance and the subjects‟ views of direct-to-consumer advertising in their analysis of 
secondary survey data (p. 270). The authors developed and tested a model representing the effectiveness of direct-
to-consumer advertisements by using secondary research: the results of nearly 7,000 telephone surveys administered 
by the Interuniversity Consortium for Political and Social Research (Wilson & Till, 2007, p. 274). According to the 
model, the major influencers in direct-to-consumer advertising‟s effectiveness include the level of respondents‟ 
involvement in their healthcare, in addition to respondents‟ health, education (which also correlates with 
respondents‟ healthcare involvement), age, and attitudes toward the U.S.‟ health care structure (p. 273). After testing 
their model against the survey data, Wilson and Till (2007) concluded that respondents who are most involved in 
maintaining their health are most likely to seek information from their physicians or inquire about the advertised 
medication (p. 278).  
Singh and Smith (2005), who administered a survey to a sample of 288 American men and women to 
determine their attitudes, knowledge, and behavioral intentions regarding direct-to-consumer advertising, concluded 






information‟s “empower[ing]” effects (p. 369). The survey consisted of 50 total questions assessing consumers‟ 
demographics, knowledge of the Food and Drug Administration‟s regulation of the practices of direct-to-consumer 
advertising, their reactions to pharmaceutical advertisements, and their likelihood of drug inquiry (Singh & Smith, 
2005, p. 373). After analyzing the survey results, Singh and Smith (2005) identified the correlation between the 
respondents‟ education and skepticism of direct-to-consumer advertising (p. 374). In addition, the survey showed 
that direct-to-consumer advertising did not make consumers feel more informed regarding their health maintenance, 
and nearly two-thirds of the sample (65 percent) did not think average Americans exposed to pharmaceutical 
advertising would effectively assess the risk and benefit claims contained within the text (p. 374). However, the 
results may have been skewed due to the high percentage of survey respondents who were well-educated: almost 
half (48.6 percent) of the sample held Bachelor‟s, Master‟s, or Ph. D. degrees (p. 373).  
Choi and Lee (2007, p. 141) explored whether consumers who consult drug brands‟ Web sites are more or 
less likely to ask their physicians about those particular prescription drugs by surveying consumers of various age 
groups who were self-reported Internet users. The researchers discovered that respondents who consulted the Web 
for medical information viewed the Internet as a credible source, and were therefore more likely to bring up the 
information during doctor visits (Choi & Lee, 2007, p. 145). In fact, Choi and Lee (2007) assert that respondents 
consider the Internet to be a more credible source for information on prescription medications than traditional media 
such as television and newspapers (p. 145).   
 
2.1 Governmental Regulation and the History of Direct-to-Consumer Advertising 
 
 
The U.S. Food and Drug Administration has regulated the safety of the foods, drugs, and cosmetics 
Americans consume since 1906, when Theodore Roosevelt approved the Pure Federal Food and Drugs Act (U.S. 
Food and Drug Administration, 2006, p. 1). The modern direct-to-consumer advertising practices of the 
pharmaceutical industry have developed from years of cooperation with the Food and Drug Administration (FDA), a 
complex relationship which began in 1938 when the FDA passed the Wheeler-Lea Act to prohibit deceitful 
advertising practices and the Food, Drug, and Cosmetic Act to promote safe labeling practices in response to the 
Elixir “therapeutic disaster” of 1937 (U.S. Food and Drug Administration, 2006, p. 4). The manufacturers of Elixir, 






medication inadvertently killed 100 people (Ballentine, 1981, ¶ 1). According to Ballentine (1981), the Food, Drug, 
and Cosmetic Act became the guiding principle for the Food and Drug Administration‟s subsequent activities (¶ 1).  
The Federal Trade Commission (FTC) regulated pharmaceutical advertising until 1962, when the 
Kefauver-Harris Drug Amendments transferred complete authority to the Food and Drug Administration (U.S. Food 
and Drug Administration, 2006, p. 5). From 1962 through the beginning of the 1980s, much of the governmental 
regulation of direct-to-consumer advertising involved the broadcast media, but pharmaceutical manufacturers‟ 
increasing integration of print media vehicles provoked some of the most dramatic changes in the regulations of 
direct-to-consumer advertising at the time (Jaramillo, 2006, p. 269).  
The FDA Commissioner in the early 1980s, Kenneth Feather, later considered a major turning point in the 
regulation of direct-to-consumer advertising to be the pharmaceutical company Ciba Geigy‟s proposal for a direct-
to-consumer advertisement that “trivialized” the usage of prescription medications (Feather, 1997, as cited in 
Jaramillo, 2006, p. 269). Feather incited the Food and Drug Administration to enact a voluntary moratorium on 
advertising to consumers in 1983 so the agency could determine subsequent regulatory actions for direct-to-
consumer advertising practices (Jaramillo, 2006, p. 269; Aikin, 25 October 2005, ¶ 6). Two years later, after 
extensive research on an audience‟s ability to interpret prescription drug warnings, the FDA ended the moratorium 
and modified its requirements for this type of advertising: direct-to-consumer advertisements needed a “brief 
summary” of the potential side effects of the product (21 U.S.C. 352[n]). Although data on the expenditures of the 
pharmaceutical industry varies somewhat depending on the source, these companies‟ spending ballooned from $11.4 
billion to $29.9 billion between 1996 and 2005 (Donohue, Cevasco, & Rosenthal, 2007, p. 1).   
In 1997, the FDA removed the “brief summary” clause for broadcast advertisements due to the limits of the 
medium, providing that the advertiser directed consumers to another source for additional information on the 
medication (Division of Drug Marketing, Advertising, and Communications, 1999, ¶ 2). Essentially, the FDA 
wanted to ensure that consumers were exposed to the medications‟ labels and risk information (Jaramillo, 2006, p. 
269). In 1999, the agency amended its regulations, requiring “…an information hotline, a recommendation to seek 
supplemental information in print form, a recommendation to seek out a physician to inquire about the drug, a 
[W]eb site, and a „major statement‟ of side effects communicated in a „consumer-friendly‟ manner” (Division of 






The FDA monitors and explores the advertising practices of the pharmaceutical industry by notifying 
companies of their regulatory violations, conducting independent research, and painstakingly reviewing the 
advertising claims of new and existing prescription medications (U.S. Food and Drug Administration, 2006, p. 2). 
While manufacturers voluntarily present these claims within the direct-to-consumer advertising campaigns to the 
Food and Drug Administration for review (Aikin, 25 October 2005, ¶ 18; Roth, 2003, p. 181), the agency does not 
approve the actual direct-to-consumer advertisements (Coleman, Hartley, & Kennamer, 2006, p. 548; Aikin, 25 
October 2005, ¶ 18). Pharmaceutical manufacturers that are incompliant with the Food and Drug Administration‟s 
direct-to-consumer advertising regulations receive violation letters from the agency (U.S. Food and Drug 
Administration, 2008c, ¶ 3; Willett, 2005, ¶ 7), and these companies must meticulously heed the FDA‟s warnings 
because of the agency‟s power to prosecute the companies, recall or seize the products, issue injunctions, or place 
the manufacturers in “administrative detention” (Roth, 2003, p. 181). 
Research indicates that the Food and Drug Administration has become increasingly scrupulous about drug 
approvals following the adverse effects, injuries and deaths caused by patients‟ long-term use of particular 
medications to treat cholesterol and heart disease such as Vioxx (Armstrong, 1 November 2007, ¶ 3, ¶ 5). The 
agency now investigates treatments for chronic illnesses much more closely, and on average, issues a declining 
number of drug approvals per month (Armstrong, 1 November 2007, ¶ 2). The FDA‟s meticulous requirements 
ensure the safety of the medications sold in the United States and that companies can provide consumers with 
extensive information on the risks and benefits of these products (U.S. Food and Drug Administration, 2006, p. 2).  
However, the lengthy approval process can frustrate manufacturers, who are required to await the Food and 
Drug Administration‟s approval prior to launching a direct-to-consumer advertising campaign (Bren, 2007, ¶ 12-13). 
For instance, the agency may issue “approvable letters” which list concerns the companies must address before the 
medication can be approved (Armstrong, 1 November 2007, ¶ 5). Complying with the FDA‟s requests can be 
problematic because of the extensive research the agency may require to address the concerns of the approvable 
letter (Armstrong, 1 November 2007, ¶ 5). For example, Bristol-Meyers Squibb received an approvable letter from 
the FDA about its diabetes treatment, Pargluva, in 2005 (Armstrong, 1 November 2007, ¶ 5). The letter required the 
manufacturer to submit additional research on the cardiovascular impact of the medication, but Bristol-Meyers 
Squibb abandoned its efforts to obtain the FDA‟s approval after realizing that obtaining that data would require an 






Other governmental agencies also help protect consumers from misleading information in direct-to-
consumer campaigns: one of the most recent investigations of direct-to-consumer advertising involves Pfizer, the 
manufacturer of the top-selling cholesterol treatment, Lipitor, and the House Energy and Commerce Subcommittee 
on Oversight and Investigations (“House subcommittee investigates Lipitor ads,” 8 February 2008, ¶ 1). The House 
must determine whether some of Pfizer‟s campaign executions used a stunt double for Lipitor‟s celebrity endorser, 
Robert Jarvik, who developed the artificial heart (“House subcommittee,” 8 February 2008, ¶ 1; Owens, Parks, 
Petyerak, Ibanga, 2008, ¶ 1). The House subcommittee alleges that Pfizer‟s representation of Jarvik as a “medical 
expert” is misleading: he is a medical scientist, not a certified cardiologist or a licensed physician (“House 
subcommittee,” 8 February 2008, ¶ 2). Pfizer has cooperated with the government‟s investigation and voluntarily 
removed the questionable Lipitor advertisements (“Pfizer voluntarily withdraws Lipitor advertising featuring Dr. 
Robert Jarvik,” 25 February 2008, ¶ 1).  
However, some investigations may inadvertently affect the Food and Drug Administration‟s ability to 
regulate direct-to-consumer advertising practices, such as the class action lawsuits consumers use to police the 
industry (Willett, 2005, ¶ 15). Willett (2005) describes the negative implications of this “follow on litigation,” 
defined as class action lawsuits filed by the public against pharmaceutical manufacturers citing damages inflicted by 
the defendants‟ advertising claims (¶ 11). She believes these attempts to “regulate through litigation” undercut the 
U.S. Food and Drug Administration‟s ability to regulate the industry and “…create an unfair burden” for the 
manufacturers involved in the litigation because the company already complied with the FDA‟s regulations in order 
to receive the approval to market the drug (Willett, 2005, ¶ 15).  
For example, in 2001, a group of consumers filed a class action lawsuit against Schering-Plough, the 
manufacturer of Claritin, for false advertising (Willett, 2005, ¶ 17). The New Jersey Supreme Court‟s decision for 
the Claritin trials reflects the reasoning of Willett‟s argument: the court ultimately rejected the petition for 
certification the plaintiffs requested due to the Food and Drug Administration‟s jurisdiction and expertise over the 
issue and the products‟ unavailability to consumers in the absence of a prescription. Unfortunately for the state‟s 
taxpayers, the trial lasted for two years just to reaffirm the FDA‟s decision that the advertisements were permissible 
(Willett, 2005, ¶ 21). 
Consumers also filed a class action lawsuit against Merck & Co. in 2004 for wrongful death and personal 






Vioxx trials are currently in process, the plaintiffs have been less successful than Merck & Co. at convincing the 
jury of the drug‟s harm (Nordqvist, 22 November 2006, ¶ 3). Of the eleven cases that had issued verdicts by 
November 2006, the plaintiffs had won four lawsuits, while Merck & Co. had won seven (Nordqvist, 22 November 
2006, ¶ 11). However, the successful plaintiffs received millions of dollars for their injuries, and since Merck & Co. 
opted to handle each of the 24,000 lawsuits filed within the class action suit individually, the company‟s ultimate 
price will likely be much higher (Nordqvist, 22 November 2006, ¶ 3).  
State agencies can also determine what advertising practices are permitted, although experts cite the 
considerable obstacles to this practice (“Read Two Drug Ads and Call Me in the Morning,” 2002, ¶ 5). Several state 
legislatures have initiated bills regarding the nature of direct-to-consumer advertising; however, many bills die 
before reaching Congress (“Read Two Drug Ads,” 2002, ¶ 8). For example, in 2001, twelve state legislatures 
proposed direct-to-consumer advertising legislation, but only West Virginia adopted the bill as a law. The West 
Virginia statute directs drug manufacturers to disclose advertising expenditures and the subsequent effect on the 
prices of medications to the West Virginia Public Employees Insurance Agency (“Read Two Drug Ads,” 2002, ¶ 5).  
 
2.2 The Direct-to-Consumer Advertising Debate 
 
 
Scholars, pharmaceutical industry representatives, physicians, governmental agencies, and consumer 
groups continue to debate the advertising practices of the pharmaceutical industry (Coleman, Hartley, & Kennamer, 
2006, p. 548; Jaramillo, 2006, p. 270, 273-275). While some studies indicate direct-to-consumer advertising helps to 
fortify consumers‟ role in managing their own healthcare and encourages patients to seek additional information 
from their physicians (Singh & Smith, 2005, p. 371), other research indicates that healthcare costs have risen partly 
because of Americans‟ more frequent doctor visits (Willett, 2005, ¶ 10).   
Further, within the eleven years since the Food and Drug Administration‟s modifications, researchers have 
identified trends within the pharmaceutical industry that coincide with the growth of direct-to-consumer advertising, 
including exponential increases in spending by pharmaceutical companies on advertising and promotion (Huh & 
Langteau, 2007, p. 151; Findlay, 10 September 2002, p. 2), as well as by consumers on prescription medications 
(Veracity, 31 July 2005, ¶ 3; Findlay, 10 September 2002, p. 3). American doctors now prescribe a greater quantity 
of prescriptions to patients: in 1992, the average U.S. citizen held 7.3 prescriptions; by 2000, the average reached 






consumer spending on prescription medications rose considerably from approximately $46.9 billion annually in 
1990 to $140.6 billion in 2001. By 2007, Americans spent nearly $200.7 billion on prescription drugs (Kaiser 
Family Foundation, 2007, p. 1).  
 
2.2.1 Opposition to Direct-to-Consumer Advertising 
 
 
Opponents of direct-to-consumer advertising believe the pharmaceutical manufacturers‟ marketing tactics 
too closely mirror those of commercial advertising (Jaramillo, 2006, p. 272, 277). These critics do not believe 
pharmaceutical manufacturers can successfully balance their profit motives with educating consumers since 
financial goals may discourage these corporations from providing completely thorough information about the 
medications (Bell, Wilkes, & Kravitz, 2000, p. 1092). Moreover, the success of direct-to-physician marketing 
concerns critics of direct-to-consumer advertising because the general public is much more vulnerable to persuasion 
than these well-schooled professionals who are already familiar with the risks associated with the medication (Bell, 
Wilkes, & Kravitz, 2000, p. 1092). 
Jaramillo (2006) believes the tendency of the pharmaceutical industry and the FDA to view direct-to-
consumer advertising as typical commercial advertising for mainstream products ultimately harms consumers, and 
she raises ethical questions about direct-to-consumer advertising in spite of its widespread usage (p. 261, 277). 
Admittedly, the media vehicles of direct-to-consumer advertising of prescription medications and advertising for 
traditional products are identical, including broadcast media such as radio and cable and network television, print 
media such as magazines and newspapers (Jaramillo, 2006, p. 270, 272), and advertising on the Internet (Macias & 
Lewis, 2004, p. 43), including banner advertisements and brand Web sites. 
Just as mainstream advertisers, direct-to-consumer advertisers utilize celebrities, inventors, doctors, 
politicians, and other public figures to promote products (“House Subcommittee Investigates Lipitor Ads,” 8 
February 2008, ¶ 1). Pharmaceutical manufacturers may issue video news releases (VNRs) (see Roche, 2007) to 
television networks, or press releases (see Pfizer, 2008e) to magazines and newspapers. Many companies offer free 
trial periods or samples of the products to prospective consumers (see Eli Lilly & Co., 2007). For instance, Merck‟s 
Viagra offers a Value Card that qualifies consumers to receive their fourth prescription of the year at no charge 






Furthermore, critics question whether the advertisers‟ motives are to aid consumers or to attain more profits 
(Singh & Smith, 2005, p. 371), especially since pharmaceutical manufacturers‟ profits have increased considerably 
since direct-to-consumer advertising was deregulated in 1997 (Jaramillo, 2006, p. 271). According to a Fortune 
Global 500 report, the top ten pharmaceutical manufacturers in 2007 earned profits ranging from approximately 
$11.05 million (Johnson & Johnson) to $4.2 million (Wyeth) (“Fortune Global 500 Industries: Pharmaceuticals,” 23 
July 2007). Controversy over pharmaceutical manufacturers‟ expenditures has also grown following a recent study 
that indicates these companies spent more money on product promotion than on research and development in 2004 
(24.4 percent versus 13.4 percent of each sales dollar) (ScienceDaily, 8 January 2008, ¶ 2).  
The hype and demand created by direct-to-consumer advertising also detracts from the advantages of 
generic medications (Singh & Smith, 2005, p. 371), which often provide the same benefits as the branded 
medications (Jaramillo, 2006, p. 273). Pharmacists at CVS, a national drugstore chain, recommend generic 
medications to patients because the lack of advertising costs results in a lower-priced product (CVS, 2008, ¶ 2). In 
many cases, the same companies that promote the branded medications also manufacture the generic versions, which 
require approval from the Food and Drug Administration just as the branded medications (CVS, 2008, ¶ 3). 
Just as within commercial advertising, the ethics and accuracy of the content of direct-to-consumer 
advertising is debatable (Huh, DeLorme, & Reid, 2004b, p. 570; Macias & Lewis, 2004, p. 43). As Cox, Cox, and 
Zimet (2006, p. 79), and Singh and Smith (2005, p. 372) discuss, critics believe the risk information contained in 
direct-to-consumer arguments is too complex for the average person to comprehend, and therefore patients cannot 
adequately determine the seriousness of the potential complications. Coleman, Hartley, and Kennamer (2006) also 
explain that direct-to-consumer advertising may “false[ly] comfort” consumers who seek health information (p. 
548).  
Further, Singh and Smith (2005) explain that the “…breakthrough advances pharmaceutical manufacturers 
advertise may not be entirely truthful, and that in some cases, older (and more established) treatments may be more 
effective” (p. 369). For example, Anderson (2001) argues that the advertising claims of Searle and Merck (the 
manufacturers of Celebrex and Vioxx, respectively), may have magnified the benefits of the medications: both drugs 
utilize COX-2 specific inhibitors to prevent ulcer development in patients, yet the companies‟ consulting physicians 
explained that not all arthritis sufferers need medications that included COX-2s because of the slight chance of 






COX-2s can benefit all arthritis sufferers when used as a preventative measure and help patients avoid spending 
money on medications to treat side effects from other arthritis medications (Anderson, 2001, p. 453).   
Finally, critics contend that the tendency of direct-to-consumer advertisers to encourage consumers‟ self-
diagnosis can potentially be detrimental to their health if they seek a potentially dangerous or harmful product 
(Singh & Smith, 2005, p. 371). In addition, direct-to-consumer advertising may compromise the traditional doctor-
patient relationship by allowing the consumer more control over his or her healthcare, whereas before the growth of 
this type of advertising, physicians held the ultimate authority over patients (Huh, DeLorme, & Reid, 2004b, p. 570).  
 
2.2.2 Advocacy of Direct-to-Consumer Advertising 
 
 
While prominent advocates of direct-to-consumer advertising include the Food and Drug Administration 
and the U.S. pharmaceutical manufacturers (Coleman, Hartley, & Kennamer, 2006, p. 549), many consumers also 
support the practice. Advocates of direct-to-consumer advertising believe the advertisements provide consumers 
with much-needed information about their health by helping them identify the condition that may be affecting their 
health and encouraging them to visit their doctors (Kaiser Family Foundation, 2003, p. 9). In response to critics‟ 
arguments about manufacturers‟ inability to fully reconcile the goals of profit and consumer education in direct-to-
consumer advertisements, proponents of the practice believe these goals can coexist (Bell, Wilkes, & Kravitz, 2000, 
p. 1092). Advocates believe not only are consumers capable of effectively assessing the risks and benefits of these 
medications, but manufacturers also realize that withholding information ultimately does not benefit them (Bell, 
Wilkes, & Kravitz, 2000, p. 1092). 
Pharmaceutical manufacturers and other proponents of direct-to-consumer advertising believe that arming 
consumers with information on treatment options expands their role in their healthcare (Huh, DeLorme, & Reid, 
2005, p. 790). Further, the U.S. Food and Drug Administration‟s audience research data indicates that consumers 
can indeed process the risks presented within direct-to-consumer advertisements (Jaramillo, 2006, p. 269). 
Proponents argue that information from direct-to-consumer advertising helps patients recognize whether they may 
be suffering from the condition advertised, become knowledgeable about potential treatment options, or increase 
their awareness of alternatives to their current treatments (Huh, DeLorme, & Reid, 2004b, p. 572; Kaiser Family 
Foundation, 2003, p. 9). In addition, the traditional “paternalistic” doctor-patient relationship (Singh & Smith, 2005, 






the time-sensitive nature of this type of advertising can also improve patients‟ healthcare. Consumers no longer must 
rely solely on their doctors to communicate the benefits of a newly introduced medication, since direct-to-consumer 
advertising potentially “bridges the information gap between pharmaceutical companies and doctors/patients” 
(Singh & Smith, 2005, p. 370). 
Moreover, third-party research indicates that direct-to-consumer advertising does not automatically result 
in prescriptions for consumers for the advertised product (Kaiser Family Foundation, 2007, p. 7). The Kaiser Family 
Foundation (2003) reports that direct-to-consumer advertising increases sales of the product category (i.e. arthritis 
treatments), but does not increase sales for particular drugs more than others within the category (p. 7). The report 
surmises that direct-to-consumer advertising potentially “…prompts previously untreated patients to talk to their 
doctors about advertised treatments,” but the doctors do not prescribe the patients the drug they requested (Kaiser 
Family Foundation, 2003, p. 7). However, additional studies on this possibility are necessary in order to make these 
claims with certainty (Kaiser Family Foundation, 2003, p. 7).    
In response to concerns over the rising prices of prescription medications and the profit motives of 
pharmaceutical manufacturers, direct-to-consumer advertising practices may soon change. In November 2007, 
economist James Love of Knowledge Ecology International proposed that the Food and Drug Administration 
replace the patents presented to pharmaceutical companies with cash prizes from an “innovation fund” of $80 billion 
(Simons, 30 November 2007, ¶ 3). Love and his supporters believe this clause would prevent the costs of 
prescription drugs from continuing to rise: since the drugs would not be patent-protected, other manufacturers could 
develop their own versions, creating competition which would eventually decrease the market price of the products 
(Simons, 30 November 2007, ¶ 3). Love explains that the federal government can recoup the cost of the “innovation 
fund” over time since it will no longer pay high prices for these products through the Medicare program (Simons, 30 
November 2007, ¶ 14). 
Finally, the increased reliance on the Internet by pharmaceutical manufacturers to disseminate product data 
and by consumers to retrieve health information further intensifies the debate over the attributes of direct-to-
consumer advertising. Currently, 80 percent of Americans habitually access the Internet for health information (Von 
Koop et al., 2003, as cited in Macias & Lewis, 2004, p. 43), and the World Wide Web has recently become a 
substantial tool for pharmaceutical advertisers to promote prescription medications. Unfortunately, neither 






direct-to-consumer advertising on the Internet to ensure that all relevant information is included on prescription 
medication Web sites; while the agency has established regulations for print and broadcast direct-to-consumer 
advertisements, no guidelines exist for Internet advertising of prescription medications (Knowles, 1997, ¶ 1).  
As Neil Postman writes in Amusing Ourselves to Death (1986), the limits inherent within each mass 
communication medium determine the quality of the information presented to consumers (p. 6). Thus, 
pharmaceutical manufacturers‟ widespread usage of the Internet to reach consumers may foreshadow future changes 
to the Food and Drug Administration‟s regulations, since modifications to its policies on direct-to-consumer 
advertising typically are responses to trends in the dominant media vehicles of direct-to-consumer advertising.  
 
2.3 Direct-to-Consumer Advertising on the Internet 
 
 
Internet advertisers‟ ultimate objective is to attract consumers to the products‟ home pages to elicit an array 
of potential behavioral responses (Cox, Cox, & Zimet, 2006, p. 47). Message characteristics of Internet advertising 
which may influence consumers‟ motivation, opportunity, and ability to process messages include “ . . . attention 
devices, encoding variability, message framing, and choice of message mood tone” (Cox, Cox, & Zimet, 2006, p. 
47).  Researchers have identified several message strategies of direct-to-consumer advertisements on the Internet 
(Macias & Lewis, 2004, p. 49). Macias and Lewis (2004), who examined the interactive characteristics of 90 
prescription medication Web sites, found that direct-to-consumer advertisements utilized a greater quantity of 
monetary inducements than commercial advertisements (p. 49). In addition, Cox, Cox, and Zimet (2006) have 
identified Internet advertising strategies such as “popups,” “popunders,” banner advertisements, sponsorship Web 
sites, viral messaging, and home pages (p. 47). Sponsorship Web sites are essentially editorials about the particular 
product, while viral messaging, which has only recently emerged among these more established Internet advertising 
vehicles, is deliberate e-mail marketing between consumers (Cox, Cox, & Zimet, 2006, p. 47).   
For consumers seeking health information, a major appeal of the Internet is the abundant Web sites that 
provide detailed health-related content free-of-charge to Internet users. For instance, the Mayo Clinic offers an 
interactive guide to help patients identify the condition from which they are suffering by requesting users to mark 
their symptoms on a checklist (Mayo Clinic, 2008, ¶ 1). After the Mayo Clinic‟s interactive guide narrows down 
patients‟ possible illnesses, the site offers users multiple pages of information about the plausible conditions, their 






Medicine Web site offers free “podcasts,” downloadable educational health videos that are viewable on users‟ 
portable media devices (Winter, 1 October 2007, ¶ 1). The Cleveland Clinic‟s Health Edge videos are also a popular 
source for educational health videos, boasting 8,000 subscribers in 2007 (Winter, 1 October 2007, ¶ 10). Finally, 
Microsoft Corporation also became a host of health information in late 2007 by unveiling its search engine and 
information portal called “Health Vault” (“Health care: The vault is open,” 4 October 2007, ¶ 3). Health Vault‟s 
search engine capabilities and customizable home pages allow advertisers to target consumers based on the 
particular information they seek (“Health care,” 4 October 2007, ¶ 7). 
Since the Internet has become such a valuable resource for Americans concerned about their health (Macias 
& Lewis, 2004, p. 43), direct-to-consumer Internet advertising accounts for an increasingly large portion of 
pharmaceutical advertisers‟ media mix (Putrevu & Lord, 2003, p. 45). Von Koop et al.‟s (2003, as cited in Macias & 
Lewis 2004, p. 43) survey of patients‟ usage of the Internet to obtain health information showed that 80 percent of 
consumers consult the Web, and nearly all of those respondents reported a better comprehension of their respective 
conditions afterwards. In fact, of the consumers who are the most heavily involved in their medical treatment, 
slightly more patients chose the Internet over their healthcare provider as their primary source for medical 
information (Von Koop et al., 2003, as cited in Macias & Lewis, 2004, p. 43). Therefore, the content of these 
product Web sites and the quality of the information hold significant implications for the majority of American 
consumers who retrieve health information from these sites. Unfortunately, even though the U.S. Food and Drug 
Administration has modified the regulations on direct-to-consumer advertising after Americans‟ adoption of the 
Internet in the 1990s, specific parameters do not yet exist for direct-to-consumer advertising on the Internet 
(Knowles, 1997, ¶ 1).  
Regardless of the absence of the Food and Drug Administration‟s regulations on direct-to-consumer 
advertising on the Internet, advertisers have capitalized on the interactive features of the World Wide Web. 
Novartis‟ Fluvirin campaign in September 2007 emphasizes the freedom and creativity the Internet allows 
pharmaceutical advertisers if they adopt “Web 2.0,” a more innovative approach to advertising on the Internet that 
encourages the use of rich media content like audio and video (Donnelly, 1 February 2008, ¶ 4). Novartis and its 
advertising agency, Cadient, developed an Internet-based contest hosted on YouTube, a popular video-sharing site, 
to promote Fluvirin, Novartis‟ vaccine for the influenza virus (Donnelly, 1 February 2008, ¶ 1). The pharmaceutical 






affected their lives, and the first-place winner in each of the three categories received $500 (Donnelly, 1 February 
2008, ¶ 1).  
The campaign was immensely successful: the contest drew 12,000 viewers and Novartis‟ sample entries 
attracted 800,000 users (Donnelly, 1 February 2008, ¶ 9). The employees of Novartis‟ agency Cadient note how 
much easier placing the video contest on YouTube was than if the agency would have promoted the competition via 
Novartis‟ Web site or a health-related site (Donnelly, 1 February 2008, ¶ 4). While the contest was unbranded, 
Novartis provided a hyperlink to information about its vaccine (Donnelly, 1 February 2008, ¶ 5), and users could 
view the commercials for numerous branded pharmaceutical products, in addition to the Fluvirin advertisements 
(Donnelly, 1 February 2008, ¶ 4). This campaign illustrates pharmaceutical manufacturers‟ eagerness to convey 
advertising messages through many different methods, and the Internet provides nearly limitless possibilities. 
 
2.3.1 Interactivity of Web Sites 
 
 
Coyle and Thorson (2001) believe the nontraditional medium of the Internet is capable of dramatically 
changing users‟ experience in evaluating products and developing attitudes toward brands (p. 75). The World Wide 
Web has steadily gained importance within the branding sector of the advertising industry (Hansell, 1998, as cited in 
Coyle & Thorson, 2001, p. 65) partially due to the medium‟s ability to present users with a more realistic experience 
than traditional media through interactive rich media (Coyle & Thorson, 2001, p. 65). Rich media engage users‟ 
senses through video, audio, and animation, and have become integral to many Internet advertisers‟ repertoires 
(Hansell, 1998, as cited in Coyle & Thorson, 2001, p. 65).  
The vividness and interactive qualities of the rich media on the Internet can create a virtual world that can 
potentially prevail over users‟ reality, a phenomenon called telepresence (Coyle & Thorson, 2001, p. 66). Vividness 
refers to the medium‟s ability to simulate reality through stimulating users‟ senses, and Coyle and Thorson (2001) 
believe animated graphics, video, and audio contribute significantly to the vividness of a medium (p. 68). 
Essentially, the greater number of senses the medium can arouse, the more vivid the experience becomes to users 
(Coyle & Thorson, 2001, p. 68).   
Communication researchers offer several interpretations of the concept of interactivity. For instance, Steuer 
(1992, p. 84, as cited in Coyle & Thorson, 2001, p. 67) equates the term with the users‟ ability to “modif[y] the form 






p. 3, as cited in Coyle & Thorson, 2001, p. 65) believe “interactivity” refers to the interrelatedness or consistency 
within a progression of messages, while Blattberg and Deighton (1991, as cited in Coyle & Thorson, 2001, p. 65) 
argue that interactivity facilitates direct communication unbound by space or time. Coyle and Thorson (2001) 
maintain that many Web sites‟ usage of metaphors communicates the advertisers‟ comfort with the interactive 
capabilities of this nontraditional medium: the authors cite Alligator Records‟ Web site, which features a virtual 
downtown scene with “clubs” users can enter to hear the record label‟s artists (p. 67). McMillan and Hwang (2002) 
agree that a Web site‟s layout, especially the inclusion of extensive interactive elements or graphics, can affect the 
users‟ inclination to spend time on the site by causing slow loading (as cited in Starr, 2006, p. 16). Coyle and 
Thorson (2001) also argue against the usage of extensive graphics, which can make the site appear too “busy” and 
may affect viewers‟ desire to remain on the site (p. 67-68).  
Coyle and Thorson (2001) tested the effects of varying levels of interactivity and vividness on users‟ 
attitudes toward Web sites experimentally (p. 68). The researchers posited that the highly vivid and extremely 
interactive Web sites would cultivate the most significant changes in attitudes, since these dimensions help cultivate 
the medium‟s telepresence and create a more realistic experience for users (p. 68). The researchers presented 68 
subjects with sixteen variations of four Web sites, each using different levels of audio, animation, choice ability, and 
mapping (the latter two variables are dimensions of interactivity). To the surprise of the researchers, only Web sites 
with high levels of vividness—and not those using high interactive levels—produced statistically-significant 
changes in the respondents‟ attitudes toward the Web site (Coyle & Thorson, 2001, p. 75). Despite these findings, 
Coyle and Thorson (2001) encourage further research on the effects of these dimensions of nontraditional media, as 
well as advertisers‟ usage of the Internet for marketing products in general (p. 75).  
Macias and Lewis (2004) used specific criteria to determine each Web site‟s interactivity in their content 
analysis of 90 prescription medication Web sites (p. 51). Interactive content on Web sites is designed to attract 
consumers, encourage them to further explore the Web site, and convey advertising messages (Macias & Lewis, 
2004, p. 44). Due to the Internet‟s capability to host interactive features and rich media, the authors argue that 
prescription medication Web sites may meet the Food and Drug Administration‟s criteria for pharmaceutical 
advertising more easily than traditional media (Macias & Lewis, 2004, p. 44). Interactive content on a prescription 
medication Web site may include quizzes for the viewer of the advertisement, live chat or instant message, message 






newsletters, glossaries, frequently-asked questions, and site maps within their content analysis of prescription 
medication Web sites, but also reported a variety of unclassifiable interactive elements such as pollen forecasts and 
flu reports (p. 51). The researchers had predicted the importance of this category early in their report, since they 
anticipated they would encounter many items that did not fit well into the existing categories for this variable 
(Macias & Lewis, 2004, p. 48).  
 
RQ1.  What percentage of the prescription medication Web sites included in the study uses each of the following 
interactive features: quizzes, live chat, message boards, videos, audio, text-size adjustments, animated 
graphics, e-mail updates/newsletters, frequently-asked questions, glossaries, site maps, or other? 
 
 
2.4 Framing through Textual Cues 
 
The appeals, strategies, and visual and textual cues of this type of advertising present challenges best 
addressed by framing theory, which originated within motivational psychology. Framing theory examines the 
techniques advertisers use to construct messages, the qualities and effectiveness of “approach” versus “avoidance” 
frames, and the effects of framed messages on an audience (Wedell, 1997, as cited in Tsai 2007, p. 364). Entman 
(1993), the first mass communication researcher to apply framing to the media, links frames to the potential power 
of the text‟s ideas on the audience (p. 51). Due to framing‟s capacity to strongly influence the audience, he 
encourages scholars to develop a more comprehensive understanding of the paradigm in order to contribute to the 
foundation of mass communication research (Entman, 1993, p. 51).  
Entman (1993) maintains that frames seek to “diagnose, evaluate, and prescribe” (p. 52). Frames are 
typically difficult to detect due to their subtlety and cannot be immediately classified as “positive” or “negative” 
without accounting for the many contributing factors within the frame‟s context (Entman, 1993, p. 52). In addition, 
Vasterman (2005) explains that authors can subconsciously transmit frames: “Selective perception prevails; news 
that seems to confirm the chosen frame will be reported, while other facts and opinions are neglected…” (p. 514). 
Positive (“approach”) frames emphasize the benefits the consumer gains through purchasing the brand, 
while negative (“avoidance”) frames communicate how the brand can help the consumer avoid pain or 
psychological losses (Tsai, 2007, p. 364). News frames are present within the text itself, and consumers use their 







While many advertisers use media frames to effectively communicate with the consumer, the type of frame 
that is most effective for accomplishing the advertisers‟ goals depends upon the characteristics of the target audience 
(Tsai, 2007, p. 367; Cox, Cox, & Zimet, 2006, p. 81). Consumers‟ receptivity to advertising frames depends upon 
how motivated they are to interpret the message, whether they have the opportunity to do so, and how skillfully they 
are able to decode the information (MacInnis et al., 1991, as cited in Cox, Cox, & Zimet, 2006, p. 47). Although 
much of the research on positive versus negative framing is conflicting, studies consistently show that negative 
framing works best on consumers with “high processing motivation” or who are highly-involved in the decision-
making process (Tsai, 2007, p. 366).  Within the advertising realm, consumers with high processing motivation have 
developed solid schema on the arguments of the advertisement (Tsai, 2007, p. 367), and are invested in evaluating 
the logic of the argument because the issue is personally relevant or they have an acute need to process the 
information. For instance, college students would be less highly motivated to process the arguments of an 
advertisement citing their personal risk of Alzheimer‟s disease than an audience comprised of people over 60 years 
old.   
While framing theory frequently guides the research of mass communication scholars (see D‟Angelo, 2002; 
De Vreese, Peter, & Semetko, 2001; Entman, 1993), considerably less research examines the framing practices of 
direct-to-consumer advertising in nontraditional media such as the Internet. In addition, the Internet‟s development 
and widespread usage seems to parallel the growth of direct-to-consumer advertising over the previous eleven years, 
and examining the relationship between these forms of communication may uncover trends not yet visible or present 
within the executions designed for traditional media.     
 
2.4.1 Framing in the Pharmaceutical Industry    
 
 
Pharmaceutical marketers recognize the importance of communicating early detection behaviors to 
consumers, especially with the symptom-free or rapid onset of many potentially life-threatening or chronic diseases. 
Often, these companies convey the dangers of ignorance to consumers through positive, negative, or combined 
framing of advertising messages (Cox & Cox, 2001, p. 91). In fact, pharmaceutical companies‟ frames are often 
dominant enough to reach national news coverage (Coleman, Hartley, & Kennamer, 2006, p. 548-549). Coleman, 
Hartley, and Kennamer (2006) analyzed the frames of national newspapers‟ coverage of prescription drugs and 






technology; drawbacks; doctor-patient relationship, and cost” (p. 556). By identifying these frames, the researchers 
outlined the pharmaceutical industry‟s role in “framing the debate” over direct-to-consumer advertising (p. 558). 
While the researchers found that reporters of these newspapers used “drawback” frames most often, they used 
“benefits” frames nearly as often, indicating their attempt to balance the coverage (Coleman, Hartley, & Kennamer, 
2006, p. 555-556). Most of the frames of pharmaceutical industry sources focused on the power relationship with the 
Food and Drug Administration, yet these sources presented benefits frames almost as frequently (Coleman, Hartley, 
& Kennamer, 2006, p. 554). When the newspapers cited the Food and Drug Administration as a source, benefits 
frames were most prevalent (Coleman, Hartley, & Kennamer, 2006, p. 556).  
Anderson (2001) compared the frames within the corporate press releases for Celebrex and Vioxx to the 
subsequent news coverage of Searle and Merck & Co., the respective manufacturers of the medications (p. 452). The 
first frame Anderson (2001) recorded was “painkiller without side effects” (p. 452), followed by cost frames, and 
finally by the positioning frame which helped Merck & Co. and Searle position the items within the news coverage 
as desired (p. 453).  Even though over a third of the news stories were coded as “neutral,” Anderson (2001) noted 
the companies‟ relative success in setting the agenda for the coverage, since four times as many stories presented 
“favorable” rather than “unfavorable” coverage (p. 452). The framing techniques Searle and Merck & Co. employed 
in their respective press releases helped both companies foster positive consumer attitudes towards the brands and 
also generated impressive sales (Anderson, 2001, p. 452).  
The risks inherent in taking prescription drug medications inspired the research of Cox, Cox, and Zimet 
(2006), who examined how consumers process the product risk information included in direct-to-consumer 
advertisements based upon the gain- or loss-framing of the messages (p. 80, 82-83). Cox, Cox, and Zimet (2006) 
conducted two experiments to test how gain- and loss-framed advertisements affected consumers‟ reactions to risk 
information: the topic of the first experiment was skin cancer, while the topic of the second was Hepatitis-B (p. 83, 
86). In both experiments, the authors presented gain- and loss-framed messages for both detection and prevention 
products to respondents: the advertisements for detection products encouraged consumers to get tested to determine 
whether they may be affected, while the advertisements for the prevention products explains the benefits of using 
the product to ward off future negative outcomes (Cox, Cox, & Zimet, 2006, p. 84, 87). Contrary to their 
hypotheses, Cox, Cox, and Zimet (2006) discovered that loss-framed messages did not encourage consumers‟ “risk-






consumers‟ “risk avoidance” behavior or their use of the prevention products (p. 88).  Instead, the authors report that 
loss-framed messages elicited reluctance in both sets of respondents to engage in risk-seeking behavior (both 
immediately and in the long-term). In addition, Cox, Cox, and Zimet (2006) did not observe any difference in 
respondents‟ behavioral intentions after exposure to the prevention products and the detection products (p. 88).  
Contrastingly, Lauver and Rubin (1990, as cited in Cox & Cox, 2001, p. 91) found no conclusive evidence 
on the effectiveness of either type of framing, Banks et al. (1995, as cited in Cox & Cox, 2001, p. 91) cite the 
persuasiveness of loss framing, and Rothman et al. (1993, as cited in Cox & Cox, 2001, p. 92) argue that gain 
framing is more effective. However, when researchers accounted for the involvement of subjects, the effectiveness 
of these types of frames became more evident.  
Although some media scholars believe positively framed (gain) messages elicit a similar type of response 
from consumers, other researchers suggest that negatively framed messages encourage cognitive elaboration among 
respondents, which is both an important factor in message evaluation and may lead to eventual acceptance of the 
advertising message (Tsai, 2007, p. 365). Rothman and Solvey‟s 1997 experiment (as cited in Cox & Cox, 2001, p. 
93) uncovered the effect of the type of health behavior advocated (disease detection versus prevention) on the 
persuasiveness of gain versus loss-framed messages. Disease-detection messages were more effective when framed 
negatively, as opposed to prevention messages, which were more persuasive when framed positively (Cox & Cox, 
2001, p. 93). Rothman and Solvey (1997, as cited in Cox & Cox, 2001, p. 93) discussed potential causes for the 
varying effectiveness of gain and loss frames for the promotion of disease-detection versus prevention behaviors, 
including respondents‟ existing associations with the behavior and probable negative perception of detection 
behaviors. Despite the audience‟s likely negative associations with the disease-detection behavior, the authors 
believe reminding consumers that the potential negative outcomes of the illness are much worse than the distress 
elicited by the disease-detection behavior (Cox & Cox, 2001, p. 93).  
However, Tsai (2007) explains that data is conclusive regarding the gain/loss frame and high-involvement 
topics, such as the risk information on prescription medications (p. 364). Tsai (2007, p. 364) and Maheswaran and 
Meyers-Levy (1990, as cited in Cox & Cox, 2001, p. 92) discovered that loss-framed messages persuade highly 
involved respondents more effectively than gain-framed messages. For instance, consumers who believe a medical 
condition directly applies to them report the loss-framed messages to be more persuasive (Cox & Cox, 2001, p. 92). 






H1.  A greater number of the direct-to-consumer Web sites for pharmaceutical medications included in the 
  study will contain more dominant loss (risk) frames than dominant gain (benefit) frames.  
 
 
To examine the information quality of direct-to-consumer prescription drug Web sites, Macias and Lewis 
(2004, p. 45) used a scale employed by Bell, Wilkes, and Kravitz (2000, p. 331) to group the medical information. 
Bell, Kravitz, and Wilkes (2000) conducted a content analysis of 320 direct-to-consumer advertisements for 
prescription medications from magazines from 1989-1998 (p. 329). While the frequencies of the fifteen conditions 
are not directly comparable to the present study due to Bell, Kravitz, and Wilkes‟ (2000) inclusion of multiple 
advertisements of the same brands (p. 332), understanding which conditions appeared most often within the 
magazines in their study underscores the importance of direct-to-consumer advertising for that brand during the 
nine-year time period. The frequencies of each of the medical conditions for Bell, Kravitz, and Wilkes‟ (2000) study 
were: allergies (n = 46), obstetric/gynecologic (n = 45), dermatologic (n = 37), cardiovascular (n = 36), HIV/AIDS 
(n = 33), tobacco addiction (n = 23), urologic (n = 19), musculoskeletal (n = 17), gastrointestinal-nutritional (n = 
17), and psychiatric-neurological (n = 17), infectious (non-HIV) (n = 16), diabetes (n = 9), respiratory (n = 3), and 
cancer (n = 2) (p. 332-334). Bell, Kravitz, and Wilkes (2000) also noted the increase in direct-to-consumer 
advertising of medications for chronic, potentially dangerous conditions such as diabetes and HIV/AIDS over the 
nine-year period: 75 percent of the brands (n = 101) within the sample treated these types of conditions (p. 334).  
Of the 90 prescription medication Web sites of Macias and Lewis‟ (2004) study, the most frequently 
occurring condition was psychiatric/neurological disorders (n = 14) (p. 48). Treatments for this condition included 
brands such as Aricept, Wellbutrin, and Zoloft (p. 48).  The least frequently occurring medical conditions in Macias 
and Lewis‟ (2004) study included cancer, diabetes, gastrointestinal conditions, and tobacco addiction (n = 2) (p. 48).  
 
RQ2.  Of the 15 medical conditions the Web sites in this study are classified into, which medical condition uses 
 loss/risk frames most often? 
 
 
2.4.2 Advertising Appeals 
 
 
According to Macias and Lewis (2004), the goal of direct-to-consumer advertising appeals is to convince 
and motivate the audience to act: to ask their physicians about the brand, discuss treatment options with their friends 






informational CDs or DVDs (p. 46). Both Macias and Lewis (2004, p. 46-67) and Roth (2003, p. 182) classified the 
advertising appeals within their respective content analyses as transformational or informational.  
The transformational appeals Macias and Lewis (2004) discuss are considered emotional appeals, and 
typically utilize “warmth, humor, or fear” to convey the advertising message (p. 46). According to the elaboration 
likelihood model proposed by Petty and Cacioppo (1986), transformational appeals are most conducive to peripheral 
processing, which does not elicit high elaboration (consideration) from the audience because the arguments are less 
likely to be evaluated rationally (p. 125, 128). The other appeal Macias and Lewis (2004) cite within direct-to-
consumer advertisements is the informational appeal, which includes “comparative advertising, open versus close-
ended comparisons, and one versus two-sided comparisons” (p. 46). In contrast to emotional or transformational 
appeals, consumers evaluate informational appeals through central processing methods, meaning that they focus on 
and evaluate the logic of the argument. Therefore, in the case of direct-to-consumer advertisements, transformational 
appeals may negatively affect consumers‟ ability to process the arguments, which could be detrimental to their 
information gathering for such a high involvement decision as choosing to take a prescription medication. Macias 
and Lewis (2004) explain that informational appeals include “…comparative advertising, open versus close-ended 
comparisons and one versus two-sided comparisons” (p. 46). Woloshin et al. (2001, as cited in Macias & Lewis, 
2004, p. 45-46) have uncovered considerably more instances of emotional appeals and ambiguous language in 
direct-to-consumer print advertisements than scientific data (67 percent, 87 percent, and 50 percent, respectively). 
In Roth‟s (2003) content analysis of the advertising appeals within 143 different magazine advertisements 
for prescription medications, he hypothesized that the direct-to-consumer magazine advertisements in his study 
would feature more informational appeals than transformational appeals. Roth‟s (2003) data confirmed his 
assumption: 81 percent of his sample was coded as “Informational only,” while 19 percent was coded as 
“Transformational only” (p. 186). Another major element of Roth‟s (2003) study concerned the effectiveness of the 
advertising messages with the transformational or informational appeals (p. 182). However, he discovered that the 
transformational strategy, which communicates happiness and social approval, was more effective than the 
informational strategy in terms of advertising awareness (p. 187). The informational strategy alone, which contained 
disease and symptom information, was negatively correlated with advertising awareness (p. 186). 
Despite the negative association with advertising awareness Roth (2003, p. 186) discovered in his study of 






Web sites indicate that the informational advertising appeal was used more frequently than the transformational 
appeal. Consequently, Macias and Lewis (2004, p. 53) also discovered that the risk information on the Web sites 
was more extensive than in Bell, Wilkes, and Kravitz‟s (2000) content analysis on print advertisements. 
 
H2.  A greater number of the direct-to-consumer Web sites for pharmaceutical medications included in the study 




The researcher adopted only the advertising appeals portion of Roth‟s (2003) study because the other 
variables did not correspond to the present study. For example, while advertising awareness is a major variable in 
Roth‟s (2003, p. 183) research, the variable was not included in the present study. Secondly, Roth‟s (2003) sample 
consisted of magazine advertisements (p. 183), and much more data on advertising awareness exists on print 
campaigns than on Internet direct-to-consumer advertising. Finally, even if the researcher had chosen to replicate 
Roth‟s (2003) study entirely, his use of secondary data instead of original research to determine advertising 
awareness (p. 183) decreased the credibility of his study.  In addition, the secondary data Roth (2003) consulted to 
determine the effects of direct-to-consumer advertising on awareness consisted of “field studies” each year from 
1996 to December 1999 (p. 183). While compiling longitudinal data improves the reliability of the data, Roth‟s 
study was published in 2003, when even the newest data set was four years old (p. 183).  
 
RQ3. Of the 15 medical conditions the Web sites in this study are classified into, which medical condition uses 
 informational advertising appeals most often?  
 
 
2.4.3 Instrumental Motivational Cues 
 
 Advertisers employ various instrumental motivational cues within the text of the campaigns to encourage 
the audience to take action. Young and Cline (2005), who assessed the texts of 225 magazine advertisements for 
prescription medications, define instrumental motivational cues as incentives such as the informational rewards, 
medical rewards, and instrumental punishments that help communicate the drug‟s benefits to consumers and 
encourage drug inquiry (p. 355). Macias and Lewis (2004) believe Bell, Kravitz, and Wilkes (2000, as cited in 
Macias & Lewis, 2004, p. 45) contributed significantly to the study of direct-to-consumer advertising by identifying 
these coupons and other incentives as “inducements,” and categorizing the persuasive appeals the pharmaceutical 






Macias and Lewis (2004) categorized reminder cards, free samples, free trials, and vouchers or coupons as 
inducements, and discovered through their content analysis of 90 direct-to-consumer Web sites that over half 
included financial motivators such as “money-saving offers, books and monographs, reimbursements, and gift 
certificates for completing patient feedback surveys” (p. 49). Interestingly, only 2.7 percent of the Web sites in 
Macias and Lewis‟ (2004) study offered programs designed to support consumers in their treatment; examples 
include the e-mail-based Zyban Advantage program and weight management plans (p. 49). In response to the lack of 
patient support programs, the authors argue that a primary purpose of the Web sites should be to assist and support 
consumers in their decisions regarding treatment options through offering detailed information and forums for 
consumers‟ queries (Macias & Lewis, 2004, p. 49). 
Macias and Lewis (2004, p. 43) partially developed their research design from Bell, Kravitz, and Wilkes‟ 
(2000, p. 329) study, although these teams of researchers utilized different types of samples (direct-to-consumer 
Web sites versus print advertisements). Bell, Kravitz, and Wilkes (2000) content-analyzed 101 unique print 
advertisements for prescription medication brands published in magazines from 1989-1998; however, much of the 
data presented is for the total of 320 advertisements within the study (p. 333). Within Bell, Kravitz, and Wilkes‟ 
(2000) study, the print advertisements‟ usage of inducements was varied: less than 9 percent of the brands advertised 
offered rebates, 4 percent offered free samples, and 3 percent of the brands presented money-back guarantees (p. 
333). According to the authors, 39 percent volunteered additional information, including printed materials or 
video/audio (p. 333). Overall, 17 percent of the brands mentioned one or more incentives within the advertisements 
(Bell, Kravitz, & Wilkes, 2000, p. 333).  
 
Informational Rewards. Informational rewards are textual cues which motivate patients to seek  
information through toll-free phone numbers (Young & Cline, 2005, p. 355), subscribing to e-mails or newsletters, 
joining patient support groups, and sending for informational DVDs or CDs, brochures, or binders (Macias & Lewis, 
2004, p. 49). Other informational rewards include links to the brands‟ or companies‟ press releases, news coverage, 
and third-party editorials or Web sites sponsoring the products (Young & Cline, 2005, p. 355). Young and Cline 
(2005) reported that almost all (97 percent) of the print advertisements included in their study offered one type of 
informational reward, and many offered as many as three types (p. 357-358). Macias and Lewis (2004) discovered 






Bell, Kravitz, and Wilkes (2000) reported similar findings (p. 333). When grouped by condition, nearly half 
of the total advertisements for allergy medications provided information offers, while 46 percent offered monetary 
inducements (Bell, Kravitz, & Wilkes, 2000, p. 333). All of the cancer medications (100 percent) within their study 
volunteered additional information to users, followed by over half (52 percent) of tobacco addiction treatments, 48 
percent of allergy treatments, 46 percent of dermatologic medications, and 44 percent of cardiovascular medicines 
(p. 333). Forty-two percent of urologic medications, in addition to 40 percent of obstetric-gynecologic drugs, 33 
percent of diabetes and respiratory medications, and 18 percent of musculoskeletal and psychiatric-neurological 
treatments, included “additional information” offers in the advertisements (Bell, Kravitz, & Wilkes, 2000, p. 333). 
Thirteen percent of infectious (non-HIV) medicines, as well as 12 percent of gastrointestinal-nutritional drugs and 6 
percent of HIV/AIDS medications, also offered additional information (p. 333).  
While thirty percent of tobacco addiction medications and 5 percent of urologic drugs provided patient 
support, none of the other conditions offered this service (Bell, Kravitz, & Wilkes, 2000, p. 333). Over two-thirds of 
respiratory medicines offered monetary inducements, followed by 46 percent of allergy medications, 41 percent of 
dermatologic drugs, 16 percent of obstetric-gynecologic medicines, and 13 percent of infectious (non-HIV) 
treatments (p. 333). Smaller percentages of the other conditions offered financial inducements, including 9 percent 
of tobacco addiction treatments, 6 percent of cardiovascular, musculoskeletal, and psychiatric-neurological 
medications, and 5 percent of urologic medicines (Bell, Kravitz, & Wilkes, 2000, p. 333).   
Bell, Wilkes, and Kravitz (2000) used a similar sample of 101 unique direct-to-consumer print 
advertisements (320 total executions) to explore the educational value of direct-to-consumer advertisements of 
prescription medications (p. 1092). The researchers examined the presence of five types of medical condition 
information, including the identification of the particular condition, misconceptions, precursors, prevalence, and 
symptoms; in addition, Bell, Wilkes, and Kravitz (2000) identified treatment information present within the 
advertisements, including competing treatments, mechanisms of action, success rates, supportive behaviors, time 
required for the medications‟ onset, and the duration of treatment (p. 1094). The researchers concluded that while 
the direct-to-consumer print advertisements were informative overall, most of the information was “superficial” (p. 
1096) and could be improved dramatically (p. 1092).  
Of Bell, Wilkes, and Kravitz‟ (2000) condition information codes, 95 percent of the 320 total print 






advertisements included symptom information (p. 1095). However, less than 30 percent mentioned precursors to the 
condition, roughly 12 percent mentioned the condition‟s prevalence, and only 9 percent provided misconceptions (p. 
1095). Regarding the treatment information categories of Bell, Wilkes, and Kravitz‟ (2000) study, 36 percent 
explained how the medications worked (“mechanism of action”), less than 30 percent mentioned competing 
treatments, and 24 percent cited supportive behaviors (p. 1095). Approximately 20 percent described the 
medications‟ onset of action, 12 percent mentioned the treatment duration, and only 9 percent cited the medications‟ 
success rate (Bell, Wilkes, & Kravitz, 2000, p. 1095). In addition, coders identified relatively few charts and graphs 
(2 percent of all advertisements) (p. 1096).  This study emphasizes the importance of more comprehensive risk 
information within direct-to-consumer advertisements, in addition to explanations of the effectiveness of the 
medications and how they work within patients‟ systems (p. 1096).    
 
Medical Rewards. Following inducements, Young and Cline‟s (2005) second classification within the  
Instrumental Motivational Cues category is medical rewards, which includes general or specific effectiveness claims 
as well as claims of the products‟ ability to extend patients‟ lives or improve particular “clinical indicators” (p. 355). 
The researchers also placed claims of negative rewards and comparative claims within this category (Young & 
Cline, 2005, p. 355).  Most commonly, Young and Cline (2005) identified medical rewards in their content analysis 
(p. 348).   
The medical rewards Bell, Kravitz, and Wilkes (2000) uncovered in their content analysis mainly focused 
on the brands‟ effectiveness, innovativeness, convenience, and symptom control (p. 329). Effectiveness claims were 
identified in 57 percent of the 320 non-unique advertisements within the study, while symptom control assertions 
and innovative claims totaled 41 percent (Bell, Kravitz, & Wilkes, 2000, p. 333). Claims of “psychological 
enhancement” were identified in 11 percent of the advertisements. Claims of “reduced mortality” due to the 
medication were present in 7 percent of the total sample (n = 320), while “lifestyle enhancement” assertions were 
identified in 6 percent (p. 333). 
 
Instrumental Punishments. Finally, instrumental punishments include claims of negative outcomes and 
disclaimers (Young & Cline, 2005, p. 356-357). The researchers identified at least one of these textual cues in half 






treatment advertisements, yet identified in nearly 80 percent of both cardiovascular and diabetes advertisements 
(Young & Cline, 2005, p. 357). 
 
RQ4.  What percentage of direct-to-consumer Web sites in the study uses each type of instrumental motivational 
 cues: inducements, informational rewards, medical rewards, or instrumental punishments?  
 
 
RQ4a.  Of the 15 medical conditions that the prescription medication Web sites are classified into, which 
 condition uses each of the following most often: inducements, informational rewards, medical rewards, or
 instrumental punishments? 
 
 
2.4.4 Identity Motivational Cues  
 
According to Young and Cline (2005), identity motivational cues include claims of enabling or improving 
patients‟ lifestyles, overall positive feelings, outward appearance, strength/power, control over the condition, or 
intelligence (p. 355-356). The authors also classified claims of the condition‟s universality and “personal appeals” 
from the actor in the advertisement within this category. The results of Young and Cline‟s (2005) content analysis of 
225 direct-to-consumer print advertisements indicated that advertisers utilized at least one identity motivational cue 
relative to the products (p. 361). The cues advertisers most commonly used to entice consumers include personal 
control (“freedom”) and the universality of the condition, cited within over a quarter of the advertisements (Young 
& Cline, 2005, p. 348, 361). Intelligence and gaining power were identified least often within the print 
advertisements (p. 361).  
 
RQ5.  What percentage of direct-to-consumer Web sites in the study uses each type of identity motivational 
 cues: claims that the product will enable/improve patients‟ lifestyles, improve patients‟ overall positive 
 feelings, improve patients‟ outward appearance, improve patients‟ strength/power, improve patients‟ 
 control over the condition, improve patients‟ intelligence, claims of the condition‟s universality, and 
 personal appeals from the main actor in the advertisement?     
 
 
RQ5a.  Of the 15 medical conditions that the prescription medication Web sites are classified into, which 
condition uses each of the following most often: claims of enabling/improving the patient‟s 
lifestyle, overall positive feelings, outward appearance, strength/power, control over the condition, 














2.5 Framing through Visual Cues 
 
Like the textual cues of direct-to-consumer advertisements, the visual cues of the campaigns can convey a 
major part of the advertising message. Cline and Young (2004, p. 138) contend that the visual cues of direct-to-
consumer advertisements are a crucial variable of these campaigns because while the Food and Drug Administration 
requires that prescription drug advertisements must either include risk information or directions to sources for 
additional information (Division of Drug Marketing, Advertising, and Communication, 1999, ¶ 3), the agency does 
not regulate the visual components of these campaigns (Cline & Young, 2004, p. 132). The prevalence of visual 
cues in mass communication inspired Cline and Young (2004) to analyze the imagery in 225 print direct-to-
consumer magazine advertisements in order to explore the potential implications on consumers (p. 136, 140). Visual 
cues can encourage peripheral processing (O‟Keefe, 1990, as cited in Cline & Young, 2004, p. 138), which can 
divert the audience‟s attention from the informational content within the advertisement. Some scholars argue that 
medications possess a “symbolic value” because of the various connotations they hold for consumers (Karp, 1996; 
Montagne, 1996; as cited in Cline and Young, 2004, p. 137); for instance, the image of a healthy person in an 
advertisement for a medication to treat a chronic, debilitating disease can give suffering consumers the impression 
that the medicine will return their previous healthy identity to them (Cline & Young, 2004, p. 137). Cline and Young 
(2004) found that healthy models were the most common images in print direct-to-consumer advertisements, and 
healthiness and physical activity are visual cues associated with identity rewards, which the ads frequently depicted 
(p. 147).  
On average, Cline and Young (2004) report 1.8 people in each direct-to-consumer print advertisement for 
prescription drugs, although some ads depicted no people and others depicted as many as nine. In addition, in 
advertisements with two people, the actors were typically male and female, while single-person advertisements 
featured females most often (p. 144). Bell, Kravitz, and Wilkes‟ (2000) study of 320 print direct-to-consumer 
advertisements for prescription medications offered similar findings: 72 percent of the brands targeted both men and 
women, yet more medications targeted women only (18 percent) than men only (10 percent) (p. 333).  
The visual cues Cline and Young (2004, p. 142) identified within their sample 225 unique direct-to-







Table 1. Visual Cues of 225 Print Direct-to-Consumer Advertisements (Cline & Young, 2004, p. 142).  
 
Visual Element Presence in Percentage of Print Advertisements* 
 
Humans 82.65 %* 
Objects  32.65% 
Text/Words 26% 




             *Average of study‟s two coders. 
 
RQ6.  What percentage of the prescription medication Web sites included in the study uses each of the following 
 visual cues: people, cartoons, animals, trade characters, body parts, products, or other? 
 
 
RQ6a.  Of the 15 medical conditions that the Web sites in this study are classified into, which percentage 
 uses each of the following  visual cues: people, cartoons, animals, trade characters, body parts, products, or 
 other? 
 
Just as within the commercial advertising realm, consumers‟ socioeconomic status, gender, and race 
influence the effectiveness of direct-to-consumer advertising messages (Mastin, Andsager, Choi, & Lee, 2007, p. 
49). Cline and Young (2004), who applied social identity theory to the imagery, determined that the actors typically 
did not fit the demographics of the audiences prone to the particular disease because most advertisements featured 
only Caucasians (p. 153-154). Mastin, Andsager, Choi, and Lee (2007, p. 49) also used social identity theory to 
content-analyze a decade of direct-to-consumer magazine advertisements, and the results mirrored those of Cline 
and Young‟s (2004, p. 153-154) study: the majority of models in the direct-to-consumer ads were Caucasian.  
Pharmaceutical companies cannot achieve their advertising and marketing goals without recognizing the 
demographic and psychographic characteristics of the intended audience. Since the groups absent in the majority of 
these direct-to-consumer advertisements—such as African-Americans and Asians—typically report poorer health 
than whites, Cline and Young (2004, p. 154) argue that pharmaceutical manufacturers may not only be alienating 






Cline and Young (2004) also examined the age of the actors within the direct-to-consumer magazine 
advertisements, and identified adult actors and actors from multiple generations most often (p. 147).  The 
researchers also noted a comparatively small percentage of older actors and children (p. 147).   
 
RQ7.   Of the Web sites for prescription medications included in this study, what are the gender, ethnicity, and 
 age of the main actor within the advertisement? 
 
2.5.1 Identity Rewards and Relational Rewards 
  
Cline and Young (2004) also coded these magazine advertisements based upon the relational rewards 
displayed in each of the advertisements, including activity level, health, and friendliness (p. 147). Physical activity 
surfaced most often, and social activity was the second most frequent activity depicted (Cline & Young, 2004, p. 
147). Most commonly, healthy-appearing actors were used, and over two-thirds of the sample portrayed a smiling 
person (Cline & Young, 2004, p. 147).  
  
RQ7a. In what percentage of the direct-to-consumer Web sites in the study does the main actor appear 
 healthy, active, or friendly? 
 
Cline and Young (2004) examined the relational rewards of the magazine advertisements within their 
sample, such as social, family, romance, and work settings (p. 149). Social contexts were the most common type of 
relational reward (Cline & Young, 2004, p. 149). Further, Cline and Young (2004) discovered that many of these 
advertisements featured a person alone, a setting they considered a “nonrelational context” (p. 149).  
 
RQ7b. In what percentage of the direct-to-consumer Web sites in the study does the main actor appear in 






CHAPTER 3. METHODOLOGY 
The researcher drew from the methodologies of direct-to-consumer advertising researchers such as Cline 
and Young (2004, p. 139-142), who analyzed the visual cues in direct-to-consumer advertisements, and Macias and 
Lewis (2004, p. 43), who conducted a content analysis of the incentives and the quality of the information found on 
90 prescription drug Web sites. In turn, Macias and Lewis (2004, p. 45-47) built their coding practices upon the 
methodologies of Roth (1996, p. 183) and Bell, Kravitz, and Wilkes (2000, p. 331), two studies that also influence 
this study. The instrument for the present study, depicted in Appendix A, was based upon the visual and textual cues 





Although Macias and Lewis‟ (2004) study provided the foundation for the present study (p. 47-49), the 
researcher enriched the study by incorporating additional elements of direct-to-consumer prescription medication 
Web sites which illustrated how pharmaceutical advertisers are using the Internet to communicate with consumers. 
In addition, coders participated in a pilot test to examine the integrity of the instrument; the test involved coding 10 
Web sites for prescription medications that were not among the 100 top-selling products included in the study. 
Operational definitions for each of the variables included within this study can be found in Appendix B.  
 
3.2 Coding Practices 
 
 
To ensure the validity of the sample and the fairness of the study, the researcher collected the Web sites for 
both the pilot study (10 total Web sites) and the main study (100 total Web sites) at approximately the same time. 
The Web sites were identified and then accessed using the Google search engine, since merely typing the brand 
name as the Web address did not necessarily lead to the correct Web site. Once each Web site fully loaded, the 
researcher used the command “Control + Print Screen” to save the entire Web site as viewed on the monitor. Next, 
the researcher pasted the Web site onto a new document in Adobe Photoshop CS3 using the command “Control + 
V” and saved each document in JPEG format for quick access. If the site continued below the images and text 
visible on the screen upon the site‟s initial loading, the researcher scrolled as far down as possible while ensuring 
that the information was continuous from the text and images visible upon the first viewing. In addition, the 






sites‟ loading to ensure that all possible images were visible within the JPEGs. All of the images for each of the sites 
included within the pilot study and the main study were then saved onto a one-gigabyte USB disk for the two coders. 
This data collection technique enabled the researcher to efficiently collect the data for multiple Web sites, so 
relatively little time elapsed between collecting the first and the last sites within the samples for the pilot study and 
the main study. 
However, several Web sites on IMS Health‟s list of the top-selling prescription medications in 2006 were 
generic drugs, now available without a prescription, did not have a stand-alone Web site, or did not have a Web site 
at all. For example, arithromycin and sertaline hydrochloride are generic medications, and Zyrtec is now available 
over-the-counter (McNeil-PPC, 2008b, ¶ 1). Other medications on IMS Health‟s list either did not have a stand-
alone Web site or did not have a Web site at all, including Camptosar, CellCept, Clopidogrel, Forteo, Hyzaar, Lotrel, 
Mobic, Omnicef, Oxycontin, Pravachol, Previtar, Simvastin, Tryvadia, Zofran, and Zosyn. The preceding Web sites 
were eliminated from the study because they did not represent the population accurately. 
To ensure the study‟s sample reached 100 medications, the researcher consulted the medications on IMS 
Health‟s list of the top-selling medications in 2006 that were ranked between numbers 101-110. The medications 
selected to compensate for the unavailable drugs on the list included Arimidex, Asacol, Combivir, Kaletra, 






CHAPTER 4. RESULTS 
Prior to collecting the data for the main study of 100 direct-to-consumer Web sites for prescription 
medications, the researcher conducted a pilot test of 10 Web sites outside of the primary study‟s sample, equivalent 
to 10 percent of the primary study‟s sample, to ensure coders‟ effectiveness at identifying the listed items within the 
instrument and test the integrity of the instrument. 
 
4.1 Pilot Test 
 
 
The researcher selected the sample for the pilot study by choosing every tenth prescription medication from 
IMS Health‟s list of the top-selling drugs from January through December 2006, beginning with Number 110 
(Lamb, 2007, p. 36). The researcher began at the 110
th
-ranked prescription medication instead of the 101
st
-ranked 
medication to leave a buffer in case some of the Web sites for the medications among the top 100 were unavailable 
or nonexistent. Among every tenth Web site ranked between 110 and 200, several medications chosen for the 
sample either did not have a working Web site or the site could not be located on the Internet. In those cases, the 
researcher chose the medication immediately following the original drug chosen for the sample. Once the researcher 
reached the end of the list of the 200 medications, she continued counting every tenth medication by returning to the 
110
th
-ranked drug and eliminating any choices that had already been chosen or were marked as not having an 
available Web site. Based on these criteria, the pilot study included the following medications: Duoneb, Genotropin, 
Gamunex, Ortho-Tri-Cyclen Lo 28, Reyataz, Rhinocort Aqua, Sandostatin LAR, Trizivir, Xalatan, and Xeloda. 
Intercoder reliability for the pilot test ranged from 80 to 100 percent, and average 93.75 percent for the total of 64 
variables (see Appendix B for the intercoder reliability scores for each variable within the pilot study).     
 
4.2 Modifications to Instrument 
 
While intercoder reliability for the pilot study was quite high, the initial study helped illustrate areas that 
required refinement within the instrument. Following the pilot study, the researcher determined that other categories 
had to be added to certain sections of the instrument in order to reflect the composition of the Web sites more 
accurately. First, within the Condition section of the instrument, the researcher recognized the need for an additional 
category, “Two or More Unrelated Ailments,” since many medications have been approved by the Food and Drug 






moderate-to-severe chronic plaque psoriasis, and Crohn‟s disease (Abbott Laboratories, 2008e). Treatments for two 
or more related ailments within an existing condition category were classified within that single condition. For 
instance, the medication Lamictal treats the related conditions of biopolar disorder and epilepsy, which both 
represent the psychiatric-neurological category (GlaxoSmithKline, 2008h), and so the coders categorized Lamictal 
as treating that condition instead of the category for “Two or More Unrelated Ailments.” The category “More Than 
Ten Actors” was added to the Number of Actors section after the pilot study due to the incidence of Web sites 
featuring large numbers of human actors. Further, within the Identity Rewards section, an “Indeterminate/ Multiple 
Actors who are Smiling and Not Smiling” code was added to the Friendliness category because of the incidence of 
body parts shown on these Web sites as well as the sites‟ tendency to depict multiple actors who are smiling and not 
smiling. 
Following the pilot study, the researcher also added two more categories for the Age section of the 
instrument detailing the appearance of the actors: “Indeterminate” and “Multiple Actors of Multiple Ages.” The 
“Indeterminate” code was used for Web sites showing only actors‟ body parts, providing that the subject was human 
and not a cartoon, trade character, animal, product, or other non-human entity. Coders marked the “Multiple actors 
of Multiple Ages” code if no dominant actor was shown on the Web site, such as for sites featuring “personal 
stories” about several actors‟ experience with the condition and prescription medication. If multiple actors were 
featured on the Web site, yet all were classified within the same age and gender categories, the coders were 
instructed to record that age and gender within the Appearance of Main Actor section.  
Within the Gender category, a code was added to accommodate those Web sites that featured only human 
actors‟ body parts: “Unable to Determine from Image.” The pilot study also uncovered the necessity of a “Male and 
female/Multiple Actors of Both Genders” category because of the incidence of both genders shown together without 
one appearing more dominant. Finally, for the Informational Rewards section, the pilot study exhibited very few 
Web sites which featured specific contact information such as telephone numbers, e-mail addresses, and/or mailing 
addresses on the home page of the Web site, yet many of the sites offered a “Contact Us” link. The “Contact Us” 
category was added to account for this occurrence.  
After the pilot study was complete, each of the two independent coders was alternately assigned half of the 
100 Web sites (50 sites each), in order to record the frames, visual and textual cues, message characteristics, and 






4.3 Study Descriptives 
 
The identification variables included the manufacturer of the prescription medication, the condition, and the 




The primary study sample contained brands manufactured by 46 companies functioning independently or in 
collaboration. GlaxoSmithKline manufactured and marketed nine percent (n = 9) of the brands within the sample of 
the 100 top-selling prescription medications. Pfizer earned the next-highest number of brands within the sample (8 
percent; n = 8), followed by AstraZeneca (6 percent; n = 6) and Novartis Pharmaceuticals Corporation/ Sanofi- 
Aventis U.S. (5 percent; n = 5). Amgen, Eli Lilly & Co., and Merck & Co. each marketed four percent (n = 4) of the 
brands in the sample, and Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Inc. marketed 
three percent (n = 3), respectively. Bayer Health Care Pharmaceuticals, Cephalon Inc., Forest Pharmaceuticals, Inc., 
Genentech, Inc., King Pharmaceuticals, Inc., Merck & Co./Schering-Plough, and Serpracor Inc. each manufactured 
two brands (2 percent) within the sample. Finally, the following corporations marketed one brand each (1 percent of 
the total sample): Amgen/Wyeth, Astellas Pharma U.S. Inc., Biogen Idec, Boehringer Ingelheim, Boehringer 
Ingelheim/Astellas, Bristol-Myers Squibb, Bristol-Myers Squibb/Merck & Co./IM Clone Systems, Inc., Bristol-
Myers Squibb/Otsuka America Pharmaceutical, Inc., Bristol-Myers Squibb/Sanofi-Aventis, Centocor, Inc., Eli Lilly 
& Co./Abbott Laboratories, Elsai/Ortho-McNeil, Elsai/Pfizer, EMD Serono, Inc., Endo Pharmaceuticals, 
Genentech/Biogen Idec, McNeil PPC, MedImmune, Ortho-Biotech Products, L.P., Pfizer/Boehringer Ingelheim, 
Proctor & Gamble Pharmaceuticals, Proctor & Gamble Pharmaceuticals/Sanofi-Aventis, Schering-Plough, Shire 






The 100 brands of prescription medications and the corresponding manufacturers included within the 










The most represented condition was for medications treating psychiatric-neurological ailments, which 
accounted for 22 percent (n = 22) of the total sample (n = 100). Closely following psychiatric-neurological 
treatments were medications for musculoskeletal ailments (15 percent; n = 15), cardiovascular ailments (13 percent; 
n = 13); cancer (10 percent; n = 10), and respiratory ailments (8 percent; n = 8). Other conditions listed included 
urologic and obstetric-gynecologic ailments (5 percent; n = 5), gastrointestinal-nutritional, infectious (non-HIV), 
and more than one unrelated ailment (4 percent; n = 4), diabetes and HIV/AIDS (3 percent; n = 3), and ailments that 
were not disclosed within the advertisement (2 percent; n = 2). Dermatologic conditions and allergies were the least 
represented conditions (n = 1), each comprising one percent of the total sample.  
 
4.4 Hypothesis Testing 
 
 
In order to address the two hypotheses of the present study, the researcher performed the following 
statistical tests: frequencies, crosstabluations, chi-square, and Pearson‟s Product Moment Correlation Coefficient, in 
addition to computing the measures of central tendency (mean, median, and mode).  
 
 
H1.  A greater number of the direct-to-consumer Web sites for pharmaceutical medications included in the 




Coders categorized the dominant frames of each of the study‟s 100 Web sites for prescription medications 
into the following classifications: “Gain Frame: Social Approval,” “Gain Frame: Happiness,” “Loss Frame: 
Happiness,” “Mix of Gain/Loss Frames,” and “Indeterminate/No Frame.”  The coded data does not support H1, 
which posited that loss frames would be more prevalent within direct-to-consumer advertising on prescription 
medication Web sites. Gain frames were by far the most frequently used dominant frames of the sample; in fact, the 
combined frequencies of “Gain Frame: Social Approval” and “Gain Frame: Happiness” amount to 66 percent of the 
coded Web sites (n = 66). When combined, the two types of loss frames (“Loss frame: Social Approval” and “Loss 
Frame: Happiness”) are the dominant frames in only five percent (n = 5) of the total sample of 100 Web sites. 
Individually, the classifications varied considerably. Sixty-four percent of the sample (n = 64) utilized the 






of the coded material. The “Indeterminate/No Frame” category was used second-most often (20 percent; n = 20). 
Loss frames were not used often; in fact, “Loss Frame: Social Approval” was not recorded for any of the Web sites.  
The researcher performed a chi-square test on the frequencies of the dominant frame categories recorded 
for the Web sites within the present study. Since five categories of frames existed and the sample consisted of 100 
Web sites, the expected N of each category was 20. The differences between the expected N and the actual 
frequencies of the five categories were so great that the chi-square test revealed that X
2
 = 130.3; df = 4; p = .000. 
Therefore, just like the results of the dominant advertising appeals of these prescription medication Web sites, the 
distribution of the sample‟s dominant frames could not be attributed to chance.  
 
Figure 1. Frequency of Gain/Loss Frames Within Sample.  
 
 
           Note: N = 100 
  
H2.  A greater number of the direct-to-consumer Web sites for pharmaceutical medications included in the 
 study will contain dominant informational advertising appeals, rather than dominant transformational 
 advertising appeals. 
 
The data collected from the sample of advertisements supported H2. Of the dominant advertising appeals 
recorded within the 100 direct-to-consumer Web sites for prescription medications, half (n = 50) used a dominant 
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while 11 percent (n = 11) utilized the transformational appeal. The dominant advertising appeals in two percent (n = 
2) of the advertisements were indeterminate or absent.  
In order to determine whether the distribution of the dominant advertising appeal for this sample of 100 
direct-to-consumer Web sites could be attributed to chance, the researcher computed a chi-square test for the types 
of dominant advertising appeals recorded (“Informational,” “Transformational,” “Mixed,” and “Indeterminate/No 
Appeal”). Results of the chi-square test for the dominant advertising appeal were: X
2 
= 59.76; df = 3; p = .000, and 
indicate that the significantly greater usage of the dominant informational advertising appeal by the Web sites within 
the study could not be attributed to chance.  
 
4.5 Research Questions 
 
 
To answer the research questions within the study, the researcher applied frequency tests and 
crosstabulations, tested for chi-square as well as Pearson‟s r, and computed measures of central tendency such as the 
mean, median, and mode.  In addition, the researcher created multiple indices to illustrate the single and multiple 
uses of variables within the major categories of the study, including interactivity, inducements, informational 
rewards, medical rewards, instrumental punishments, and identity motivational cues.  
 
RQ1.  What percentage of the prescription medication Web sites included in the study uses each of the following 
interactive features: quizzes, live chat, message boards, videos, audio, text-size adjustments, animated 
graphics, e-mail updates/newsletters, frequently-asked questions, glossaries, site maps, or other?  
 
 
Altogether, 70 percent (n = 70) of the Web sites for the prescription medications coded for the present 
study used some type of interactive feature: quizzes, live chat, message board, videos, audio, text-size adjustments, 
animated graphics, e-mail updates/newsletters, frequently-asked questions, glossaries, site maps, or other. Several 
correlations between the categories of interactive elements were significant. First, the Web sites‟ usage of animated 
graphics and videos together strongly correlated (r = .278; p < .01), in addition to glossaries and site maps (r = .287; 
p < .01), and, as expected, video and audio (r = .815; p < .01). Other significant correlations between elements 
included videos and quizzes (r = .224; p < .05), as well as text-size adjustments and live chat (r = .197; p < .05). 
To determine the percentage of the sample that used multiple types of inducements, the researcher created 
an Inducement Index that summed the frequencies of the variables (quizzes, live chat, message boards, video, audio, 






maps, or other). Twenty-one percent (n = 4) of the total sample (n = 100) used three of the interactive elements, 
twenty percent (n = 20) utilized two, 19 percent (n = 19) offered four, 13 percent used one, 5 percent used six, 4 
percent (n = 4) did not utilize any inducements, 3 percent (n = 3) provided seven, and 1 percent used one interactive 
element. Figure 2 illustrates the frequencies of interactive elements when grouped into broader numerical categories. 
 
Figure 2. Number of Interactive Elements Within Percentage of Sites in Sample.  
 
 
           Note: N = 100 
Results for the individual interactive features varied considerably. Site maps were the study‟s most 
frequently used interactive feature: 74 percent (n = 74) of the coded Web sites offered this information to users. 
However, no significant correlation exists between the condition and the usage of site maps (r = -.133). “Other” 
interactive features followed closely behind advertisements‟ use of site maps: 70 (70 percent) of the coded Web sites 
offered other interactive options such as pollen counts for users‟ ZIP codes (Nasonex) or downloadable cookbooks 
(Zocor). The test for Pearson‟s r did not uncover any significant correlations, however (r = .058).  
Frequently-asked questions were also a relatively a popular interactive features: 35 percent (n = 35) of the 
sites included links to common questions or even posted the questions and answers on the home pages. Thirty-two 
percent (n = 32) of the coded Web sites in the study (n = 100) utilized animated graphics. The test for Pearson‟s r 















Twenty-one percent (n = 21) of manufacturers provided videos either as links on the brands‟ home pages or 
as an introduction or guide to the site that played immediately after the sites loaded, while 79 percent (n = 79) of 
these sites did not utilize videos. Twenty-one percent (n = 21) of manufacturers also included the option of text-size 
adjustments on the brands‟ home pages. Nineteen of these brands‟ Web sites (19 percent) included links to 
glossaries or “common terms,” while 16 percent of the 100 direct-to-consumer Web sites (n = 16) in the main study 
used quizzes designed for users to “diagnose” themselves with the condition treated by the advertised medication, to 
determine the severity of their symptoms, or to help them evaluate whether their lifestyles made them susceptible to 
the ailment.  
Of the 100 sites coded, fifteen percent (n = 15) used audio. The discrepancy between the Web sites that 
utilized video (n = 21) and those sites using audio is due to six Web sites that offered videos that immediately 
played upon the site‟s loading or could be played without leaving the home page; therefore, the coders were certain 
of these videos‟ usage of audio. Coders could not assume the links to videos that directed the users away from the 
home page included audio because the coders were instructed not to navigate away from the sites‟ home pages. The 
test for Pearson‟s r revealed no significant correlation between the condition and the usage of videos (r = -.036).  
Other interactive features were less common. Fourteen percent (n = 14) of the sites in the study used e-mail 
updates and newsletters. According to the data, pharmaceutical manufacturers did not frequently utilize another 
interactive element: the live chat capabilities of the World Wide Web: only three percent of Web sites for 
prescription medications offered the live chat option (n = 3). Finally, none (0 percent; n = 0) of the 100 Web sites 
coded for the present study included links to a message board. 
 
RQ2.  Of the fifteen medical conditions the Web sites in this study are classified into, which medical condition 
 uses loss/risk frames most often?  
 
 
Only 5 percent (n = 5) of the entire sample utilized any loss/risk frames. A crosstabulation of the medical 
conditions and the dominant frames of the prescription medication Web sites indicates that the advertisements for 
urological ailments employ the loss/risk frames most often (2 percent; n = 2). Besides urological ailments, 
musculoskeletal, obstetric-gynecologic, and psychiatric-neurological ailments use loss frames second-most often (1 
percent; n = 1). The specific loss frame each of these conditions employed was the “Loss Frame: Happiness,” and no 






Pearson‟s r was also conducted to identify significant correlations between the condition and dominant frame of the 
advertisement; no significant correlation existed (r = .052). 
 As a whole, these fifteen conditions were twice as likely to utilize a mix of gain/loss frames in the 
advertisements (n = 9) as loss frames (n = 5). Cardiovascular and psychiatric-neurological ailments, in addition to 
infectious (non-HIV) diseases, utilized the mix of gain/loss frames most frequently (n = 2). Diabetes and 
musculoskeletal and obstetric-gynecologic ailments mixed gain/loss frames next-most often (n = 1).  
 Altogether, the fifteen conditions were most likely to use the “Gain Frame: Happiness” approach (n = 64). 
Except for the “Undisclosed” condition category, at least one Web site classified into each of these fifteen 
conditions utilized the “Gain frame: Happiness.” The conditions that appeared most frequently on the list of the sites 
that utilized the “Gain Frame: Happiness” were psychiatric-neurological (n = 15), musculoskeletal (n = 10), and 
cardiovascular ailments (n = 9). Only two Web sites used the dominant frame of “Gain Frame: Social Approval” (2 
percent of the total sample), and these advertisements fell within the psychiatric-neurological classification.  
 Of the 100 Web sites for prescription medications included within the study, twenty percent (n = 20) either 
did not use a frame clearly or did not use any frame at all. Web sites for cancer medications did not use discernible 
frames (or did not use frames at all) most frequently (n = 4). Treatments for musculoskeletal ailments were also 
recorded to use either indiscernible or absent frames in the advertisements (n = 3). Other reported conditions with 
unclear or absent frames in advertising included cardiovascular, psychiatric-neurological, respiratory, undisclosed 
ailments, or two or more unrelated ailments (n = 2). Other conditions with one Web site utilizing the 
“Indeterminate/No Frame” approach included gastrointestinal-nutritional and urologic ailments, as well as infectious 
(non-HIV) diseases. 
 
RQ3.  Of the fifteen medical conditions the Web sites in this study are classified into, which medical condition 
 uses informational advertising appeals most often?  
 
 
 Of the 50 recorded uses of dominant informational appeals, the medical condition which used the most 
informational appeals was psychiatric-neurological ailments (26 percent; n = 13), followed by musculoskeletal 
illnesses (16 percent; n = 8), cardiovascular ailments (14 percent; n = 7), cancer (10 percent; n = 5), respiratory 
conditions (8 percent; n = 4), urologic ailments (6 percent; n = 3), infectious (non-HIV), obstetric-gynecologic, 






as diabetes and HIV/AIDS (2 percent; n = 1) also used the informational appeal. No Web sites (n = 0) for treatments 
for allergies, dermatologic, or gastrointestinal-nutritional ailments utilized the informational appeal. No significant 
correlation existed between the medical condition and the dominant advertising appeal.  
 By dividing the amount of Web sites within each of these conditions that utilized the informational 
advertising appeal by the total number of Web sites classified into each of the fifteen conditions, the data appears 
slightly different. When analyzed in this manner, 100 percent of the total amount of Web sites for undisclosed 
ailments used the informational appeal, followed by 66 percent of all urologic medications in the sample, 59 percent 
of all psychological-neurological medications in the study, roughly 54 percent of cardiovascular medications, 53 
percent of musculoskeletal ailments, 50 percent of cancer, respiratory, and infectious (non-HIV) treatments, in 
addition to medications treating two or more unrelated ailments, 40 percent of all obstetric-gynecologic medications 
coded, 33 percent of the diabetes and HIV/AIDS medications, and zero percent of all treatments for allergies, 
gastrointestinal-nutritional, and dermatologic conditions. 
Transformational appeals were used by only 11 Web sites included in the study: cardiovascular treatments 
(27 percent; n = 3), musculoskeletal and obstetric-gynecologic medications (18 percent; n = 2), and infectious (non-
HIV), psychiatric-neurological, respiratory, and neurologic drugs (9 percent; n = 1). However, 37 medications 
within the sample (n = 100) mixed informative and transformative appeals. Mixed appeals were popular among 
medications for psychiatric-neurologic conditions (n = 6), cancer and musculoskeletal ailments (14 percent; n = 5), 
and gastrointestinal-nutritional conditions (11 percent; n = 4), as well as cardiovascular and respiratory ailments (8 
percent; n = 3), allergies (3 percent; n = 1), dermatologic (3 percent; n = 1), infectious (non-HIV) (3 percent; n = 1), 
obstetric-gynecologic (3 percent; n = 1), and urologic (3 percent; n = 1) illnesses.  
Usage of the mixed appeals was then analyzed relative to the total amount of medications classified into 
each of the fifteen conditions. By these standards, 100 percent of the allergy, dermatologic, and gastrointestinal-
nutritional medications utilized mixed appeals, in addition to 66 percent of all HIV/AIDS, musculoskeletal, and 
diabetes medications, half of all cancer treatments and medications for two or more unrelated ailments, 38 percent of 
respiratory medicines, 27 percent of all psychiatric-neurologic medications, 25 percent of infectious (non-HIV) 
medications, 23 percent of cardiovascular treatments, and 20 percent of all urologic and obstetric-gynecologic 
medications. Undisclosed ailments were the only category that did not employ any mixed advertising appeals. 






sample (n = 100). Psychiatric-neurologic medications were the only category in which the medications‟ Web sites 
featured indeterminate or absent appeals.   
 
RQ4.  What percentage of direct-to-consumer Web sites in the study uses each type of instrumental motivational 
 cues: inducements, informational rewards, medical rewards, or instrumental punishments? 
 
 
 To answer this question, the researcher created indices to sum the variables present in each of these four 
categories (inducements, informational rewards, medical rewards, and instrumental punishments). Altogether, the 
Web sites were most likely to utilize medical rewards, present in 97 percent of the Web sites, followed by 
informational rewards (94 percent), instrumental punishments (86 percent), and inducements (70 percent).   
 
Inducements. To compute the frequencies of Web sites within the sample that used either single or 
multiple inducements, the researcher created an Inducement Index by summing the five variables within the 
category: “Reminder Cards,” “Free Samples,”  “Free Trials,” “Vouchers/Coupons,” and “Other” inducements. 
Seventy percent (n = 70) of the advertisements within the total sample offered some type of inducements, whether 
the offerings were among those listed or not. According to the data, 44 percent (n = 44) of the sample utilized one 
inducement, 30 percent of the Web sites (n = 30) did not utilize inducements at all, 20 percent (n = 20) presented 
two inducements, 5 percent (n = 5) used three inducements, and 1 percent (n = 1) utilized four inducements. Fifteen 
percent (n = 15) of the total sample (n = 100) offered vouchers/coupons, 12 percent (n = 12) provided free trials, 4 
percent (n = 4) supplied reminder cards, and 2 percent (n = 2) provided free samples. However, the most popular 
individual variable within this category was “Other” inducements, present in 70 percent (n = 70) of the sample. 
While the frequency of inducements classified within the “Other” category seems to suggest the need for additional 
categories to accommodate these variables, the items were highly varied. Also, since the coders were instructed to 
remain on the sites‟ home pages, they had to include items with ambiguous titles that did not clearly fit into the 
defined categories within this category. “Other” inducements included downloadable symptom checklists, recipes 
and cookbooks, progress logs, financial assistance plans and PPA information, television commercials, “articles,” 
“resources,” “appointment simulators,” sweepstakes to win an iPod, surveys, and an invitation for each hormone 
therapy patient to share “HerStory.”  
The researcher computed a chi-square test to determine whether the distribution of these Web sites‟ usage 








 = 16; df = 1; p = .000. In addition, a test for Pearson‟s r uncovered no significant correlations between the 
condition and the presence of inducements. 
  
Informational Rewards. Manufacturers used various types of informational rewards to entice consumers 
as well, including “Contact Us” links, telephone numbers, mailing addresses, patient support programs, 
informational CDs/DVDs, brochures/binders, press releases, third-party editorials/sponsorship Web sites/other Web 
sites, news coverage, and other informational rewards. The researcher created the Informational Reward Index to 
sum the usage of these types of elements within the sample.  
Altogether, 94 percent (n = 94) of the Web sites within the sample used at least one type of informational 
reward. Thirty-five percent (n = 35) of the sample used two informational rewards, 24 percent (n = 24) employed 
one, 23 percent (n = 23) used three, 7 percent (n = 7) used four, 3 percent (n = 3) used 5, and 1 percent (n = 1) used 
six types and seven types, respectively. The frequency of the individual variables within the Informational Rewards 
category was scattered, as evident in Figure 3 below.  
 
Figure 3. Types of Informational Rewards Within Sample.  
 
 
           Note: N = 100 
Medical Rewards. To entice consumers, pharmaceutical manufacturers cited medical rewards such as 
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lives, improve clinical indicators, and provide negative rewards. Computation of the frequency of Web sites that 
used single or multiple types of medical rewards required the researcher to create a Medical Rewards Index. 
The Medical Rewards Index revealed that overall, 97 percent (n = 97) of the Web sites within the sample (n 
= 100) cited at least one type of medical reward. Thirty-nine percent (n = 39) of the sample cited four medical 
rewards, 19 percent (n = 19) used 5 medical rewards, 14 percent (n = 14) mentioned two, 12 percent (n = 12) cited 
three, 9 percent (n = 9) mentioned one, four percent (n = 4) cited six, and 3 percent (n = 3) did not utilize any 
medical rewards.  
Individual variables within the Medical Rewards category received the following frequencies: 93 percent (n 
= 93) of the sample (n = 100) utilized general effectiveness claims, 84 percent (n = 84) cited negative rewards, 65 
percent (n = 65) presented claims of the medications‟ abilities to improve clinical indicators, while 64 percent (n = 
64) employed specific effectiveness claims. Twenty-nine percent (n = 29) offered comparative claims, while13 
percent (n = 13) claimed to extend patients‟ lives.  
 
Instrumental Punishments. Manufacturers also cited instrumental punishments such as negative outcomes 
and disclaimers within the direct-to-consumer advertisements. The researcher created an Instrumental Punishments 
Index to sum the Web sites‟ usage of single and multiple variables within this category. According to the index, 86 
percent (n = 86) of the sample cited some type of instrumental punishment. Sixty-one percent (n = 61) used both 
claims of negative outcomes and disclaimers, 25 percent (n = 25) presented one type of instrumental punishment, 
and 14 percent (n = 14) did not employ either element. As for the individual variables within the Instrumental 
Punishments category, 74 percent (n = 74) cited negative outcomes, while 73 percent (n = 73) offered disclaimers. 
 
RQ4a.  Of the 15 medical conditions that the prescription medication Web sites are classified into, which 
 condition uses each of the following most often: inducements, informational rewards, medical rewards, or 
 instrumental punishments? 
 
  
To address this question, the researcher first employed a crosstabulation of the fifteen conditions and the 
indices used to compute the frequency of the inducements, informational rewards, medical rewards, and 
instrumental punishments utilized within the sample. Next, to compute the percentage of the Web sites within each 






cue by the total amount of Web sites coded for that condition. Table 2 depicts the percentage of Web sites within 
each of the fifteen conditions that used at least one type of motivational cue from the categories. 
 
Table 2. Percentage of Web sites using One or More Incentives, by Condition. 
 







Allergies (1) 100% 100% 100 % 0% 
Cancer (10) 50% 90% 90% 100% 
Cardiovascular (13) 62% 100% 100% 85% 
Dermatologic (1) 100% 100% 100% 100% 
Diabetes (3) 100% 100% 100% 100% 
Gastrointestinal-nutritional (4) 100% 100% 100% 75% 
HIV/AIDS (3) 0% 100% 100% 100% 
Infectious (non-HIV) (4) 25% 100% 100% 100% 
Musculoskeletal (15) 73% 93% 100% 100% 
Obstetric-gynecologic (5) 80% 100% 100% 80% 
Psychiatric-neurologic (22) 77% 91% 100% 82% 
Respiratory (8) 75% 88% 100% 75% 
Urologic (5) 100% 100% 100% 60% 
Undisclosed (2) 50% 100% 0% 50% 
2+ Unrelated ailments (4) 75% 75% 100% 100% 
 
           Note: N = 100 
 
Use of Inducements by Condition. The frequencies of these conditions‟ usage of inducements such as 
reminder cards, free samples, free trials, vouchers/coupons, or other types were also tabulated.
1
 By performing a 
crosstabulation of the condition and consulting the Inducement Index, the researcher discovered the following: 100 
percent of allergy Web sites utilized two inducements, and 100 percent of dermatologic treatments used one 
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inducement. Seventy-five percent of gastrointestinal-nutritional Web sites used two inducements and 25 percent 
used one, and 60 percent of urologic treatments used two inducements, while 40 percent used one.  
Other conditions with high usage of inducements were musculoskeletal treatments, 60 percent of which 
used one inducement, while 27 percent used none and 13 percent used two. In addition, 55 percent of psychiatric-
neurologic medications used one inducement, 23 percent used no inducements, approximately 14 percent used two, 
and 9 percent used three. Inducement use among respiratory medications was similar to that of psychiatric-
neurologic treatments: 50 percent of respiratory medicines used one inducement, 25 percent used none, and 
approximately 13 percent used two and three inducements, respectively. Further, 50 percent of treatments designed 
for more than one unrelated ailments used one inducement, while 25 percent used no inducements or two. Fifty 
percent of cancer medications used one inducement and 50 percent used none, while 40 percent of obstetric-
gynecologic treatments used one inducement, 40 percent used two, and 20 percent used no inducements.  
 Several conditions used inducements sparingly or not at all: medications designed to treat HIV/AIDS 
offered no inducements, while 75 percent of infectious (non-HIV) medications used none and 25 percent used only 
one. Finally, 38 percent of cardiovascular treatments used no inducements, 23 percent used two, 15 percent used one 
inducement and three inducements, respectively, and roughly 8 percent used four inducements.  
 
Use of Informational Rewards by Condition. The same method was used to analyze each condition‟s 
usage of informational rewards, including “Contact Us” links, telephone numbers, e-mail addresses, mailing 
addresses, patient support programs, informational CDs/DVDs, brochures/binders, press releases, third-party 
editorials/sponsorship Web sites/other Web sites, news coverage, and other elements not listed. Performing a 
crosstabulation of the conditions and the Informational Reward Index yielded the following results: 100 percent of 
allergy medications used one informational reward, in addition to 100 percent of dermatologic treatments. Seventy-
five percent of infectious (non-HIV) medicines offered two informational rewards and 25 percent provided one, 
while 66 percent of diabetes treatments used three and 33 percent used two. In addition, 66 percent of HIV/AIDS 
medications used one informational reward and 33 percent used three, followed by obstetric-gynecologic treatments: 
60 percent of sites classified within this condition used one informational reward, while 40 percent used three.  
Cardiovascular medicines also utilized informational rewards heavily: 54 percent used two, 23 percent used 






undisclosed treatments used two informational rewards and 50 percent used three, the same results as Web sites 
within the gastrointestinal-nutritional condition category (50 percent used two and 50 percent used three 
informational rewards). For Web sites classified into the condition “Two or More Unrelated Ailments,” 50 percent 
used two and 25 percent used none or three informational rewards, respectively. Urologic medications also used 
informational rewards relatively often: 40 percent offered two, 40 percent used four, and 20 percent provided three. 
Finally, 40 percent of musculoskeletal treatments used one informational reward, over 13 percent used two, four, 
and five, respectively, and roughly 7 percent used three, six, or none.  
 Respiratory medications utilized this type of reward less often: 38 percent of the Web sites classified into 
this category used two informational rewards, 25 percent used four, and approximately 13 percent used none, one, or 
three. Over 36 percent of psychiatric-neurologic medications used two informational rewards, 32 percent used three, 
18 percent used one, 9 percent used no informational rewards, and almost 5 percent used seven. Finally, 20 percent 
of cancer drugs used one informational reward, 40 percent used two, and 30 percent used three. Ten percent of 
cancer drugs did not provide an informational reward.  
 
Use of Medical Rewards by Condition. Within the 100 Web sites included in the sample, pharmaceutical 
manufacturers made claims of general and specific effectiveness, of extending patients‟ lives, of the medications‟ 
ability to improve clinical indicators, and of negative rewards. These companies also used comparative claims as 
well. One hundred percent of dermatologic medications used five medical rewards and 100 percent of allergy drugs 
cited four medical rewards. Sixty-six percent of diabetes treatments cited four medical rewards and 33 percent used 
three, while 54 percent of Web sites classified into the cardiovascular condition used four medical rewards, 31 
percent used five, and approximately 8 percent used one and six medical rewards, respectively. Half of 
gastrointestinal-nutritional drugs used four medical rewards, while 25 percent used three and 25 percent used five. 
Next, 50 percent of respiratory medications used four medical rewards, while roughly 13 percent used one, two, 
three, or five types. Half of infectious (non-HIV) treatments used two medical rewards, 25 percent used four, and 25 
percent used five, while 40 percent of cancer drugs used four, 20 percent used three, and 10 percent used none, one, 
two, and six medical rewards, respectively. Forty percent of musculoskeletal treatments offered four medical 
rewards, and over 13 percent used one, two, three, and five medical rewards, respectively. Roughly 7 percent used 






Forty percent of obstetric-gynecologic treatments used four medical rewards, while 40 percent used five 
and 20 percent used three. Similarly, 40 percent of urologic medicines used two medical rewards, while 20 percent 
used one, three, and four, respectively. As for psychiatric-neurologic medications, 36 percent cited four, 23 percent 
used two and five, respectively, and 9 percent used one and three medical rewards, correspondingly. Among the 
least-frequent usages of medical rewards were HIV/AIDS medications, 33 percent of which cited one, three, and 
five medical rewards, respectively. One-quarter of medications designed to treat more than one unrelated ailment 
used two medical rewards, 25 percent used four, 25 percent used five, and 25 percent used six. Finally, no urologic 
treatments cited medical rewards.  
 
Use of Instrumental Punishments by Condition. These conditions‟ usage of instrumental punishments 
also varied. First, 100 percent of dermatologic medications used both types of instrumental punishments (claims of 
negative outcomes and disclaimers), followed by 80 percent of cancer drugs using both types, and 20 percent that 
used one instrumental punishment. Similarly, 80 percent of obstetric-gynecologic medicines used both types of 
instrumental punishments, although 20 percent did not utilize instrumental punishments. Seventy-five percent of 
infectious (non-HIV) drugs used both types, while 25 percent used one; next, 73 percent of musculoskeletal drugs 
used both and nearly 27 percent used one.  
Diabetes medications used instrumental punishments less frequently: 66 percent used both and 33 percent 
used one type; similarly, 66 percent of HIV/AIDS drugs used both and 33 percent used one. Sixty-four percent of 
psychiatric-neurologic treatments used both types of instrumental punishments, while 18 percent used none and 18 
percent used one. Next, 54 percent of cardiovascular medications used both types, 31 percent used one, and over 15 
percent used none. Half of medications designed to treat more than one unrelated ailment used one instrumental 
punishment, while the other half used both types. Similarly, half of gastrointestinal-nutritional medications used one 
type of instrumental punishment, although 25 percent used none, and 25 percent used both. Undisclosed medications 
were relatively similar: 50 percent used none of the types of instrumental punishments, while 50 percent used both 
types; in addition, 40 percent of urologic medications used no instrumental punishments, 40 percent used both, and 
20 percent used one. As for respiratory drugs, 38 percent used one type of instrumental punishment, 38 percent used 
both, and 25 percent used none. None of the allergy medications used instrumental punishments. Table 3 depicts the 






Table 3. Greatest Frequencies of Each Type of Instrumental Motivational Cue, by Condition.  
Instrumental Motivational Cue               Percentage of Sites Using 2+ Cues from Category 
 
Inducements Allergies/Dermatologic (100%); Gastrointestinal-
Nutritional (75%); Urologic (60%) 
 
 
Informational Rewards  Gastrointestinal-Nutritional/Undisclosed/Urologic 
(100%); Diabetes (99%); Cardiovascular (78%) 
Infectious (non-HIV)/Unrelated ailments (2+) (75%) 
 
Medical Rewards Allergies/Dermatologic/HIV/AIDS/Obstetric-
Gynecologic (100%); Diabetes (99%); Cardiovascular 
(93%); Psychiatric-neurologic (91%) 
 
Instrumental Punishments  Dermatologic (100%); Cancer/Obstetric-Gynecologic 





RQ5.  What percentage of direct-to-consumer Web sites in the study uses each type of identity motivational 
 cues: claims that the product will enable/improve patients‟ lifestyles, improve patients‟ overall positive 
 feelings, improve patients‟ outward appearance, improve patients‟ strength/power, improve patients‟ 
 control over the condition, improve patients‟ intelligence, claims of the condition‟s universality, and 
 personal appeals from the main actor in the advertisement?     
 
  
Improving patients‟ control over the illness was by far the most heavily represented identity motivational 
cue within the sample of 100 direct-to-consumer Web sites of prescription medications, present in 84 percent (n = 
84) of the advertisements. Claims of the medications‟ abilities to improve patients‟ strength and power were also 
frequent: 38 percent (n = 38) of the Web sites featured this identity motivational cue. Thirty percent (n = 30) of these 
brands claimed to improve patients‟ lifestyles, 27 percent (n = 27) emphasized the commonality of the condition 
treated by the advertised medication, and 23 percent (n = 23) of brands within the sample promised to improve 
positive feelings. Coders also identified personal appeals from the actors in twenty percent (n = 20) of the Web sites, 
claims of the medications‟ abilities to improve intelligence in four percent (n = 4), and claims of the prescription 
drugs‟ capacity to improve patients‟ outward appearance in one percent (n = 1).  
The researcher also developed an Identity Motivational Cues Index to determine the usage of single or 
multiple variables within this category. According to the index, 90 percent (n = 90) of the overall sample utilized 
some form of identity motivational cue. Twenty-eight percent (n = 28) of the sample used two types of identity 






presented four types, 5 percent (n = 5) used six types, and 4 percent (n = 4) utilized five types of identity 
motivational cues.  
Eighty-four percent (n = 84) of the sample suggested that the medications would improve the patients‟ 
control over the condition, while 38 percent (n = 38) claimed to improve patients‟ strength or power, 30 percent 
claimed to improve users‟ lifestyles, 27 percent (n = 27) cited the conditions‟ commonality, and 23 percent (n = 23) 
claimed to improve patients‟ positive feelings. Twenty percent (n = 20) of the sample used personal appeals from the 
actors in the advertisements, 4 percent (n = 4) claimed to improve patients‟ intelligence, and one percent (n = 1) 
claimed to improve patients‟ outward appearance. 
 
RQ5a.  Of the 15 medical conditions that the prescription medication Web sites are classified into, which 
condition uses each of the following most often: claims of enabling/improving the patient‟s 
lifestyle, overall positive feelings, outward appearance, strength/power, control over the condition, 




 Just as for the other motivational elements of these Web sites, the researcher performed a crosstabulation of 
the fifteen conditions and the appropriate index; in this instance, the researcher used the Identity Motivational Cues 
Index, originally used to answer RQ7. The data illustrated the following: 100 percent of allergy drugs used three 
identity motivational cues, and 100 percent of dermatologic medications used one cue. Eighty percent of urologic 
medications used four cues, while 20 percent did not use any. Three-fourths of medications designed to treat more 
than one unrelated ailment used one motivational cue, while 25 percent used six; in addition, two-thirds of 
HIV/AIDS medicines used five motivational cues and one-third used two cues. Diabetes medications also used 
many of the listed motivational cues: 66 percent used two and 33 percent used four. Half of infectious (non-HIV) 
treatments used one motivational cue, 25 percent used two, and 25 percent used five, while half of gastrointestinal-
nutritional medicines used one cue, 25 percent used two, and 25 percent used three cues. 
Forty percent of obstetric-gynecologic treatments used two motivational cues, 40 percent used four, and 20 
percent used three, while 40 percent of cardiovascular medications used one motivational cue, 40 percent used two, 
and 20 percent used none. Next, 36 percent of psychiatric-neurologic drugs used two motivational cues, 18 percent 
used one, and approximately 14 percent used four and six, respectively. One-third of musculoskeletal treatments 
used three motivational cues, 27 percent used two, 13 percent used none, and roughly 7 percent used one, four, five, 






one, 25 percent used two, and approximately 13 percent used three and four identity motivational cues, respectively. 
Finally, none of the Web sites for undisclosed conditions cited any identity motivational cues. 
 
RQ6.  What percentage of the prescription medication Web sites included in the study uses each of the following 
 visual cues: people, cartoons, animals, trade characters, body parts, products, or other? 
 
 
Eighty-one percent (n = 81) of the sample utilized human actors in the advertisements, the most frequently 
used visual cue, followed by “Other” items (24 percent; n = 24), including visuals of newsletters and quizzes. 
Advertised products were used in 19 percent (n = 19) of the sample, while ten Web sites (10 percent) presented 
cartoons, including illustrations of humans or animals that were not considered trade characters, and ten sites used 
body parts (10 percent).  Three percent of the advertisements (n = 3) presented trade characters, and two percent (n = 
2) included photographs of animals. Although humans were the most frequently occurring visual cue within these 
advertisements, no significant correlation exists between the condition and the advertisements‟ usage of human 
actors (r = -.105). 
The “Number of Actors” category is also within the Visual Cues section of the instrument, and the category 
measured how many human actors were shown within these advertisements. The results are as follows: 19 percent 
(n = 19) of the Web sites within the study did not include a human actor. Twenty-six percent (n = 26) of the 
advertisements depicted one actor, 19 percent (n = 19) used two actors, 16 percent (n = 16) portrayed three actors, 9 
percent (n = 9) presented four actors, 4 percent depicted six actors, 2 percent (n = 2) presented either five actors, 
eight actors, or more than ten actors, and one percent (n = 1) depicted nine actors. To analyze this data, the 
researcher computed the measures of central tendency: M = 2.29, Mdn. = 2, Mode = 1. 
 
RQ6a.  Of the fifteen medical conditions that the Web sites in this study are classified into, which 
 condition uses each of the following visual cues: people, cartoons, animals, trade characters, body parts, 
  products, or other? 
 
 
The researcher conducted a crosstabulation of the fifteen conditions and the visual cues used as subjects of 
the advertisements (people, cartoons, animals, trade characters, body parts, products, and other), illustrated in Table 
4 below.  
However, some medications used more than one of the listed visual cues as subjects in the advertisements 






the product and also used cartoons and trade characters.  Thus, the usage of each visual element in Table 4 was 
divided by the total amount of Web sites classified into that particular condition; hence, 100 percent of the allergy 
medication Web sites used products, cartoons, and/or trade characters.   
 
Table 4. Usage of Visual Cues by Condition. 
 
Condition       People        Other          Product       Body           Cartoons    Trade          Animals 
               Parts                   Characters 
 
Allergies 0 0 1 0 1 1 0 
Cancer 8 2 2 1 0 0 1 
Cardiovascular 12 4 2 4 2 0 0 
Dermatologic 1 0 1 1 0 0 0 
Diabetes 2 1 2 1 0 1 0 
Gastrointestinal-nutritional 4 0 1 1 1 0 0 
HIV/AIDS 3 0 0 0 0 0 0 
Infectious (non-HIV) 3 1 2 1 0 1 0 
Musculoskeletal 13 4 1 0 2 0 0 
Obstetric-gynecologic 5 0 1 0 0 0 0 
Psychiatric-neurologic 18 6 1 0 3 0 0 
Respiratory 5 3 4 0 1 0 0 
Urologic 3 1 0 0 0 0 0 
Undisclosed 0 0 0 0 0 0 0 
Unrelated ailments (2+) 4 2 1 1 0 0 1 
      n = 81          n = 24 n = 19       n = 10          n = 10          n = 3          n = 2 
 
Psychiatric-neurological treatments accounted for 22 percent (n = 22) of the total sample (n = 100). Eighty-
one percent of these treatments used people, 27 percent used other subjects, and 13.7 percent employed cartoons. 
Less than .5 percent included the product in the advertisements. The next most represented condition within the 






sites used people as visual cues; 26 percent employed other subjects, over 13 percent used cartoons, and nearly 7 
percent presented the products.  
Cardiovascular treatments comprised 13 percent of the sample (n = 13), and used the following visual cues: 
people (over 92 percent), body parts and other subjects (nearly 31 percent), and products and cartoons (over 15 
percent). Web sites for cancer medications (n = 10) used people most often (80 percent), followed by products and 
“other” subjects (20 percent), in addition to body parts and animals (10 percent). Sixty-three percent of respiratory 
medication Web sites (n = 8) depicted people, while half displayed products, 38 percent showed other subjects, and 
13 percent used cartoons. Sixty percent of the 5 urologic conditions in the sample used people, and 20 percent used 
other subjects.  
All of the obstetric-gynecologic medication Web sites (n = 4) displayed people, while 20 percent showed 
other subjects. Similarly, all of the Web sites for gastrointestinal-nutritional ailments (n = 4) used people; however, 
25 percent showed the products and body parts as well. Three-quarters of the infectious (non-HIV) medication Web 
sites (n = 4) used people, half showed the products, and a quarter depicted other subjects.  
Each of the four sites advertising treatments for more than one unrelated ailment portrayed people as the 
subjects, while half used other subjects and 25 percent displayed products, body parts, and animals. Two-thirds of 
diabetes medication Web sites (n = 3) used people and products, and one-third of the sites presented trade 
characters, body parts, and other subjects.  All of the HIV/AIDS treatment advertisements (n = 3) displayed people, 
and none of the sites depicted any of the other subjects. Neither of the two undisclosed ailments used any of the 
visual cues listed, while 100 percent of the Web sites for dermatologic treatments (n = 1) used people, products, and 
body parts.  Table 5 lists the most prominent visual cues within the Web sites classified into each condition.  
The researcher performed the test for Pearson‟s Product Moment Correlation Coefficient to explore the 
correlation between the conditions and the visual cues used as subjects within the advertisements (people, cartoons, 
animals, trade characters, body parts, products, and other subjects). Significant correlations existed between the 
advertisements‟ usage of particular pairs of visual cues. For instance, Web sites‟ usage of people and trade 
characters correlates significantly (r = -.214; p < .05), as well as usage of people and cartoons (r = -.263; p < .01) 
and body parts and trade characters (r = .332; p < .01). In addition, the test for Pearson‟s r revealed a significant 







Table 5. Most Frequent Visual Elements Used by Condition. 
 
Medical Condition             Most Frequent Visual Elements (>25% of total) 
 
Allergies (n = 1)  Product, Cartoons, Trade Characters 
Cancer (n = 10) People* 
Cardiovascular (n = 13) People*, Body Parts, Other 
Dermatologic (n = 1)  People*, Products*, Body Parts* 
Diabetes (n = 3) People*, Products* 
Gastrointestinal-nutritional (n=4) People*, Products, Body Parts 
HIV/AIDS (n = 3) People* 
Infectious (non-HIV) (n = 4) People*, Products*, Other 
Musculoskeletal (n = 15) People*, Other, Cartoons 
Obstetric-Gynecologic (n = 4) People* 
Psychiatric-Neurologic (n = 22) People*, Other  
Respiratory (n = 8) People*, Products*, Other 
Urologic (n = 5) People* 
Undisclosed (n = 2) None 
Unrelated Ailments (2+) (n = 4) People*, Other*, Products 
 
 
RQ7.   Of the Web sites for prescription medications included in this study, what are the gender, ethnicity, and 
 age of the main actor within the advertisement?  
 
 
 The frequencies of the actors‟ gender varied considerably. First, no actors were present in 19 percent (n = 
19) of the direct-to-consumer Web sites for prescription medications. Thirty-four percent (n = 34) of the entire 
sample (n = 100) used males and females or multiple actors of both genders, 31 percent (n = 31) used females, 12 
percent (n = 12) depicted males, and 4 percent (n = 4) used actors whose gender was indeterminate. Accounting for 
only the advertisements featuring people (n = 81), nearly 42 percent of the Web sites used males and females or 
multiple actors of both genders; 38 percent used females only; almost 15 percent portrayed males only; and roughly 






 Of the complete sample (n = 100) of prescription medication Web sites, the ethnicity of the actors was 
primarily White/Caucasian (41 percent; n = 41), although multiple actors of multiple ethnicities were well 
represented as well (20 percent; n = 20). Blacks/African-Americans and actors whose ethnicity was indeterminate 
accounted for seven percent (n = 7) of the sample; three percent of the actors were Hispanic (n = 3), two percent (n = 
2) were Asian, and the ethnicity of the actors in one percent (n= 1) of the sample did not fit into the above 
classifications. No significant correlation existed between the condition and the ethnicity of the actors within the 
advertisements. 
 Removing the advertisements featuring non-human actors or no actors at all (19 percent; n = 19) provides 
the opportunity to further analyze the data on the actors‟ ethnicities. Within the Web sites using human actors (n = 
81), over half used White/Caucasian models, nearly a quarter used multiple actors of multiple ethnicities, almost 8 
percent used either Blacks/African-Americans and actors whose ethnicity was indeterminate, roughly four percent 
depicted Hispanics, over two percent displayed Asians, and one percent portrayed other ethnicities.  
 Within the entire sample (n = 100), the advertisements used multiple actors of multiple ages most 
frequently (18 percent; n = 18), followed by actors who were 30-39 years old (15 percent; n = 15), followed by 20-
29 years old (13 percent; n = 13), and of indeterminate ages (10 percent; n = 10). Eight percent (n = 8) of the Web 
sites used actors who were 40-49 years old and 60+ years old; seven percent (n = 7) employed actors ages 50-59 
years old; and two percent (n = 2) used children. None of the advertisements used adolescents. The test for Pearson‟s 
r revealed a correlation between the condition treated by the advertised medication and the age of the actors within 
the advertisement (r = -.220, p < .05). 
 
RQ7a. In what percentage of the direct-to-consumer Web sites in the study does the main actor appear 
 active, healthy, or friendly? 
 
 
 Among the identity rewards coders recorded within the sample of 100 direct-to-consumer advertisements 
were the activity level, health, and friendliness of the actors. When analyzed relative to the entire sample (n = 100), 
actors were active in 78 percent of the Web sites (n = 78) and passive in 4 percent (n = 4). Of only the Web sites 
featuring human actors (n = 81), over 96 percent included active subjects and roughly 5 percent depicted passive 
subjects. The test for Pearson‟s Product Moment Correlation Coefficient revealed no significant correlations 






 Healthiness was another identity reward included within the 100 direct-to-consumer Web sites for 
prescription medications. Of the complete sample (n = 100), 68 percent (n = 68) of the Web sites depicted healthy 
actors, 19 percent (n = 19) did not include humans, 8 percent (n = 8) depicted actors whose health was 
indeterminate, and 5 percent (n = 5) portrayed ill actors. When analyzed for just the Web sites depicting humans (n 
= 81), roughly 84 percent showed healthy people, nearly 10 percent showed people whose health was indeterminate, 
and over 6 percent portrayed ill people.  The results of the test for Pearson‟s Product Moment Correlation 
Coefficient revealed no significant correlations between the condition and the health of the actor. 
 Coders also documented the friendliness of the actors in the advertisements. Within the entire sample (n = 
100), 64 percent (n = 64) of the actors were smiling, 11 percent (n = 11) of the Web sites included either multiple 
actors who were smiling and not smiling or actors whose friendliness was indeterminate, and 6 percent (n = 6) 
contained unsmiling actors. Of just the advertisements featuring people (n = 81), 79 percent were smiling, over 13 
percent included either multiple actors that were smiling and not smiling or actors whose friendliness was 
indeterminate, and over 7 percent of actors were “unfriendly” (not smiling). No significant correlations were found 
between the condition and the friendliness of the actor, but strong correlations were identified between the 
friendliness of the actor and the health of the actor (r = .9; p < .01) and the actors‟ activity level (r = .852; p < .01).   
 
RQ7b.  In what percentage of the sample does the main actor appear in each of the following settings: 
 family, romance, work, social, recreational, or other? 
 
 The most frequent relational reward depicted within the sample of the 100 direct-to-consumer 
advertisements was the “Recreational” setting (38 percent; n = 38). Frequency of the other relational rewards is 













Figure 4. Usage of Relational Rewards. 
 


















CHAPTER 5. DISCUSSION 
The noteworthy findings of this content analysis of 100 direct-to-consumer Web sites for prescription 
medications provide insight into the framing practices of direct-to-consumer advertisers on prescription medication 
Web sites, most notably the more pronounced usage of gain frames than loss frames. The study also indicates these 
pharmaceutical manufacturers have applied the informational appeals commonly used in print executions to Internet 
advertisements. Furthermore, the present research reveals the overwhelming usage of Caucasian actors as the main 
actors in the advertisements and the depiction of recreational settings as relational rewards.  
The following discussion of the present study‟s visual, textual, and interactive elements explores the 
differences between print and Internet direct-to-consumer advertisements, and examines the implications of this 
study‟s major findings.  
 
5.1 Comparison to Previous Literature  
 
By combining multiple studies on visual and textual cues used to entice consumers to ask their doctors 
about the advertised medications, this research tests the findings of other studies on direct-to-consumer 
advertisements. The present study supports data from previous Internet-based studies on direct-to-consumer 
advertisements, such as Macias and Lewis‟ (2004) content analysis of the attributes of 90 prescription medication 
Web sites, yet offers an updated and expanded perspective of the interactive elements and visual and textual cues 
used by these pharmaceutical manufacturers. In addition, the present study demonstrates the similarities and 




Macias and Lewis (2004, p. 47) reported 28 unique manufacturers of the 90 prescription medication Web 
sites in their study, or approximately 3.2 brands per manufacturer. When the researchers compiled the data in 2001, 
the most frequent manufacturers operating the Web sites for prescription medications were AstraZeneca and Ortho-
McNeil Pharmaceuticals (with 8 each), as well as to Roche Labs, Pharmacia, Pfizer, and GlaxoSmithKline (with 7 
each). The present study revealed marked differences: 46 manufacturers offered one or more Web sites for 
prescription medications, an average of 2.17 brands per manufacturer. The differences in the numbers of 






(2004) and the researcher of the present study, increased competition within the pharmaceutical industry, or the 




Pharmaceutical manufacturers have expanded their product selection and now offer many versions of 
products, including generics or over-the-counter versions. Thus, brands qualified for inclusion within the present 
study were much more numerous than for Macias and Lewis‟ (2004, p. 47) study of direct-to-consumer 
advertisements on the Internet.  Macias and Lewis‟ (2004) Internet study utilized all the Web sites for prescription 
medications that were available in 2001, but only 90 prescription medication Web sites qualified for their study (p. 
47). Similarly, Bell, Kravitz, and Wilkes‟ (2000) content analysis consisted of 101 unique brands, but the 
researchers consulted 18 magazines over a nine-year period to collect the sample (p. 329).  
Whereas Macias and Lewis‟ encountered difficulty in finding any Web sites at all for any prescription 
medication, recent increases in manufacturers‟ use of the Internet for promotional and marketing purposes provides 
an excellent population for this research and for subsequent studies. The 100 Web sites within the previous study 
were chosen from a list of 200 top-selling drugs published by IMS Health in 2006 (Lamb, 2007, p. 35), and many 
more medications could have been sampled: IMS Health also publishes a list of the 500 best-selling medications 
(“PharmaLive.com special reports: Top 500 prescription drugs of 2006,” p. 3). In fact, barring the time constraints 
of the present study, potentially thousands of Web sites could have been included in the sample. 
The ease of access to the sites in the present study dramatically contrasts with Macias and Lewis‟ (2004; p. 
47) sample; unless medications were generic or discontinued, the vast majority of the present study‟s population was 
functioning Web sites. The researcher chose not to include more than one hundred sites (besides the ten sites 
collected for the pilot study) to ensure the sample was comparable to other studies‟ samples and also to provide a 
strong foundation for future research involving direct-to-consumer advertising on the Internet.  
 
5.1.3 Condition  
 
 Macias and Lewis (2004) assigned the highest number of the 90 brands in their sample to the following 
conditions: psychiatric-neurologic (roughly 16 percent), obstetric-gynecologic and other (9 percent), and 






of direct-to-consumer print advertisements were classified into the dermatologic, HIV/AIDS, and obstetric-
gynecologic conditions most commonly (p. 329). Least common were tobacco addiction, cancer, diabetes, infectious 
(non-HIV), and respiratory treatments. According to Bell, Kravitz, and Wilkes (2000), 30 percent of the sample 
included brands for life-threatening conditions, including HIV/AIDS and cardiovascular ailments; in addition, 75 
percent of the conditions were chronic (p. 334). 
 The present study echoes the usage of psychiatric-neurologic and musculoskeletal treatments in Macias and 
Lewis‟ (2004) study, but contrasts with Bell, Kravitz, and Wilkes‟ (2000) study due to the present study‟s low 
frequencies of HIV/AIDS treatments and of dermatologic medications. In addition, cancer medications were 
represented more strongly in the present study than in Bell, Kravitz, and Wilkes‟ (2000) research (p. 333).  
The reasons for the higher representation of certain conditions within the present sample could potentially 
be due to the variety of medication classes now utilizing the Internet due to the increased competition among 
medications in the class. In addition, the sample for Macias and Lewis (2004, p. 47) was based upon the availability 
to the data (whether the Web site existed) and Bell, Kravitz, and Wilkes (2000) collected their data over a nine-year 
period, while this study was based upon the drugs‟ popularity in terms of sales (p. 329).  
 
5.1.4 Dominant Gain Frames (Hypothesis 1) 
 
The first hypothesis of this study asserted that a greater percentage of the direct-to-consumer 
advertisements within the sample would utilize loss/risk frames than gain/benefit frames. Despite the inconclusive 
research on gain and loss frames in general, the researcher assumed the sample‟s prevalence of risk/loss frames due 
to Tsai‟s (2007, p. 365) and Cox and Cox‟s (2001, p. 93) research indicating the greater effectiveness of loss-framed 
messages specifically for health communication. 
However, the data obtained from this content analysis of direct-to-consumer Web sites did not support this 
hypothesis. In fact, the results of the frequencies of the dominant frames were dramatically different from Tsai‟s 
(2007, p. 365) study. “Gain Frame: Happiness” was dominant within two-thirds of the sample in the present study, 
and loss frames were present in only 5 percent, and no use of the “Loss Frame: Social Approval” was identified. 
 The hypothesis was likely unsupported in the present study for several reasons. While research indicates 






creating these direct-to-consumer Web sites for prescription medications. Tsai‟s (2007, p. 365) data is relatively 
new, and although the data for the present study was collected in 2008, the list of top-selling medications is derived 
from sales figures from 2006. Finally, manufacturers may be reluctant to negatively-frame a sensitive topic like 
disease since the people seeking medication for their ailments likely grapple with the negative effects of the 
condition on a daily basis. Possibly, the manufacturers deliberately employ the loss frames to motivate the passive 
audiences of print media who are not actively seeking the information on the medications to visit the brands‟ Web 
sites. To a consumer who was initially motivated by the fear or risk avoidance messages of the print advertisements, 
the gain frames of the Web sites are comparatively comforting and reassuring. Ultimately, the prospective patient 
attends his or her doctor‟s appointment with positive attitude towards the advertised medication, since the Web site 
was likely the most recent medium the patient actively utilized to obtain this medical information.       
 
5.1.5 Dominant Informational Advertising Appeals (Hypothesis 2) 
 
 The second hypothesis for this study posited that a greater percentage of direct-to-consumer advertisements 
of prescription medications would utilize informational advertising appeals than transformational appeals. The 
researcher based this supposition upon research by Roth (2003, p. 181), in addition to authors whose studies formed 
the basis for the investigation into this topic over the previous several decades, such as Petty and Cacioppo (1986, p. 
125). Roth (2003) discovered 81 percent of his sample utilized informational appeals and 19 percent used 
transformational (p. 181). 
 Unlike the first hypothesis of the study, the second was supported by the data, since the majority (50 
percent) of the direct-to-consumer Web sites utilized a dominant informational appeal.  Mixed appeals were used 
quite often as well, present in 37 percent of the sample.  Only 11 percent of the sample in the present study used the 
transformational frame. The discrepancy between data from the present study and Roth‟s (2003, p. 181) study could 
be attributed to the coding procedures: Roth (2003) utilized just two coding categories for the advertisements‟ 
appeals: “Transformational only” and “Informational only” (p. 181). The lack of categories in Roth‟s (2003, p. 181) 
study likely limited his data collection procedure, and consequently, the depiction of the advertisements‟ usage of 
these elements. Additional choices within the present study yielded data that provides a better overall indication of 







5.1.6 Visual Cues 
 
 The sample‟s usage of visual cues contrasted with the results of Macias and Lewis (2004, p. 49) and Young 
and Cline (2005, p. 142), studies that contribute to the foundation for the current investigation. The most notable 
contrasts within this category include the relational rewards, number of actors, and the subjects of the 
advertisements.  
 
 Relational Rewards. Young and Cline (2005) found the social setting to be most prevalent, yet the 
relational rewards of the advertisements included in the present study were most often a “Recreational” or “Other” 
setting (p. 147-148). Differences in the settings of the advertisements may have been due to Cline and Young‟s 
(2004) sample: print advertisements selected from various magazines (p. 131). Magazines are highly targeted 
vehicles, and the advertisements could have reflected the lifestyle of the publications‟ readers. Due to the varying 
demographics of Internet users and the medium‟s wide appeal, Web sites for prescription medications cannot easily 
tailor advertisements to an audience with certain expected characteristics. Therefore, these manufacturers may be 
attempting to present settings that are appealing to as many people as possible, and since the majority of people 
typically cherish leisure activities, the recreational setting was employed most often. 
 
Number of Actors. Cline and Young (2004, p. 144) reported 1.8 actors as the most frequent number of 
people present within the direct-to-consumer advertisements, while the present study utilized more people per 
advertisement (M = 2.29). These Web sites‟ inclusion of more human actors per advertisement than in the print 
advertisements of Cline and Young‟s (2004, p. 144) study may be attributed to the sites‟ attempts to convey the 
universality of the condition, or to appeal to a greater number of people. For instance, most of the sites employing 
multiple actors included actors of both genders, providing that the medication was not gender-specific. 
 
Usage of People, Animals, and Other Subjects. Macias and Lewis (2004, p. 50) reported 80 percent of 
their sample of 90 prescription medication Web sites used humans or animals, a figure almost identical to these 
visual cues in the present study (81 percent used people; 2 percent used animals). Surprisingly, fewer advertisements 
in the present study (32 percent) utilized animated graphics than Macias and Lewis‟ (2004, p. 50) study (48 percent). 






only the home pages of each of the Web sites. Finally, the present study uncovered correlations between several of 
the visual elements, a finding absent from both Macias and Lewis‟ (2004) and Bell, Kravitz, and Wilkes‟ (2000) 
studies. The significant correlations were identified in the usage of body parts and trade characters, as well as 
between people and cartoons. 
 The combination of trade characters and body parts could be attributed to advertisers‟ need to ensure their 
brand is memorable without associating their product with an identifiable person, and the visuals for the 
advertisements for medications that treat specific body parts tended to depict that specific body part. For instance, 
the medication Lamisil, a treatment for nail fungus, portrays the brand‟s trade character, a menacing creature 
resembling an evil gremlin, standing beside a person‟s foot. Of course, the correlation between people and cartoons 
may be also due to the high frequency of people included in the advertisements, but another possible reason could be 
the need for another illustrative or informative element besides the person included in the advertisement. Yet if these 
pharmaceutical manufacturers employ a cartoon to convey the risks, benefits, or other information about the 
medication, the human actor‟s presence in the advertisement may not be crucial to the communication of the 
message of the advertisement. Potentially, advertisers may place humans in these direct-to-consumer 
advertisements—even when they are not pivotal to the message—to identify with consumers on a personal level. 
With that reasoning, however, the usage of primarily Caucasian actors in the advertisements may negatively affect 
the advertisers‟ opportunity to connect with consumers of other ethnicities.   
 
5.1.7 Identity Rewards  
 
 
Activity Level. The usage of active people in the advertisements echoed Cline and Young‟s (2004, p. 147) 
study on the visual cues of the advertisements; only 5 percent of the actors in the present study‟s sample were 
identified as passive. The reinforcement of Cline and Young‟s (2004, p. 147) data on the activity level of the actors 
communicates the literal version of being proactive about treatment. 
 
Health of Actor. Manufacturers‟ frequent usage of healthy actors in the present study also mirrored the 
results of Cline and Young (2004, p. 147). When the Web sites did depict ill people, the actors very rarely appeared 
sick. For instance, an HIV/AIDS medication identified two separate actors by their names and as HIV-positive. 






“symbolic value” of a healthy person with the same disease as the viewer is typically very positive and inspiring (p. 
137). The suffering viewers do not want to see a mirror image of themselves; rather, the viewer is more receptive to 
the message when confronted with an ideal.  
 
Friendliness of Actor. Like Cline and Young‟s (2004, p. 147) study, the vast majority of the actors in the 
advertisements appeared friendly because they were smiling. The consistent use of friendly actors is likely due to the 
same reasons as the frequent usage of healthy actors within direct-to-consumer advertisements, regardless of the 
medium the campaigns appear: patients likely aspire to become an idealized version of themselves. Instead of 
feeling isolated and suffering quietly, they want to appear friendly, happy, and approachable.   
Another interesting finding within the advertisements‟ usage of friendly actors included the significant 
correlations between several of the elements. Correlations were identified between friendliness and activity level, 
which were not present in Cline and Young‟s (2004, p. 147) study. In addition, the researcher found correlations 
between friendliness and health. Not only do the correlations show the powerful association between happiness and 
pro-activity, they also suggest that a patient who is not pro-active cannot be happy, and a patient who is not healthy 
cannot appear friendly.    
 
5.1.8 Appearance of Actor  
 
 
Gender. The usage of female actors in the advertisements of the present study differed dramatically from 
Macias and Lewis‟ study. Females were identified in 81 percent of Macias and Lewis‟ (2004, p. 50) study, while the 
present study featured females in 31 percent of advertisements. Further, males were depicted in 70 percent of 
advertisements within Macias and Lewis‟ (2004, p. 50) study, but were shown much less often (12 percent) in the 
present study. The Web sites within the present study‟s sample also were much more likely to utilize males and 
females together (34 percent of the total) than to portray a single gender, although Macias and Lewis did not utilize 
this coding category.  
This difference could be due to Macias and Lewis‟ (2004) exposure to multiple executions of the same 
campaign, since they examined 18 magazines appealing to readers of practically every demographic (p. 47). For 
instance, if a prescription drug treats a condition relevant to males and females, the advertiser would likely not 






The present study supports data from Cline and Young‟s (2004, p. 144) study, which also identified the 
direct-to-consumer advertisements‟ frequent usage of multiple actors. In addition, single-gender advertisements used 
women most often, just as in the present study. The consistency of this element within both of these studies indicates 
the higher likelihood of women to seek health information. However, since the instances of female-only 
advertisements were less pronounced within the present study than in both Macias and Lewis‟ (2004, p. 50) and 
Cline and Young‟s (2004, p. 144) study, pharmaceutical advertisers of medications for both genders may have 
begun to recognize the vast appeal of the Internet to many demographics and may be using female-only 
advertisements less often to appeal to a wider target.  
 
Age. Most often, the Web sites within the present study used multiple actors of multiple ages (18 percent). 
Of the age categories, however, 30-39 year-old actors were used most frequently, followed by 20-29 year olds. Only 
8 percent of the Web sites in the present study used actors classified into the oldest category, “60+ years old.” 
Children were used even less often in Macias and Lewis‟ (2004, p. 50) study: 38 percent of the Web sites portrayed 
children, while the Web sites in the present study reported very few Web sites that used children. Cline and Young‟s 
(2004, p. 147) study reflected the usage of actors within advertisements within the present study. Actors of multiple 
ages were used very often, and the authors noted few children or elderly people.  
Interestingly, the researcher discovered a correlation between the condition and the age of the actors within 
the advertisement that was not identified in Cline and Young‟s (2004) study. This finding appears to contrast with 
the actors‟ age data in the previous paragraph, since the advertisements appear to favor younger actors. However, 
the usage of actors of particular ages in relation to the condition sheds a favorable light on the manufacturers, since 
they apparently are not promising youth with the usage of the medication. Yet, when analyzed in terms of the high 
activity level of the actors in the advertisements, perhaps the manufacturers are instead promising youth in the form 
of vitality.  
 
Ethnicity. Overall, the ethnicity of the actors within the current study‟s sample of direct-to-consumer 
advertisements for prescription medications was White/Caucasian, noted in 42 percent of the advertisements. 
However, multiple actors of multiple ethnicities were also used, albeit half as often as White/Caucasian actors. 
Surprisingly, only 3 percent of the sample utilized Hispanic actors, yet multiple manufacturers offered the option for 






advertisements echoes the data of Cline and Young (2004, p. 144), whose research also identified a majority of 
White actors.  
Interestingly, no correlation existed between the condition and ethnicity, a finding that suggests the 
advertisers cast primarily White/Caucasian actors in the advertisements for a reason other than the relevance of the 
condition to this particular ethnic group.  Alienating ethnic groups by including only Caucasians in advertisements 
serves neither the manufacturers nor the consumers. However, the current study‟s use of multiple actors of multiple 
ethnicities is promising, even though this category was cited much less often than the White/Caucasian 
classification. The inclusion of races other than Caucasians (in addition to many of the sites‟ availability in Spanish) 
indicates manufacturers‟ recognition of the disparate demographics of not only Web users, but of the ethnic makeup 




Within the present study, manufacturers‟ usage of several of these interactive elements is more pronounced 
than in Macias and Lewis‟ (2004, p. 51) content analysis of direct-to-consumer Web sites potentially because these 
researchers collected data in March 2001, over seven years before the data collection period for present study (p. 
47). Pharmaceutical manufacturers have increasingly offered Web sites for prescription medications over the 
previous decade, and coupled with the Americans‟ usage of the Internet for health information, the increased 
emphasis on the interactive elements is logical. 
Macias and Lewis (2004) explained that the “Other” category proved quite beneficial within their content 
analysis because of the array of elements outside of the defined categories of their instrument, and this category was 
also advantageous within the present study (p. 48). However, “Other” features were five times more frequent within 
the present study than in Macias and Lewis‟ (2004) study: the researchers reported the presence of “Other” elements 
in just 14 percent of their sample (p. 48). Site maps were the most frequent interactive element offered on the 100 
Web sites for prescription medications, present in almost three-fourths of the sample, while only 50 percent of 
Macias and Lewis‟ (2004) sample of Web sites utilized site maps (p. 48). This increase in manufacturers‟ usage of 






The data was also fairly similar in terms of other elements: Macias and Lewis (2004, p. 51) identified 
quizzes in 14 percent of their sample of 101 direct-to-consumer prescription medication brands, while 16 percent of 
the sample for the current study used this interactive element. Frequently-asked questions were present in two-thirds 
of Macias and Lewis‟ (2004, p. 51) sample, while in only 35 percent of the present study. Macias and Lewis (2004) 
also found that 30 percent of their sample utilized personal appeals (p. 50), while this element was only present in 20 
percent of the present study. 
Although the present study may appear to mirror—or even fall short of—Macias and Lewis‟ (2004, p. 49-
52) study in several of these elements, the former study‟s exploration of the entire Web sites of these brands may 
have yielded links to items not visible from the home page, which is the only Web page coded for each of these 
medications in the present study. Therefore, the concentration of such a variety of elements on the home page of 
these Web sites indicates manufacturers‟ strong efforts to provide a visually stimulating, content-rich Web site that 
will instantly capture consumers‟ attention and entice them to explore the information and tools provided.  
 
Vividness. Data from Coyle and Thorson‟s (2001, p. 65) interactivity study help illustrate the benefits of 
the Web sites‟ usage of interactive features within the present study. For example, Coyle and Thorson (2001) 
explain that vivid elements of Web sites, which include audio, videos, and animation, cultivate stronger attitudes 
among users towards the Web site and the brand (p. 67-68). Thus, manufacturers apparently have become 
increasingly cognizant of how increasing Web sites‟ telepresence, or creation of a virtual experience that more 
closely mirrors reality, ultimately can benefit their brands. 
The rich media available on a Web site can convey dramatically different messages about the advertised 
brands. Macias and Lewis‟ (2004) study and the current study identified roughly the same amount of videos (20 
percent and 21 percent, respectively) and audio (13 percent and 15 percent, respectively) (p. 50-51). However, some 
of the Web sites within the present study utilized “site guides,” providing videos of hosts (often nurses or other 
credible spokespeople) who helped users navigate the Web sites. Whether the viewer chooses to utilize the site 
guide or site map, this element communicates the manufacturers‟ commitment to informing the patients and helping 
them use the site to their benefit to a greater extent.  
Despite the stereotypes of older people‟s reluctance to adapt to new technologies such as the Internet, the 






adjustments, which shows how the manufacturers have accommodated older patients with poor or failing eyesight. 
These companies definitely realize that elderly Americans seek health information on the Internet quite often, and 
also recognize this group‟s buying power. In addition, elderly people‟s greater reliance on prescription medications 
to treat the many conditions that affect primarily older people, including arthritis, menopause, and impotence, makes 
this demographic an excellent target. In spite of these factors, however, younger actors were still used more 
frequently than older actors in the advertisements that did not portray a group of people of multiple ages. Perhaps if 
the advertised drugs are taken to prevent a condition from occurring later in patients‟ lives, these Web sites may 
indeed be targeting a younger demographic than their primary target audience. Another potential reason advertisers 
may include mainly younger actors in the advertisements may be similar to the reason they include healthy (rather 
than ill) actors: so consumers can view an idealized version of themselves. Consequently, the viewers then link the 
brand‟s effect on their health to the ideal of being young again.  
  
5.1.10 Instrumental Motivational Cues 
 
 
Inducements. Inducements for Bell, Kravitz, and Wilkes‟ (2000) study were classified into different 
categories than in the present study; the authors used patient support inducements, financial, and informational 
inducements (p. 333). While the categories for the corresponding items in the present study were adapted from 
Young and Cline‟s (2005, p. 357) study instead, many of the individual variables roughly correspond to the 
following sections of the instrument:  inducements, informational rewards, medical rewards, instrumental 
punishments, and identity motivational cues. Thus, some of the categories are comparable. For example, Bell, 
Kravitz, and Wilkes (2000, p. 333) identified monetary inducements such as rebates in their study, which 
corresponds to the variable “Vouchers/Coupons” within the inducement section of the present study‟s instrument. In 
addition, Young and Cline (2005) reported relatively little usage of product and/or financial incentives, identifying 
this element in only 17.3 percent of the entire sample (p. 357).  
Usage of inducements in the present study was quite pronounced in comparison to Macias and Lewis‟ 
(2004) study: 70 percent of the present study‟s sample offered some type of inducement, and over a quarter of the 
Web sites in the current study utilized multiple inducements (p. 50-52). In contrast, Macias and Lewis (2004) 
identified financial inducements or motivators in only 39 percent of advertisements (p. 49). The more extensive 






from opponents of direct-to-consumer advertising for offering monetary inducements or other incentives in 
exchange for higher sales figures. Another possible reason for the pronounced role of financial inducements in these 
Web sites could be that the advertisers recognize consumers‟ hesitance about paying the high prices of prescription 
medications, and are willing to cater to the public to eradicate this reluctance. Also, now that the public is aware of 
direct-to-consumer advertising‟s ultimate role in increasing the prices of the promoted brands, the advertisers may 
be attempting to erase this mindset by associating financial inducements with the direct-to-consumer advertisements.   
 
Informational Rewards. Informational rewards were used very frequently within the present study: 94 
percent of the Web sites within the sample presented at least one type of informational reward. The sites offered 
“Contact Us” links and “Other” elements most often, followed by patient support programs, found in approximately 
36 percent of the sample. Support groups were used more frequently by Web sites in the present study than in Bell, 
Kravitz, and Wilkes‟ (2000, p. 333) study, which only identified this informational reward in 4 percent of the 
sample.  
However, 39 percent of the advertisements in Bell, Kravitz, and Wilkes‟ (2000) study offered to send 
additional information (p. 333), whereas additional information such as brochures and binders and other print 
materials were offered much less often in the present study. Macias and Lewis (2004) also reported a high incidence 
of Web sites‟ offers to send additional print materials (32 percent) (p. 49). The disparity between the offers of 
additional information, namely print, could be attributed to Americans‟ increased usage of the Internet to obtain 
health information. Waiting for a brochure to arrive in the mail is no longer necessary; by accessing an Internet 
search engine, users can access virtually infinite information on the advertised medication.   
 
Medical Rewards. Successful direct-to-consumer advertisements typically convey the medications‟ ability 
to help patients control their conditions, so citing negative rewards is ultimately a major part of most campaigns. 
The present study confirmed this assertion: 84 percent of these advertisements included claims of increasing users‟ 
control. Similarly, Bell, Kravitz, and Wilkes (2000) discovered that the most commonly cited benefits of the 
advertised medications were the effectiveness and control over the symptoms (p. 333). However, the most common 






the sample (p. 359). Like the present study, claims of extending patients‟ lives were infrequent, except for 
cardiovascular treatments (Young & Cline, 2005, p. 359).  
 The statements of control, the most common medical reward present in Bell, Kravitz, and Wilkes‟ (2000, p. 
333) research and the present study, indicate the manufacturers‟ recognition of the patients‟ need to feel as if their 
disease does not necessarily have to ruin their lives. As for the lack of advertisers‟ claims that using these brands can 
extend patients‟ lives, the advertisements technically cannot outright guarantee this result, since the effects of the 
medications ultimately depend on the individual. However, the Web sites that offered personal appeals from the 
actors in the advertisement did seem to insinuate the respective advertised medications‟ role in saving their lives (i.e. 
by preventing another heart attack). Since the medications‟ life-saving abilities, as described by the endorsers, are 
not typically reflected in the fine print of the advertisements, the personal stories of the actors in the advertisement 
almost seem to be anomalies or even embellished versions of the occurrences.   
 
Instrumental Punishments. Instrumental punishments, such as negative outcomes and disclaimers, were 
quite prevalent within the present study: nearly three-quarters of the sample provided one or both of these items. 
Young and Cline (2005), contrastingly, noted significantly fewer instances of the items within this category: 50.7 
percent of their sample contained one type of instrumental punishment (p. 359). While Macias and Lewis (2004) did 
not explicitly term the item “instrumental punishments,” the authors identified legal information such as privacy 
policies within 81 percent of advertisements (p. 50). Considering the U.S. Food and Drug Administration does not 
yet regulate the content of direct-to-consumer advertising on the Internet, the manufacturers of the brands in the 
present study appear to be providing many of the same elements required within print and broadcast advertisements, 
a step towards more comprehensive risk and benefit descriptions for users. 
 
5.1.11 Identity Motivational Cues 
 
 
Macias and Lewis (2004) identified personal testimonials in 30 percent of the advertisements (p. 51), while 
the present study featured 20 personal appeals. Just as within Macias and Lewis‟ (2004, p. 51) study, claims of the 
medications‟ effectiveness and the patients‟ ability to control symptoms by using the medication were prevalent, 
while comparative claims were used relatively infrequently. While specific effectiveness claims were present in two-






general effectiveness, the relative shortage of comparative claims is intriguing. In addition, the 29 medications 
offering comparative claims were often not referring to a competing medication; some Web sites offered 
comparative data on varying potencies of the advertised medication. 
Essentially, these identity motivational cues are the origin of much of the controversy over direct-to-
consumer advertising of prescription medications; by employing these claims, manufacturers do appear to be 
marketing the prescription drugs as commercial, mainstream products. While the advertisers do use clinical 
indicators and other specific data to make many of these claims, they should also offer hyperlinks to more 
comprehensive data or provide that information to the consumer through print or e-mailed materials. The clinical 
studies required to be able to assert this information differ considerably in importance from the experiments 
mainstream advertisers rely upon, such as the number of uses a paper towel can withstand before being discarded, 
yet these clinical tests these claims are based upon were not always accessible to users on the home pages of these 
Web sites. 
While some direct-to-consumer advertising critics may not believe the public is capable of interpreting 
scientific data, no harm is done in providing the information, since uninterested users will likely just return to the 
home page, while interested but confused users can simply ask their doctors for further explanation of the risks and 
benefits at their upcoming appointment.  
 
5.2 Implications of Findings 
 
 Implications of the present study‟s findings exist for the Web sites‟ frequent usage of gain frames and 
informational appeals, in addition to the types of visual and interactive elements, motivational cues, and other 
incentives discovered in the sample of the direct-to-consumer Web sites for prescription medications. 
 
5.2.1 Frequent Usage of Gain Frames 
 
Loss frames were so prevalent in previous literature exploring direct-to-consumer advertisements (Roth, 
2003) that the researcher assumed the present sample would also support this data. However, this sample‟s heavy 
usage of gain frames—notably “Gain Frame: Happiness”—suggests a major change in how the direct-to-consumer 
advertising industry communicates with the audience. Perhaps gain frames are more appropriate now than in the 






Americans‟ heavy usage of the Internet to retrieve health information allows their greater understanding of the 
condition they may be suffering from; prior to the Internet, these patients may have ignored or downplayed the 
severity of their symptoms to avoid the embarrassment of seeing a doctor. This change may be especially 
noteworthy for the Web sites for psychiatric-neurologic ailments, most of which feature such a wealth of 
information that patients are not likely to dismiss symptoms as merely “in their heads.” In addition, Web sites‟ usage 
of support groups and patient testimonials allow patients to transfer the gain frames of the advertisements to their 
own lives, associating the positive feelings evoked from the advertising message with the anecdotes from other 
people who faced the same obstacles.  
Furthermore, although most of the manufacturers do not downplay the seriousness of the condition, many 
of the Web sites in the sample present the usage of medication to control these diseases as a routine necessary for 
patients to continue living happy lives. In fact, many of the sites emphasize how patients‟ lives may become even 
more fulfilled with the usage of the medication. Essentially, even patients suffering from chronic, life-threatening 
ailments such as heart disease or cancer do not have to function as if their lives are shortened by the condition.  
  
Gain Frames versus Instrumental Punishments. Interestingly, many Web sites with gain frames utilized 
instrumental punishments as well, such as negative outcomes of using the drugs and disclaimers. Apparently, 
manufacturers are attempting to balance the negative medical information with the positive messages of the 
advertisement. Understandably, these advertisers may be exercising extreme caution in this realm to avoid class 
action lawsuits or consumers complaining to the Food and Drug Administration about the claims on the Web site.  
Regardless, the balancing of the positive and negative information also conveys the manufacturers‟ recognition of 
the seriousness of presenting adequate risk and benefit information to consumers.  
  
Gain Frames versus Medical Rewards. Although two-thirds of the Web sites used gain frames, the sites‟ 
usage of medical rewards contrasted to a certain degree. For instance, a medical reward included in the 
advertisements was “Claims of Negative Rewards.” The majority of the Web sites included this element, which is 
essentially a loss frame. In addition, many Web sites with gain frames did not include claims of extending patients‟ 
lives; in fact, some sites even clearly stated the chances of the medication actually shortening patients‟ lives. 
Therefore, the Web sites‟ ability to project dominant gain frames overall, yet still present loss-framed elements or 







Gain Frames versus Visual Elements. In addition, the visuals accompanying these gain-framed Web sites 
that did not include claims of extending patients‟ lives, or even explicitly denied the medications‟ ability to do so, 
did not typically convey this message. However, if the Web sites presented visuals that depicted the lack of medical 
rewards, the sites obviously would not be effective promotional tools. Moreover, Web sites utilizing the dominant 
frame of “Gain Frame: Happiness” did not always present visuals that completely conveyed this emphasis on the 
individual‟s sense of contentment with his- or herself. For instance, visuals for many of the Web sites deemed “Gain 
Frame: Happiness” depicted more than one person. 
 
 Lack of Social Approval Frames. The researcher also explored the possible reasons for the lack of both 
gain and loss frames regarding social approval, present in only 5 percent of the sample. First, Americans are 
notoriously individualistic, especially regarding health conditions. For example, Americans often attribute an obese 
individual‟s condition to their lifestyle, instead of attributing his or her weight problem to genetics or other factors. 
Thus, these advertisements may just be projecting this mindset. However, while the sites appear to communicate the 
individuals‟ power and ability to control the disease through medication, this message may obscure the true purpose 
of instilling this sense of power: the patients‟ individual responsibility to control the disease. 
 
Notable Usage of Mixed Frames. Cardiovascular ailments may have used mixed frames most because of 
the major risks (death) and benefits (living longer) involved in taking these types of medications, as well as the 
recent lawsuits over medications such as Vioxx, the cholesterol medication that may have caused unnecessary 
deaths and injuries to users. While the usage of mixed frames indicates the manufacturers‟ commitment to 
communicating the considerable risks of the medication, loss frames may even be more effective since a serious 
illness like heart disease literally may claim the patients‟ lives at any moment.  
 
5.2.2 Frequent Usage of Informational Appeals 
 
The implications of these findings are positive for both consumers and pharmaceutical manufacturers: first, 
more informational appeals means that prospective consumers can retrieve some of the information necessary to 
weigh the risks and benefits of the advertised medication. Further, since this study only analyzed the home pages of 






presentation of the material to prospective consumers. While the visuals presented on the Web pages do not 
necessarily convey the gravity of the decision to take the advertised medication, the depth and breadth of the 
accompanying text shows manufacturers recognize the importance of information to consumers, even though the 
FDA does not currently regulate direct-to-consumer advertising of prescription drugs on the Internet. 
Increases in the wealth or quality of information provided within the Web sites may convey manufacturers‟ 
response to users‟ growing comfort with the Internet as a source for health information and treatment options. 
However, a more informative appeal is not necessarily equivalent to more information: the appeal in these 
advertisements merely contains more informational than transformational elements. In addition, these 
manufacturers‟ willingness to self-monitor by applying many of the FDA‟s print advertising standards is promising 
for consumers, the public, advertising professionals, and the future of the pharmaceutical industry.  
The positive findings of this study may benefit pharmaceutical manufacturers considerably, since the FDA 
may not see an immediate need to amend the regulations for direct-to-consumer advertising practices. The presence 
of more informative appeals than expected, coupled with the extent manufacturers have anticipated consumers‟ 
concerns, indicates that pharmaceutical companies understand the gravity of the decision to take medication to treat 
an illness. In addition, if few consumer complaints are filed with the FDA about these direct-to-consumer Web sites 
and the FDA has no basis for concern about the quality of the information presented on the sites, the agency may 
continue to allow the industry to apply its own standards to Internet advertising of direct-to-consumer prescription 
drugs. Furthermore, just as within any industry, successful businesses remain aware of the competition‟s advantages 
in terms of products or services and ensure their company can offer the same or even more advantages to the 
customer. Since most of these manufacturers‟ products‟ Web sites are public and can be accessed by any Internet 
user, these companies will likely note the advantages of the competition‟s sites and attempt to offer consumers as 
many benefits to using the medication as necessary to retain market share.  
Informational Appeals and Internet Users. Further, while some researchers (Singh and Smith, 2005, p. 
373) believe education negatively affects respondents‟ attitudes towards direct-to-consumer advertising, studies also 
show that Web users are typically better educated than average Americans. However, Web users must proactively 
seek the information they find on the Internet, either through click-through advertisements, search engines, or 






viewers. Web sites allow consumers to seek information without having to call a toll-free number, the information is 
immediately available, current, and in most cases, the entire Web site is accessible to any Internet user. Unless the 
Web users seek the information only to formulate arguments against it, the logical assumption is that Internet users 
are open to the information presented on these Web sites. Moreover, highly educated people would likely appreciate 
and be more receptive to an informative appeal more than less-educated consumers, especially when the topic 
involves their health and, in many cases, their lives.  
 
5.2.3 Cultivating Positive Attitudes through Informational Rewards 
 
 
Respondents‟ attitudes are the primary factor in determining whether to mention medications during 
appointments with their doctors, and since most consumers who request a drug leave the appointment with a 
prescription, manufacturers must do everything possible to cultivate strong, positive attitudes toward not only direct-
to-consumer advertising, but for the individual brands as well. The informative nature of the majority of these direct-
to-consumer advertisements within the study demonstrates these companies‟ recognition of consumers‟ highly 
involved decision to use medication to treat an illness, in addition to the drug‟s risks and benefits. Further, according 
to Singh and Smith (2005), the “empowering” effects of direct-to-consumer advertising can also foster positive 
attitudes toward the practice (p. 369). Thus, the informational appeals included in half of these Web sites for 
prescription medications can not only inform the customers, but also remind them that understanding their condition 
will help them overcome the obstacles they face.   
Naturally, positive attitudes towards the brand and/or the manufacturer often result in more successful 
advertising campaigns and increased sales. While these pharmaceutical manufacturers are attempting to generate 
higher sales through financial incentives like vouchers and coupons, these companies should focus more intently on 
cultivating stronger, more positive attitudes among users by appearing more concerned about patients‟ long-term 
wellbeing. For instance, providing links to more clinical studies about the brand or medication class can benefit 
users significantly. Few of these Web sites within the sample utilized this tool, although to receive FDA approval 
these drugs must first go through extensive studies, and so the manufacturers should be able to provide at least a 
minimal amount of data to further inform users of the risks and benefits of the medication. In addition, surprisingly 






site updates, or news have forfeited one of the major advantages of the Internet: the ability to instantly update 
content.  
By giving users a reason to visit the Web site regularly or visit the site again after purchasing the 
medication, the manufacturers have an opportunity to reassure the patients of their decision to take the advertised 
medication, ensure their long-term usage (if necessary), and encourage these satisfied customers to recommend that 
family and friends affected with the same condition ask their physicians about the drug. Further, the world‟s largest 
search engine, Google, typically lists Web sites in the order of the most recently updated (assuming they are not 
advertisers, which automatically receive special placement at the top or sidebar of the results) (Google, 2008). A 
frequently updated site is crucial to a strong Internet presence, since so many users employ search engines to locate 
content, especially health-related information. Overall, manufacturers have accomplished much by simply drawing 
the curious users to the Web sites, and should use this opportunity wisely. 
 
5.2.4 Achieving Consistency of Visual Elements and the Overall Message 
 
Manufacturers apparently struggle to reconcile the dangers of taking the medication and the potential 
benefits the drug can provide users. Since the U.S. Food and Drug Administration demands extensive clinical data 
from the companies prior to allowing them market the medications, the benefits of the medication typically 
outweigh the risks. However, the visual elements of the advertisements do not always convey the seriousness of the 
decision to take a medication that could potentially be harmful or elicit painful side effects.  
A more effective usage of visual elements within direct-to-consumer advertisements on the Internet would 
be to present consumers with animated graphics demonstrating how the medication works within their bodies, or 
more extensive utilization of “site guides,” videos hosted by credible spokespeople such as nurses who help the user 
navigate the content of the Web page. In addition, usage of videos allows users to expose themselves to the message 
as many times as they please, or at the very least, each time they access the site. Each viewing is another opportunity 
for manufacturers to sell the benefits of the product.  
 
5.2.5 Using Interactive Features to Build Communities for Patient Support  
 
While advertisements‟ usage of patient support programs was relatively satisfactory, manufacturers could 






virtually nonexistent usage of message boards conveys the manufacturers‟ reluctance to allow patients to 
communicate directly with each other; one possible reason for this hesitance may be to avoid users sharing negative 
comments about the medication that would be viewable to other patients and prospective consumers. 
Understandably, manufacturers do not want to facilitate the sharing of potentially harmful information between 
patients (i.e. instructions on how to increase the dosage of the medication prior to receiving a doctor‟s permission). 
However, allowing a carefully monitored message board can cultivate a community spirit, which would dramatically 
help patients who are suffering with many of these conditions, especially chronic or life-threatening illnesses such as 
HIV/AIDS or cancer. To illustrate, people‟s contact with family and friends about the drugs makes them more likely 
to ask their doctors about the medication (Lee, Simon, & Paek, 2007, p. 107), so essentially providing patients with 
an opportunity to talk with others and form social networks, even if they never meet in person, can not only help the 
patients, but will indirectly increase sales for manufacturers as well. 
Presumably, many of these sufferers already interact with other people affected with their disease, either 
through going to the local hospital for chemotherapy or attending support groups in their areas. Including message 
boards or other tools for community-building such as links to support groups, can emulate these users‟ realities by 
giving them a network of people similar to them that transcends distance and time. The simulation of reality 
contributes considerably to a medium‟s telepresence, which Coyle and Thorson (2001) discovered significantly 
strengthens users‟ attitudes towards the brand (p. 66). Naturally, the Internet is the most qualified medium to use 
elements of vividness and interactivity, so manufacturers should take advantage of all these components, especially 
since they are already paying to have an Internet presence. For example, greater usage of the Web‟s live chat 
capabilities could help solidify users‟ experience with the brands by emphasizing the manufacturers‟ commitment to 
their understanding of the risks and benefits, while message boards can help build a community of patients with the 




The present study presents several limitations, including the relatively small sample size of 100 direct-to-
consumer Web sites. A larger sample size would have increased the external reliability of the data. In addition, 
coders examined only the home pages of these prescription medication Web sites in order to determine whether the 






appear to use the transformational appeal, in some cases, examination of the entire site may have indicated that the 
informational appeal was dominant instead.  
Another limitation of this study involved sites‟ usage of videos. Since the researcher saved each of the Web 
sites in JPEG format, which does not support movies, coders had to view the sites with movies on the Internet 
instead of merely consulting the JPEG images. However, the coders only viewed these Web sites online in order to 
hear the audio (if available) accompanying the videos. No other attributes of the Web sites were coded online, and in 
case any differences between the Web site and the saved JPEG image existed, the JPEG file always prevailed. The 
researcher chose this method to minimize the chance of coders recording any changes in the sites after the data 
collection was completed. However, the researcher carefully captured multiple images of each of the sites using 
videos in order to keep the JPEG file as representative of the actual Web site as possible. This problem may be 
ameliorated if each of the Web sites with videos offered transcripts; however, only one Web site of the 100 within 
the sample provided this information.  
The final limitation of the study was accounting for the sample‟s usage of “Other” inducements, a 
phenomenon Macias and Lewis (2004) also observed in their content analysis of prescription medication Web sites 
(p. 48). While the majority of Web sites included incentives that were not identified in the other inducement 
categories, the variety of items was too great to classify into additional categories. Even if the researcher had 
classified some of these items into broad categories, many of the items inevitably would have been excluded (i.e. 







CHAPTER 6. CONCLUSIONS 
The purpose of the present study was to examine how the visual and textual cues of direct-to-consumer 
advertisements for prescription medications combine to frame the messages and form the dominant appeals of the 
advertising, and the research effectively achieved this objective. In addition, visual cues such as the subjects of the 
advertisements were analyzed in comparison to print advertisements and a study on direct-to-consumer Web sites. 
The present study achieves its purpose by contributing significantly to the direct-to-consumer advertising debate by 
indicating pharmaceutical manufacturers‟ considerable efforts to provide patients with timely, balanced, and 
accurate information. The investigation also depicts the similarities between the advertising tactics of 
pharmaceutical advertisers and commercial advertisers of mainstream products. Furthermore, the study exposes the 
shortcomings of the Web sites in presenting multiple ethnicities and especially depicting groups of actors who are all 
of non-white ethnicities. Patterns of relational and identity rewards were identified, including the noteworthy usage 
of recreational settings and healthy, active, and happy actors. Finally, this analysis of direct-to-consumer 
advertisements provides an intriguing foil to many of the elements identified in previous research on direct-to-
consumer print advertisements.  
An important finding of the present study was the Web sites‟ frequent usage of dominant informational 
frames, which previous researchers have mostly identified in print advertisements. Although the frame category of 
the present study primarily refers to the balance of transformational versus informational content and does not 
necessarily account for the quantity of the information, the initiative the companies have taken to educate patients 
remains noteworthy. Further, pharmaceutical manufacturers‟ efforts to educate consumers can potentially decrease 
the stigma associated with many of these conditions, notably HIV/AIDS and psychiatric-neurologic ailments. 
Advertisers‟ attempts to dissolve these negative associations are especially evident in the Web sites‟ overwhelming 
usage of gain frames, an unexpected finding of the study. Whether or not advertisers consciously seek to eradicate 
the stigmas attached to these conditions by educating the public, the companies‟ efforts to sell the products through 
presenting the benefits of treating the condition may ultimately be advantageous to the public.  
The results of the present study contribute to framing literature by illuminating the framing practices of 
advertisers on the Internet. Since the Internet is a relatively new medium, a greater quantity of studies on 
commercial advertising practices on the Web exists than on the Internet advertising practices of pharmaceutical 






consumer advertising from the U.S. Food and Drug Administration, the present study can provide excellent 
comparative data for subsequent researchers once the FDA enacts these regulations.   
The prominent informational element in these direct-to-consumer Web sites for prescription medications is 
promising, considering the U.S. Food and Drug Administration does not yet regulate direct-to-consumer advertising 
on the Internet. Manufacturers are basically free to structure the brands‟ Web sites as they choose, yet the majority 
voluntarily cites the negative outcomes of taking the medication and many manufacturers even explicitly claim the 
medications‟ inability to affect the users‟ lifespan. Perhaps the FDA‟s rigorous testing practices and disclosure laws 
have set the standard for direct-to-consumer advertisements in a variety of media, and if so, the FDA may not 
choose to regulate the Internet advertising of direct-to-consumer medications.  
Internet advertising research, especially for direct-to-consumer advertisements for prescription medications, 
is still a developing field, but the present study helps to depict the extent pharmaceutical manufacturers have 
embraced the Internet as a promotional and/or educational tool. Based upon literature discussing the effectiveness of 
various types of vivid elements, including rich media like videos and animated graphics not only contributes to the 
patients‟ understanding of the risks, benefits, and effectiveness of the medication, but also helps foster the users‟ 
positive attitudes toward the brand. Data from the present study indicate that most of the manufacturers of these top-
selling brands have effectively begun to harness the benefits of this interactive medium, although the causality of the 
usage of interactive elements and these brands‟ impressive sales is yet to be explored.  
These companies may benefit consumers to an even greater extent by including more hyperlinks or offers 
of additional information to supplement the advertisements‟ medical reward claims or identity motivational cues. 
Although viewers of the advertisements anticipate the promotional nature of the claims, lending credibility to these 
claims may help manufacturers avoid the negative association with commercial advertisers and reinforce the gravity 
of the consumers‟ decision to take medication. Although a greater percentage of the Web sites could have 
effectively utilized additional informational rewards such as links to news or press releases, the manufacturers of the 
brands within the sample still seem to volunteer an adequate amount of data designed to educate the consumers 
rather than strictly promote the brands. 
Although access to the information on these Web sites may benefit patients considerably, certain groups‟ 
exposure to extensive information on the condition can potentially be dangerous. For example, drug abusers could 






conditions, namely psychiatric-neurologic ailments, do not require blood tests or other laboratory procedures to 
diagnose the patient with the condition. Many medications used to treat psychiatric-neurologic illnesses are 
controlled substances and carry the potential for addiction, such as Adderall XR, an amphetamine used to treat 
attention deficit disorder. Hypochondriacs may also find the extensive symptom information unsettling enough to 
schedule an unnecessary appointment with their physicians, helping to perpetuate the cycle of higher insurance costs 
for the public. 
The data regarding the visual cues present in these direct-to-consumer Web sites is revealing, and the 
researcher identified several shortcomings. While the sites used multiple actors of multiple ethnicities most often, 
Whites were still the most dominant single ethnic group. Possibly, the manufacturers used primarily White actors in 
the Internet advertisements because the majority of American Web users are Caucasian, but as the Internet becomes 
more widely-adopted, advertisers should attempt to depict actors of a variety of ethnicities in order to avoid 
alienating consumers. In addition, many of the manufacturers already acknowledge the growing Hispanic population 
by including Spanish versions of the downloadable questions for doctors, as well as the option to view the entire site 
in Spanish. Since minorities are less informed on health matters than their white counterparts, including members of 
these races as actors within the advertisements can make the message even more personally relevant and encourage 
them to be pro-active about maintaining their health. 
The present study also presented interesting differences between the manufacturers‟ usage of the Internet 
versus print for direct-to-consumer advertising of prescription medications, namely within patterns of visual cues, 
including relational and identity rewards. For example, depictions of leisure activities were more prominent than the 
social settings identified in print advertisements, while even actors identified as sick within the advertisements 
appeared healthy and happy.  These patterns indicate the manufacturers‟ attempts to avoid any negative associations 
with the brand and/or condition, despite the potential negative outcomes of taking many of the advertised 
medications.  
Due to the range of textual, visual, and interactive elements present within the Web sites included in the 
present study, a “typical” direct-to-consumer Web site for a prescription medication cannot be defined. However, 
several elements were commonly identified on the majority of direct-to-consumer advertisements within the sample. 
Most included extensive information on the advertised product‟s side effects and offered disclaimers and legal 






many of the sites relied upon Flash technology to animate the text or make it float across the screen. However, 
although some interactive elements are commonly present on direct-to-consumer Web sites for each of the 15 
medical conditions within the present study, some Web sites utilized the interactive qualities and rich media 
capabilities of the Internet much more effectively than others. Finally, the direct-to-consumer Web sites typically 
included financial incentives, informational rewards, and various instrumental motivational cues. Of course, the 
pharmaceutical manufacturers are utilizing these sites as a promotional tool, but are accomplishing this goal in an 
information-rich and visually stimulating manner.   
Undoubtedly, the wealth of space on these Web sites facilitates the potential disclosure of the medications‟ 
benefits and risks, even though the FDA currently does not regulate direct-to-consumer advertising on the Internet. 
This study effectively illustrates the World Wide Web‟s qualifications to soon become the primary medium for 
direct-to-consumer advertising.  
 
6.1 Future Studies 
 
Since the present study included elements from multiple influential direct-to-consumer advertising 
researchers such as Young and Cline (2005), Cline and Young (2004), Macias and Lewis (2004), and Roth (2003), 
this data offers many possibilities for subsequent explorations. Recommendations for future research include 
applying this study design to a sample of direct-to-consumer Web sites larger than 100 to increase the reliability of 
the data. In addition, modifying the methodology of the present study from quantitative to qualitative could present 
the visual and textual cues of these Web sites more realistically. Additional future studies can examine the 
nontraditional usage of the Internet by pharmaceutical manufacturers, such as Novartis‟ Fluvirin campaign on 
YouTube (Donnelly, 1 February 2008, ¶ 1).  
A more detailed examination of the relationships between the conditions and major elements of the present 
study, including appeals and frames, would be an excellent topic for future studies.  For instance, an interesting 
finding of the present study involved the absence of a correlation between the condition and the dominant 
advertising appeal. This lack of relationship is unexpected, since medications which carry heavier risk or are more 
involving to the patient, such as chemotherapy treatments, seemingly would be more likely to utilize informational 
appeals, while medications for minor ailments like allergies could effectively employ transformational appeals.  






elements. The researcher also discovered an interesting relationship between the condition and the usage of loss 
frames, such as the prevalence of loss frames among urological treatments. Further exploration of these elements 
could truly contribute to academia‟s understanding of the practice of direct-to-consumer advertising and supplement 
the findings of the present study. 
Furthermore, qualitative findings of the present study are worthy of mention. For instance, while African-
Americans were infrequently depicted as the single ethnic group within the complete sample of the direct-to-
consumer Web sites, people of this race appeared overwhelmingly in Web sites for HIV/AIDS medications. While 
studies indicate that young African-Americans comprise the highest number of HIV/AIDS deaths each year (Avert, 
2008, ¶ 1), some of the HIV/AIDS Web sites identified the actors in the advertisements by name, in addition to their 
HIV-positive status. While the Web sites for several psychiatric-neurologic treatments and a hormone therapy 
medication identified patients by name who were currently taking the medication, in addition to the type of disorder 
or disease they were suffering from, identifying people as HIV-positive—even with their first name only—seems to 
have more social repercussions than depicting an actor who suffers from bipolar disorder. Admittedly, this very 
observation may inadvertently be influenced by the stigma associated with HIV/AIDS, which involves assumptions 
of the afflicted person‟s promiscuity, sexual orientation, or morality. However, many people who are suffering from 
this debilitating condition became infected with HIV/AIDS through blood transfusions or long-term partners or 
spouses who did not know they had the disease. Yet the question of whether the pharmaceutical manufacturers are 
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I. Manufacturer  
 
1 Abbott Laboratories 
2 Amgen 
3 Amgen/Wyeth 
4 Astellas Pharma U.S. Inc. 
5 AstraZeneca 
6 Bayer HealthCare Pharmaceuticals 
7 Biogen Idec 
8 Boehringer Ingelheim 
9 Boehringer Ingelheim/Astellas 
10 Bristol-Myers Squibb 
11 Bristol-Myers Squibb/Merck & Co./IM Clone Systems, Inc. 
12 Bristol-Myers Squibb/Otsuka America Pharmaceutical, Inc.  
13 Bristol-Myers Squibb/Sanofi-Aventis 
14 Centocor Inc. 
15 Cephalon Inc. 
16 Eli Lilly & Co. 
17 Eli Lilly & Co./Abbott Laboratories 
18 Elsai/Ortho-McNeil 
19 Elsai/Pfizer 
20 EMD Serono, Inc. 
21 Endo Pharmaceuticals 
22 Forest Pharmaceuticals, Inc. 
23 Genentech, Inc. 
24 Genentech/Biogen Idec 
25 GlaxoSmithKline 
26 King Pharmaceuticals, Inc. 
27 McNeil PPC 
28 MedImmune 
29 Merck & Co. 
30 Merck & Co./Schering-Plough 
31 Novartis Pharmaceuticals Corporation 
32 Ortho Biotech Products, L.P. 
33 Ortho-McNeil-Janssen Pharmaceuticals, Inc. 
34 Pfizer 
35 Pfizer/Boehringer Ingelheim 
36 Proctor & Gamble Pharmaceuticals 
37 Proctor & Gamble Pharmaceuticals/Sanofi-Aventis 
38 Sanofi-Aventis U.S. 
39 Schering-Plough 
40 Serpracor Inc. 
41 Shire U.S. Inc. 
42 Takeda Pharmaceuticals 
43 TAP Pharmaceutical Products Inc. 
44 Teva Pharmaceutical Industries Ld. 
45 UCB 
















6 Adderall XR 
7 Advair 
8 Altace 


















27 Depakote ER 
28 Detrol LA 
29 Diovan 



































































92 Wellbutrin XL 
93 Xopenex 






















8 Infectious (non-HIV) 
9 Musculoskeletal  
10 Obstetric-gynecologic 
11 Psychiatric-neurological 
12 Respiratory  
13 Tobacco Addiction 
14 Urologic  
15  Undisclosed Ailment 
16 Two or More Unrelated Ailments 
 
IV. Relational Rewards  
 
 0       Family/More than One Generation 
 1       Romance 
2       Work 
3       Social  
  4       Recreational  
  5       Other Relational Reward  
  6       No Human Actor 
 
V. Visual Elements 
 
A. Number of Actors  
0 No Actor Present/Actor is Not human 
1 One Actor 
2 Two Actors 
3 Three Actors 
4 Four Actors 
5 Five Actors 
6 Six Actors 
7 Seven Actors 
8 Eight Actors 
9 Nine Actors 
10 Ten Actors 
11 More than Ten Actors 
 
B. People 
0       Absent 
1        Present 
 
C. Cartoons 
0            Absent 
1        Present 
 
D. Animals  
0            Absent 
1        Present 
 
E. Trade Characters 
0       Absent 








F. Body Parts 
0       Absent 
1       Present 
G. Product 
0        Absent 
1        Present 
 
H. Other Visual Element  
0            Absent 
1            Present 
 
VI. Identity Rewards 
A. Activity Level 
0 Actor is Not Human/No Actor Present 
1        Passive 
2        Active  
 
B. Health of actor  
0      Actor is Not Human/No Actor Present 
1 Ill 




0      Actor is Not Human/No Actor Present 
1 Not Smiling 
2 Smiling 
3 Indeterminate /Multiple Actors who are Smiling and Not Smiling 
 
VII. Appearance of Main Actor 
 
A. Age 
   0       Actor is Not Human/No Actor Present 
1       Child 
   2 Adolescent  
3 20-29 Years Old 
4 30-39 Years Old 
5 40-49 Years Old 
6 50-59 Years Old 
7 60+ Years Old 
8 Indeterminate 
9 Multiple Actors of Multiple Ages  
 
B. Gender  
0       Actor is Not Human/No Actor Present  
1       Male 
2       Female 
3       Unable to Determine from Image   









C. Ethnicity  
0       Main Actor is Not Human/No Main Actor 
1       White/Caucasian 
2       Black/African-American 
3       Hispanic 
4       Asian 
5       Mix 
6       Indeterminate  
7       Multiple Actors of Multiple Ethnicities  
8       Other 
 
VIII. Interactivity  
 
A. Quizzes 
0           Absent 
1       Present 
 
B. Live Chat 
0           Absent 
1           Present  
 
C. Message Board 
0           Absent 
1           Present  
 
D. Videos 
0           Absent 
1           Present 
 
E. Audio 
0           Absent 
1           Present 
 
F. Text-Size Adjustments 
0       Absent 
1       Present  
 
G. Animated Graphics  
0       Absent 
1       Present 
 
H. E-mail Updates/Newsletters 
0       Absent  
1       Present 
 
I. Frequently-Asked Questions 
0       Absent 
1       Present 
 
J. Glossary 
0       Absent 









K. Site Map 
0       Absent 
1       Present 
 
L. Other 
0       Absent 
1       Present 
IX. Dominant Frame  
 
1  Gain Frame: Social Approval   
 2   Gain Frame: Happiness    
3   Loss Frame: Social Approval  
4      Loss Frame: Happiness 
5  Mix of Gain/Loss Frames  
6 Indeterminate/No Frame 
 
X. Dominant Advertising Appeal 
 
1 Informational Appeal 
2     Transformational Appeal 
3     Mixed Appeal 
4    Indeterminate/No Appeal  
 




1. Presence of Inducements 
0       No Inducements 
1       Inducements 
 
2. Reminder Cards  
0       Absent 
1       Present 
 
3. Free Samples 
0       Absent 
1       Present 
 
4. Free Trials 
0       Absent 
1       Present 
 
5. Vouchers/Coupons 
0       Absent 
1       Present 
 
B. Informational Rewards 
 
1. Contact Us 
 0           Absent 









2. Telephone Number 
0           Absent 
1           Present 
 
3. E-mail Address 
0       Absent 
1       Present 
 
4. Mailing Address 
0       Absent 
1       Present 
 
5. Patient Support Programs  
0       Absent 
1       Present 
 
6. Informational CDs/DVDs 
0       Absent 
1       Present 
7. Brochures/Binders  
0       Absent 
1       Present 
 
8. Press Releases 
0       Absent 
1       Present 
 
9. Third-Party Editorials/Sponsorship Web Sites/Other Web Sites  
0       Absent 
1       Present 
 
10.  News Coverage 
0       Absent 
1       Present 
 
11.  Other Informational Reward  
0       Absent 
1       Present 
 
C.  Medical Rewards 
 
1. General Effectiveness Claims  
0       Absent 
1       Present 
 
2. Specific Effectiveness Claims  
0       Absent 
1       Present 
 
3. Claims of Extending Patient‟s Life  
0       Absent 









4. Claims of the Medication‟s Ability to Improve Particular Clinical Indicators 
0       Absent 
1       Present 
 
5. Claims of Negative Rewards  
0       Absent 
1       Present 
 
6. Comparative Claims  
0       Absent 
1       Present 
 
D.  Instrumental Punishments  
 
1. Claims of Negative Outcomes  
0       Absent 
1       Present 
 
2. Disclaimers 
0       Absent 
1       Present 
 
XII. Identity Motivational Cues 
 
A. Claims of Enabling/Improving Patient‟s Lifestyle 
0       Absent 
1       Present 
 
B. Claims of Improving Patient‟s Overall Positive Feelings 
0       Absent 
1       Present 
 
C. Claims of Improving Patient‟s Outward Appearance  
0       Absent 
1       Present 
 
D.    Claims of Improving Patient‟s Strength/Power  
0       Absent 
1       Present 
 
E.     Claims of Improving Patient‟s Control over the Condition 
0       Absent 
1       Present 
 
F.     Claims of Improving Patient‟s Intelligence 
0       Absent 
1       Present 
 
G.     Claim of the Condition‟s Universality 
0       Absent 
1       Present 
 
H.  Personal Appeals from Actor(s) in Advertisement    
0           Absent 






APPENDIX B. OPERATIONAL DEFINITIONS FOR STUDY VARIABLES 
 
B.1 Direct-to-Consumer Web sites for Prescription Medications 
 
 
The researcher consulted IMS Health‟s list of 200 prescription medications that earned the highest sales in 
2006, the most recent data publicly available free-of-charge. The researcher chose IMS Health‟s list because the 
company‟s figures are widely cited within the pharmaceutical industry and are published yearly within Med Ad 
News, a leading publication within the direct-to-consumer advertising industry (“IMS to present at Morgan Stanley 
Global Healthcare Conference on May 1 at 3:00 P.M. ET,” 28 April 2008, ¶ 1).  
Like Macias and Lewis (2004, p. 47), the researcher eliminated Web sites for medications that are available 
over-the-counter or are generic drugs, and included only the Web sites that were “stand alone,” meaning the product 
had an independent site instead of a page on the parent company‟s Web site. In addition, only each site‟s home page 
was coded. The researcher chose to branch from Macias and Lewis‟ (2004, p. 47) study in this instance because 
products‟ home pages are how advertisers attract viewers to explore the remainder of the sites through presenting an 
overview of the Web sites‟ content through links and other interactive material, and could therefore be compared 
more readily with the content analyses on print advertisements that comprise the foundation of the present study. 
The researcher also believed the home pages of the Web sites would represent the advertisements for these brands 




 Each manufacturer of the prescription medications within the study was alphabetized and assigned a 
number between 1 and 46, representing the total amount of individual pharmaceutical manufacturers within the 
study. One hundred total manufacturers were not represented because some manufacturers marketed more than one 
top-selling brand among the 100 Web sites within the study, an increasingly common occurrence as manufacturers 
expand their variety of products. For example, in 2004, Pfizer boasted two best-selling products within the top five 
best-selling prescription medications and a total of 24 products ranked within the top 500 best-selling 
pharmaceuticals (“PharmaLive.com special reports: Top 500 prescription drugs,” 2005, p. 2). However, some 






separate manufacturer. For instance, medications manufactured by Eli Lilly & Co./Abbott Laboratories were not 




 All prescription medication brands within the study were alphabetized and then assigned a number between 
1 and 100, which the coders used to classify the brands that were ranked 1-100 within IMS Health‟s list of the top-




Prescription medication Web sites were also coded according to the condition treated by the advertised 
product. Codes for the condition were drawn from Bell, Kravitz, and Wilkes‟ (2000) study (p. 331), a scale also 
employed in Cline and Young‟s (2004, p. 143) research. The conditions included allergies, cancer, cardiovascular, 
dermatologic, diabetes, gastrointestinal-nutritional, HIV/AIDS, infectious (non-HIV), musculoskeletal, obstetric-
gynecologic, psychiatric-neurological, respiratory, tobacco addiction, urologic, and undisclosed. Since the sample 
included Web sites and not broadcast advertisements, the medical information was easily accessible with an Internet 
connection, and coders did not encounter difficulties in determining what condition the medication treated.   
 
B.5 Relational Rewards  
 
First, coders categorized the settings of the advertisement according to the relational rewards presented 
within the direct-to-consumer Web sites (Cline & Young, 2004, p. 141). As adapted from Cline and Young (2004, p. 
141), the Relational Rewards section consisted of the following items: 
 
B.5.1 Family/More than One Generation 
 
This category within the Relational Rewards section included family settings or members of more than one 
generation, such as a man and his son. Multiple generations, however, did not have to include children. For instance, 
a medication for menopausal symptoms may depict a middle-aged woman explaining to her thirty-year-old daughter 
the benefits of the advertised medication, while recommending the medication to her daughter for when she enters 








A recreational setting included one or more actors engaging in leisure activities, such as surfing or lounging 
on a hammock. Coders were instructed to distinguish between leisure activities and social activities by noting the 
number of actors in the advertisement and which category the activity typically falls within. For example, while 
some Americans may play golf for networking purposes or to close a business deal, golf is traditionally considered 




A romantic setting was recorded if the Web site included two actors who appeared affectionate towards 
each other. However, coders were instructed to use caution in case some Web sites may feature a man and a woman 
alone together but not necessarily engaged in a romantic activity. For example, a couple riding their bikes on a 




A work setting was recorded if the Web site featured actors dressed in business attire who were engaging in 
work-related activities, such as attending meetings, sitting at a computer desk, or interacting with clients or 
coworkers. Coders were instructed to be cautious in separating work settings from social settings, however, by 




A social setting was categorized if the Web site depicted two more actors engaged in social activity (such 
as a party). However, coders were instructed to use the visual and textual cues to differentiate between the “Social” 











B.5.6 Other Relational Reward 
 
This category encompassed relational rewards that did not fit effectively within the categories on the above 
list. For instance, Web sites featuring actors who were staring into the camera, in doctors‟ offices, or in classroom 
settings were classified within this category.  
 
B.5.7 No Human Actor 
 
This category was added to account for the advertisements featuring cartoons, the advertised products, 
trade characters, animals, or other non-human subjects.  
 
B.6 Visual Elements 
 
Coders also recorded the visual elements of the 100 direct-to-consumer Web sites for prescription 
medications within the study, which included relational rewards, number of actors, and the presence of people, 
cartoons, animals, trade characters, body parts, products, or other entities. Coders were instructed to classify visual 
cues that were visible within the foreground of the advertisement; however, if visual cues present in the background 
of the Web site were distinguishable, coders included those cues as well. 
 
B.6.1 Number of Actors 
 
Coders counted only humans within the total number of actors within the advertisements, and actors within 
the prescription medication Web sites had to be visible in the foreground of the advertisement, although they did not 
have to be facing the camera or the audience. If an actor was in the background of the advertisement, yet his or her 
appearance was clearly distinguishable, the coders included those actors when counting how many actors were 
present. Classifications for the number of actors within the advertisement were as follows: one, two, three, four, five, 
six, seven, eight, and nine. The classifications reached just nine actors because that was the highest number of actors 
recorded by Cline and Young (2004, p. 144). No cartoons, trade characters, animals, products, or other non-human 














The presence or absence of cartoons within the prescription medication Web sites was recorded as well. A 
variety of visual elements fit within this category: cartoons included figures that were not considered trade 
characters (such as Zoloft‟s personified rock) (Pfizer, 2008i) and non-animated illustrations of how the medication 




Animals were also classified among the visual cues within the coded prescription medication Web sites. 
Coders were instructed to classify elements within the animal category only if the animals were not cartoon 
renderings and appeared to be real (such as in the Rozerem broadcast advertisement that features a beaver speaking 
to the actor) (TV Week, 31 October 2007, ¶ 1).  
 
B.6.5 Trade Characters 
 
Coders also noted the presence or absence of trade characters within these direct-to-consumer Web sites for 
prescription medications. Coders were instructed to differentiate between cartoons and trade characters according to 
the following: trade characters typically feature more personality than cartoons, appear more attached to the product, 
and likely have the name of the prescription brand emblazoned on or around them, such as the Nasonex bumblebee 
(Schering-Plough, 2008).  
 
B.6.6 Body Parts 
 
The presence or absence of human body parts was also recorded. If the body parts were illustrations, they 
were classified within the “Cartoons” category. Body parts were also coded within the advertisements if the actor‟s 









The advertised brands‟ products were also recorded among the visual cues of the prescription medication 
Web sites. Items classified within this category included pictures of the brands‟ packages or the pills themselves.   
 
B.6.8 Other Visual Element 
 
This category encompassed any subject of these direct-to-consumer Web sites that did not fit within the 
preceding categories, such as the picture of the bell on the Actiq Web site (Cephalon, 2008).  
 
B.7 Identity Rewards 
 
 Like the coders of Cline and Young‟s (2004, p. 141) study, the present study‟s coders recorded the degree 
of identity rewards demonstrated within these direct-to-consumer advertisements, including subjects‟ activity level, 
health, and friendliness.   
 
B.7.1 Activity Level 
 
The models within the advertisements were classified as active if they were engaging in physical, 
recreational, or social activities, taking the advertised medication, or looking directly into the camera. Like the 
coders of Cline and Young‟s (2004, p. 141) study, coders were instructed to code the highest level of activity for the 
Web sites depicting more than one person. Coders categorized actors as inactive if they did not appear to be engaged 
in any activity in the picture or if they were sleeping. For instance, the Web site for Effexor XR shows a woman 
who appears to be gazing blankly into the distance; her activity level was classified as “Passive” (“Information on 
Depression Symptoms and Treatment,” Wyeth Pharmaceuticals, 2008). No cartoons, trade characters, animals, or 
products were coded as “Active” or “Passive.” Instead, these subjects were coded as “Actor is Not Human/No Actor 
Present,” a category the researcher added to this section.  
 
B.7.2 Health of Actor 
 
Human actors were coded as ill or healthy according to whether they appeared to exhibit the symptoms of 






woman clutching her head in pain, so she was classified as “Ill” (GlaxoSmithKline, 2008i). Actors were also 
classified as “Ill” if the Web site identified them personally as suffering from the disease, even if they did not 
necessarily appear to be sick. For instance, the Web site for the HIV medication Combivir featured a picture of a 
woman identified as “Michelle, diagnosed HIV positive” (GlaxoSmithKline, 2008b), and she was coded as “Ill.” 
Coders were instructed to classify the actors within the advertisement as unhealthy even if only one of the actors did 
not appear to be healthy or was identified as unhealthy by the text. Actors who were not human were coded within 
the “Actor is Not Human/No Actor Present” category.  
 
B.7.3 Friendliness of Actor 
 
Inspired by Cline and Young‟s (2004, p. 141) research, the friendliness of the actors was operationalized 
according to whether the actors were or were not smiling. Friendliness was not coded for animals, cartoons, or trade 
characters for the same reason that their gender and ethnicity were not coded. For non-human actors, coders used the 
coding category “Actor is Not Human/No Actor Present.” 
 
B.8 Appearance of Main Actor 
 
Each main actor‟s appearance was also coded. Categories for Appearance of Main Actor included age, 
gender, and ethnicity.  
 
 B.8.1 Age 
 
If the actor on the Web site was not human or if no actor was present, coders recorded the age of that actor 
as “Actor is Not Human/No Actor Present.” As for the Web sites featuring humans, the researcher coded the ages of 
the actors more specifically than Cline and Young (2004, p. 141). The present study classified the actors‟ ages 
according to whether they were children, adolescents, 20-29 years old, 30-39 years old, 40-49 years old, 50-59 years 




Each actor recorded within the 100 coded prescription medication Web sites was also classified as “Male” 






that were not classified as male or female, the researcher included the “Actor is Not Human/No Actor Present” code 




The coding categories for ethnicity included the following classifications: “White/Caucasian,” 
“Black/African-American,” “Hispanic,” “Asian,” “Mix,” or “Indeterminate.” The researcher added the codes 
“Multiple Actors of Multiple Ethnicities” and “Indeterminate” to the Ethnicity section in case the Web site utilized 
two or more actors of different ethnicities, providing that these actors were both featured within the main picture or 
another focal point of the Web site.  In addition, an “Other” category was added to account for any actor who could 
not be classified within the other ethnicities. Ethnicity was not coded for animals, cartoons, trade characters, or other 




The Interactivity section of the instrument was adapted from Macias and Lewis‟ (2004) content analysis of 
90 direct-to-consumer Web sites for prescription medications (p. 47, 51). However, the researcher first had to 
modify these researchers‟ complete list of interactive features to accommodate the present study, which only 
analyzed the sites‟ home page and not the entire Web site. Therefore, interactive features included quizzes, live chat, 
message board, videos, audio, text size adjustments, animated graphics, e-mail updates/newsletters, frequently-asked 
questions, the site‟s glossary, links to the site map, and other features. Each coder recorded the presence or absence 




The Quizzes category referred to links to self-administered, interactive tests on the Web sites for users to 
“diagnose” themselves or to assess the severity of their symptoms. Links to “Questions to Ask Your Doctor” were 









B.9.2 Live Chat  
 
The Live Chat category encompassed links to patient chat rooms or information on how users can attend or 
participate in virtual talks with nurses, doctors, company representatives, or other experts online. Podcasts and 
Webcasts were included within this category. 
 
B.9.3 Message Board 
 
Message boards were operationalized as forums where users can express their concerns or comments about 




The presence or absence of videos on the site was also recorded. For example, particular sites utilized a 
spokesperson or “guide” who appeared in a video which played immediately after the site fully loaded, while others 
provided links to patient testimonial videos, as evidenced by phrases such as “Watch Charlie‟s Story.” 
 
B.9.5 Audio  
 
The presence of audio was recorded only if the site‟s home page featured a video that played immediately 
after the site loaded or that users could instruct to play by pressing a button. Coders were instructed not to record the 
presence of audio if the site‟s home page featured only links to videos since coders could not be certain whether 
these videos utilized audio without navigating away from the home page.  
 
B.9.6 Text-Size Adjustments 
 
The presence or absence of the option of increasing or decreasing the Web site‟s font size was also 
recorded.  
 
B.9.7 Animated Graphics 
 
Coders were instructed to record the presence of animated graphics if the Web site reacted to the users‟ 






the cursor moved over a certain part of the Web site, or if the site appeared to utilize technology enabling the 
manufacturer to present information to the user in increments, similar to a television commercial. 
 
B.9.8 E-mail Updates/Newsletters 
 
The presence or absence of e-mail updates and newsletters was also recorded. E-mail updates encompassed 
various types of information, from site updates to briefings on ongoing clinical studies. Newsletters encompassed 
mainly the electronic versions, yet if a site did not specify the type of newsletter offered, offered, coders were 
instructed to record its presence within this category. 
 
B.9.9 Frequently-Asked Questions 
 
While many Web sites offered hyperlinks specifically titled “Frequently-Asked Questions,” this item was 
also often called “Common Questions.” Coders were instructed not to substitute the presence of a “Questions for 




Coders also recorded the presence or absence of a link to a glossary on the sites‟ home pages. A link to 
“Common Terms” was assumed to be a glossary as well.  
 
B.9.11 Site Map 
 
Coders also noted the presence or absence of links to the site map. However, the researcher instructed 
coders not to substitute links to the site guide for links to the site map, since some Web sites featured both of these 
elements.  
 
B.9.12 Other Interactive Elements 
 
The “Other” category for the Interactivity section accounted for links to event calendars, patient stories and 
testimonials, downloadable cookbooks, and other items utilizing the site‟s interactive features. Links to the site 
guide were also classified within this category. Macias and Lewis (2004) believe the usage of the “Other” category 






the present study benefitted from the flexibility of this category as well due to the variety of interactive features 
these manufacturers built into the advertisements. 
 
B.10 Dominant Frame 
 
Coders also classified the type of dominant textual frames within the 100 coded direct-to-consumer 
prescription medication Web sites as “Gain Frame: Social Approval,” “Gain Frame: Happiness,” “Loss Frame: 
Social Approval,” “Loss Frame: Happiness,” “Mix of Gain/Loss Frames,” or “Indeterminate/No Frame.” The 
researcher added the “Indeterminate/No Frame” code to the Dominant Frame section in case none of the other 
available choices was appropriate for the Web site. In order to categorize a Web site according to the frame (or lack 
thereof), coders determined whether messages present within the text of the 100 prescription medication brands‟ 
Web sites emphasized risks or benefits to the patient. Since many Web sites displayed both benefits (gain frames) 
and risks (loss frames) on the same Web page, coders were instructed to classify the sites according to which frame 
was more dominant on the page. In order to distinguish the dominant frame on the Web sites, coders were instructed 
to evaluate the prominence of the text that explained the gain or loss to consumers. 
Gain frames within the text of the Web sites conveyed the benefits to patients if they choose to take the 
prescription medication or treat the condition. Gain frames referred to either gaining happiness or gaining social 
approval by choosing to treat the medical condition or take the prescription medication.  
 
B.10.1 Gain Frame: Social Approval  
 
Coders were instructed to utilize the “Gain Frame: Social Approval” category if the advertisement implied 
how treating the illness with the advertised product would benefit patients‟ social lives. For example, an 
advertisement for a medication to treat acid reflux disease may depict the affected person‟s family rejoicing since 
they will finally being able to enjoy a family barbeque with him. 
 
B.10.2 Gain Frame: Happiness 
 
Web sites that focused on the positive outcomes of treating the disease, especially with the advertised 
medication, were categorized within the “Gain Frame: Happiness” code. For instance, if the home page of a 






canoeing, in addition to a small sidebar explaining the risks of taking the medication in small print, the dominant 
frame was the “Gain Frame: Happiness.”   
Loss frames were recorded when the risks of not taking the medication or not treating the condition were 
evident within the text of the Web site. In contrast to gain frames, the Web sites‟ loss frames included messages that 
the patient may lose happiness or lose social approval by choosing either to not take the medication or to not treat 
the condition. An example of a loss frame is the home page of a medication to treat a sexually-transmitted disease 
which warns consumers that treatment is the only way to reduce their risk of transmitting the disease to others. 
 
B.10.3 Loss Frame: Social Approval 
 
The Web sites for prescription medications that emphasized the negative social outcomes of the ailment 
were categorized as “Loss Frame: Social Approval.” Also, home pages that presented the social risks to the patient if 
he or she does not treat the illness with the advertised medication were classified within this category.  
 
B.10.4 Loss Frame: Happiness 
 
The “Loss Frame: Happiness” category was recorded if the Web site illustrated the risks to the patient‟s 
happiness if he or she did not treat the disease or use the advertised medication. Web sites advertising a medication 
that treats depression may utilize this type of dominant frame.  
 
B.10.5 Mix of Gain/Loss Frames 
 
If both gain and loss frames appeared to be equally prominent within the Web sites for these 100 
prescription medications, coders classified those sites as using a “Mix of Gain/Loss Frames.” 
 
B.10.6 Indeterminate/No Frame 
 
For Web sites without identifiable frames or frames that were not easily distinguished, the researcher added 








B.11 Dominant Advertising Appeal 
 
 The appeals of the direct-to-consumer prescription medication Web sites were coded based on whether they 
were informative, transformative, mixed, or indeterminate. If both transformational and informational appeals were 
present on the home page of the Web site, coders applied the same guidelines to distinguish the dominant appeal of 
the page as they used to determine each page‟s dominant frame: by assessing the prominence of each appeal relative 
to the rest of the content on that particular page. For example, if a Web site featured a large picture of a man and a 
woman having a picnic in a meadow, even if the smaller content surrounding the picture contained risk and 
symptom information, the dominant appeal was coded as “Transformational.” 
 
 B.11.1 Informational Appeal 
 
Informational appeals were recorded if the home page of the Web site for the prescription medication 
featured text (or an appeal by an actor) outlining the risks and benefits of the drug or presenting a logical argument 
to try the medication as treatment for the condition. Prominent symptom information and warnings about the 
medication were also classified within the “Informational” advertising appeals category. An example of an 
informational appeal is Zocor‟s Web site (Merck & Co., 2007), since the home page features only the downloadable 
product information for patients. 
 
 B.11.2 Transformational Appeal 
 
Coders classified an appeal as “Transformational” if the text of each Web site‟s home page elicited the 
emotions of the audience. An example of a transformational appeal is a Web site which features a picture of a lonely 
dog with no one to play with him accompanied by text asking the viewers when they will treat their allergy 
symptoms so their dog no longer will be neglected.     
 
 B.11.3 Mixed Appeal 
 
If the Web site used both transformational and informational advertising appeals relatively equally and 







 B.11.4 Indeterminate/No Appeal 
 
To account for Web sites that did not fit within any of the above three categories, the researcher added the 
category “Indeterminate/No Appeal.”  
 
B.12 Inducements  
 
 Inducements were among the instrumental motivational cues coded within the sample. The researcher 
compiled examples of inducements from the research of both Macias and Lewis (2004, p. 49) and Young and Cline 
(2005, p. 354). Coders also recorded whether the Web sites for the 100 top-selling prescription medications utilized 
inducements, which, according to Macias and Lewis (2004), include reminder cards, free samples, free trials, and/or 
vouchers/coupons (p. 49). Coders were instructed to include inducements that were evident on the front page of 
these coded Web sites, even if the sites only included a hyperlink for viewers to click on to reach the inducement.  
 
 B.12.1 Presence of Inducements 
 
Coders recorded whether the Web sites contained any inducements that were not included within the 
Inducements category.  Essentially, any material presented to consumers to encourage them to speak with their 
doctors, request samples or free trials, or purchase the medication was coded as an inducement. 
 
 B.12.2 Reminder Cards 
 
Reminder cards encompassed postcards or other mailed or e-mailed documents to remind patients to refill 
their prescriptions. E-mail reminders were also included within this category, even if they were not necessarily 
identified as “cards.” 
 
 B.12.3 Free Samples 
 
Coders also recorded the presence or absence of offers for free samples of the product. The study‟s two 








B.12.4 Free Trials 
 
The presence or absence of free trial offers on these products‟ Web sites was also recorded. Free trials 
included offers of a limited supply of the medication, such as seven days‟ worth, an entire month‟s worth, or more.  
 
 B.12.5 Vouchers/Coupons 
 
Coders identified the sites‟ usage of vouchers or coupons. The researcher instructed coders to use the sites‟ 
terminology to differentiate between these types of inducements and promises of free trials or samples, which should 
not be classified within this category.  
 
B.13 Informational Rewards 
 
Informational rewards were another category within instrumental motivational cues coded within the 
advertisements. Drawing from Young and Cline‟s (2005, p. 355) and Macias and Lewis‟ (2004, p. 47) studies on the 
textual cues of direct-to-consumer advertisements, informational rewards included telephone numbers, e-mail 
addresses, mailing addresses, patient support groups, informational CDs or DVDs, brochures/binders, press releases, 
third-party editorials/sponsorship Web sites, news coverage, or other. Just as for coding the inducements, coders 
were instructed to include informational rewards that were evident on the front page of these coded Web sites (even 
if the sites only included a hyperlink for viewers to click on to reach the informational reward). 
 
 B.13.1 Telephone Number 
 
The presence of a telephone number was recorded if the number was visible on a Web site‟s home page. 
Telephone numbers for purposes that were not directly related to the advertised brand, however, such as phone 
numbers for the parent company‟s program to help patients pay for medications, were not included within this 
category.  
 
 B.13.2 E-mail Address 
 
E-mail addresses for a site‟s Web master or hyperlinks to “E-mail the Web master” were included within 






 B.13.3 Mailing Address 
 
Mailing addresses for the manufacturers or the brands were included within the Mailing Address category. 
Coders were instructed not to record the presence of the mailing address if the Web site merely listed the city and 
state in which the manufacturer copyrighted the content. To qualify, mailing addresses had to be complete.   
 
 B.13.4 Patient Support Programs 
 
Coders also recorded the presence or absence of patient support programs for these Web sites for top-
selling prescription medications. The researcher trained the coders not to substitute plans for financial assistance for 
prescription medications for patient support programs; rather, patient support programs had to be brand-specific, 
such as Crestor‟s “Crestor 360O” support program (AstraZeneca Pharmaceuticals, 2008a). 
 
 B.13.5 Informational CDs/DVDs 
 
Coders were instructed to code the presence or absence of the site‟s use of informational CDs and DVDs as 
inducements. Sites offering to send “additional materials” to interested users were not counted within the 
Informational CDs/DVDs category because the manufacturer did not clearly state what type of materials were 
included. The exceptions were the Web sites offering to send these additional materials and accompanied the offer 
with a photo, illustration, or text indicating the inclusion of a CD or DVD. 
 
 B.13.6 Brochures/Binders 
 
The usage of brochures and binders was also recorded within the Informational Rewards section of the 
instrument. Again, coders did not record sites that offered “additional materials” unless the manufacturer or brand 
specified what type of materials were included, either through a photo, illustration, or within the text.   
 
 B.13.7 Press Releases 
 
Coders also recorded the sites‟ inclusion of press releases. Press releases may focus on the brand, the 
manufacturer, the condition, relevant clinical studies, or other subjects relevant to users. The press releases could be 






 B.13.8 Third Party Editorials/Sponsorship Web Sites/Other Web Sites 
 
An additional coding category within the Informational Rewards section of the instrument encompassed the 
presence or absence of third party editorials, sponsorship Web sites, or other Web sites. Third party editorials were 
defined as hyperlinks to another sites not affiliated with the parent company or the advertised brand, while 
sponsorship Web sites included links advertising the brand‟s partnerships and affiliations. Other Web sites could be 
link to third-party sites or non-promotional sites.     
 
 B.13.9 News Coverage 
 
The presence or absence of news coverage was also recorded for the present study. News coverage may 
include clinical trials, new findings, information about the company, or other items relevant to the sites‟ users.  
 
 B.13.10 Other Informational Reward 
 
The “Other” category encompassed any informational rewards that did not easily fit within the above 
categories, such as “additional materials” that were not specifically named by the manufacturers.  
 
B.14 Medical Rewards 
 
Medical rewards were the third type of instrumental motivational cue identified within the direct-to-
consumer advertisements. Coders were instructed to classify the following textual cues as medical rewards (Young 
& Cline, 2005, p. 356) general effectiveness claims, specific effectiveness claims, claims of the medications‟ ability 
to extend patients‟ lives, claims of the medications‟ ability to improve particular “clinical indicators,” claims of 
negative rewards, and comparative claims. 
 
 B.14.1 General Effectiveness Claims 
 
Coders recorded the presence or absence of general effectiveness claims within the Medical Rewards 
section of the instrument. General effectiveness claims were typically included within the sites‟ tag lines or main 







 B.14.2 Specific Effectiveness Claims 
 
Coders also categorized the Web sites‟ use of specific effectiveness claims. Specific effectiveness claims 
typically were included within the manufacturers‟ description of the medications‟ use as approved by the U.S. Food 
and Drug Administration, and provided more detail than general effectiveness claims. Specific effectiveness claims 
were closely linked to claims of the medications‟ ability to improve “clinical indicators.”  
 
 B.14.3 Claims of Extending Patient’s Life 
 
Claims of extending patients‟ lives were also included within the Medical Rewards section of the 
instrument. Coders were instructed to carefully read the sites‟ fine print to determine the presence of these claims, 
since some Web sites‟ main copy may have implied the medications‟ ability to extend the patients‟ lives but 
explicitly stated the drugs‟ inability to do so within the fine print.  
 
 B.14.4 Claims of the Medication’s Ability to Improve Particular Clinical Indicators 
 
In addition, coders recorded any claims of the medications‟ success at improving any clinical indicators of 
the disease treated by the advertised medication. An example of this type of medical reward would be an HIV/AIDS 
medication that can increase white blood cell count by 10 percent after six months. Coders carefully separated these 
claims from specific effectiveness claims, but typically both types of claims were present together, often in the same 
sentence.  
 
 B.14.5 Claims of Negative Rewards 
 
Negative rewards were typically included within the products‟ description, since most of these medications 
were designed to decrease the pain, discomfort, or life-threatening aspects of the conditions.  
 
 B.14.6 Comparative Claims 
 
Coders also evaluated the presence or absence of comparative claims within the home pages of these direct-






medication versus a placebo, other prescription brands, or even various potencies of the same drug. Comparative 
claims were coded regardless of whether the messages were positive or negative.   
 
B.15 Instrumental Punishments 
 
Instrumental punishments comprised the final type of instrumental motivational cues within the direct-to-
consumer advertisements. The researcher also drew from Young and Cline‟s (2005) study on the textual cues in 
direct-to-consumer advertisements to construct the instrumental punishments category (p. 356-357). Coders were 
instructed to classify claims of negative outcomes and disclaimers within this group.  
 
 B.15.1 Claims of Negative Outcomes 
 
Since many of these medications, especially medicines treating chronic, life-threatening conditions, are 
potent and therefore potentially dangerous, coders recorded the presence or absence of claims of negative outcomes 
within the advertisements. 
 
 B.15.2 Disclaimers 
 
Coders also evaluated the presence or absence of disclaimers. The researcher instructed coders to exercise 
caution when identifying disclaimers since not all were blatantly labeled “Disclaimer.” 
 
B.16 Identity Motivational Cues 
 
The identity motivational cues that coders were instructed to classify the presence or absence of included 
claims of enabling/improving patients‟ lifestyles, claims of improving patients‟ overall positive feelings, claims of 
improving patients‟ outward appearance, claims of improving patients‟ strength/power, claims of improving 
patients‟ control over the condition, claims of improving patients‟ intelligence, claims of the condition‟s 
universality, and claims (“personal appeals”) from the actor(s) in the advertisement (Young & Cline, 2005, p. 357).     
 
 B.16.1 Claims of Enabling/Improving Patient’s Lifestyle 
 
Coders recorded the presence or absence of the medications‟ claims of improving patients‟ lifestyles by 






 B.16.2 Claims of Improving Patient’s Overall Positive Feelings 
 
These claims were also identified within the 100 direct-to-consumer advertisements for prescription 
medications. Claims of improving patients‟ overall positive feelings could refer to the medications‟ abilities to 
literally improve positive feelings by treating depression or anxiety, but also could be implied by the advertisements‟ 
message of removing the negative effects of the illness and allowing users to fully embrace and enjoy their lives.  
 
 B.16.3 Claims of Improving Patient’s Outward Appearance 
 
Coders also recorded the medications‟ claims of improving patients‟ outward appearance. These claims 
may refer to literal improvement, such as dermatologic medications‟ ability to ameliorate acne, or to the noticeable 
increase in confidence gained by treating the condition, which in turn makes the patients more attractive to others.   
 
 B.16.4 Claims of Improving Patient’s Strength/Power 
 
Claims of improving patients‟ strength and power were also identified within the direct-to-consumer 
advertisements. Like the claims of improving patients‟ outward appearance, advertisements in this category may 
refer to literal increases of strength and power, such as an advertisement for a Multiple Sclerosis treatment that 
provides patients with the strength necessary to perform everyday tasks, or to figurative strength and power, such as 
equipping patients with the determination and drive to overcome the disease.  
 
 B.16.5 Claims of Improving Patient’s Control Over the Condition 
 
These claims were also recorded within the sample of Web sites for prescription medications. Just as the 
claims of improving patients‟ outward appearance or strength and power, improving patients‟ control over the 
situation could refer to literal control, such as an STD treatment which prevents outbreaks of the disease, or to 
figurative control, such as the medications‟ ability to help patients accept that living with the disease does not 










 B.16.6 Claims of Improving Patient’s Intelligence 
 
These claims could be literal, since medications such as Adderall XR, a treatment for Attention Deficit 
Disorder, may literally improve patients‟ memory, comprehension, and other learning capabilities (Shire U.S., 
2008). In other cases, these claims could be figurative, such as within advertisements implying that patients who 
treat a condition with the advertised medication are being “smart” about their treatment.  
 
 B.16.7 Claims of the Condition’s Universality 
 
Coders also explored claims of the conditions‟ universality within these 100 direct-to-consumer 
advertisements. The researcher instructed the two coders to include claims involving the number of people a disease 
has affected as well as claims about the widespread usage of the advertised medication as treatment.  
 
B.16.8 Personal Appeals From the Actor(s) in Advertisement 
 
The presence or absence of personal appeals from the actors within the advertisements was also recorded. 
Actors did not necessarily have to speak themselves in order to be qualified within this category; coders were 
instructed to include advertisements featuring names and direct quotes from the medicines‟ users, in addition to any 







 APPENDIX C. INTERCODER RELIABILITY SCORES FOR PILOT STUDY, BY VARIABLE 
 
Variable               Intercoder Reliability Score (2 coders) 
 
1. Manufacturer  100% 
2. Brand 100% 
3. Condition  90% 
4. Relational Rewards  80% 
5. Visual Elements: Number of Actors  100% 
6. Visual Elements: People 100% 
7. Visual Elements: Cartoons 90% 
8. Visual Elements: Animals 100% 
9. Visual Elements: Trade Characters 90% 
10. Visual Elements: Body Parts 100% 
11. Visual Elements: Product 100% 
12. Visual Elements: Other Visual Element 80% 
13. Identity Rewards: Activity Level 90% 
14. Identity Rewards: Health of Actor  90% 
15. Identity Rewards: Friendliness 100% 
16. Appearance of Main Actor: Age  90% 
17. Appearance of Main Actor: Gender 100% 
18. Appearance of Main Actor: Ethnicity  80% 
19. Interactivity: Quizzes 100% 
20. Interactivity: Live chat 100% 
21. Interactivity: Message Board 100% 
22. Interactivity: Videos  80% 
23. Interactivity: Audio 80% 
24. Interactivity: Text-Size Adjustments  100% 






Appendix C, continued. 
 
26. Interactivity: E-mail Updates/Newsletters  100% 
27. Interactivity: Frequently-Asked Questions 90% 
28. Interactivity: Glossary 100% 
29. Interactivity: Site Map 100% 
30. Interactivity: Other Interactive Element 80% 
31. Dominant Frame  90% 
32. Dominant Advertising Appeal  80% 
33. Instrumental Motivational Cues: Inducements 80% 
34. Instrumental Motivational Cues: Reminder Cards 100% 
35. Instrumental Motivational Cues: Free Samples 100% 
36. Instrumental Motivational Cues: Free Trials 100% 
37. Instrumental Motivational Cues: Vouchers/Coupons 100% 
38. Informational Rewards: Contact Us 100% 
39. Informational Rewards: Telephone Number 100% 
40. Informational Rewards: E-mail Address 100% 
41. Informational Rewards: Mailing Address 100% 
42. Informational Rewards: Patient Support Programs 90% 
43. Informational Rewards: Informational CDs/DVDs 90% 
44. Informational Rewards: Brochures/Binders  100% 
45. Informational Rewards: Press Releases  100% 
46. Informational Rewards: Third-Party Editorials/ 
Sponsorship Web Sites/Other Web Sites 
80% 
47. Informational Rewards: News Coverage 100% 
48. Informational Rewards: Other Informational 
Reward 
90% 
49. Medical Rewards: General Effectiveness Claims 100% 
50. Medical Rewards: Specific Effectiveness Claims 90% 








Appendix C, continued.  
 
 
Average Intercoder Reliability for Pilot Study:            93.75% 
 
52. Medical Rewards: Claims of Medication‟s Ability 
to Improve Particular Clinical Indicators 
90% 
53. Medical Rewards: Claims of Negative Rewards 100% 
54. Medical Rewards: Comparative Claims 90% 
55. Instrumental Punishments: Claims of Negative 
Outcomes 
100% 
56. Instrumental Punishments: Disclaimers  90% 
57. Identity Motivational Cues: Claims of Enabling/ 
Improving Patient‟s Lifestyle  
90% 
58. Identity Motivational Cues: Claims of Improving 
Patient‟s Overall Positive Feelings  
100% 
59. Identity Motivational Cues: Claims of Improving 
Patient‟s Outward Appearance  
100% 
60. Identity Motivational Cues: Claims of Improving 
Patient‟s Strength/Power 
80% 
61. Identity Motivational Cues: Claims of Improving 
Patient‟s Control over the Condition  
80% 
62. Identity Motivational Cues: Claims of Improving 
Patient‟s Intelligence  
100% 
63. Identity Motivational Cues: Claims of the 
Condition‟s Universality  
100% 
64. Identity Motivational Cues: Personal Appeals from 







APPENDIX D. BRANDS INCLUDED IN SAMPLE, BY MANUFACTURER 
 
Brand(s)            Manufacturer 
 
Advair, Avandia, Combivir, Coreg CR, Flovent HFA, 
Imitrex, Lamictal, Valtrex, Wellbutrin XL 
GlaxoSmithKline  
Celebrex, Detrol LA, Geodon, Lipitor, Lyrica, 
Norvasc, Viagra, Zoloft  
Pfizer  
Arimidex, Crestor, Nexium, Pulmicort Respules, 
Seroquel, Toprol XL 
AstraZeneca  
Depakote ER, Humira, Kaletra, Niaspan, Tricor, 
Zemplar 
Abbott Laboratories  
 
Diovan, Gleevec, Lamisil, Trileptal, Zelnorm 
 
Novartis Pharmaceuticals  
Ambien CR, Eloxatin, Lantus, Lovenox, Taxotere 
 
Sanofi-Aventis U.S.  
Aranesp, Epogen, Neulasta, Neupogen 
 
Amgen  
Evista, Gemzar, Strattera, Zyprexa 
 
Eli Lilly & Co.  
Cozaar, Fosamax, Singulair, Zocor 
 
Merck & Co.  
Levaquin, Risperdal, Topamax 
 
Ortho-McNeil-Janssen Pharmaceuticals 
Effexor XR, Premarin, Protonix 
 
Wyeth Pharmaceuticals, Inc.  
Betaseron, Yasmin 28 
 














Merck & Co./Schering-Plough  







Astellas Pharma U.S. Inc.  
Avonex 
 









Bristol-Myers Squibb  
Erbitux 
 










Bristol-Myers Squibb/Ostuka America Pharmaceutical 
Plavix 
 












Elsai/ Pfizer  
Rebif 
 
EMD Serono, Inc.  
Lidoderm 
 
Endo Pharmaceuticals  
Rituxan 
 
Genentech/Biogen Idec  
Concerta 
 












Proctor & Gamble Pharmaceuticals  







Shire U.S. Inc.  
Actos 
 
Takeda Pharmaceuticals  
Prevacid TAP Pharmaceutical Products  
 
Copaxone Teva Pharmaceutical Industries  
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